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Abstract 
Background: Sustained engagement in HIV care, including adherence to antiretroviral 
therapy (ART) and retention in HIV services, is essential to optimize maternal health and 
prevent perinatal, postnatal and sexual HIV transmission. However, engagement in care 
remains a substantial challenge for pregnant and postpartum women. Women’s experience of 
and response to barriers to engagement in care, including ART side effects, transfer of care 
and mobility, may be altered by the transitions experienced in pregnancy and motherhood, 
and there have been few quantitative analyses of these risk factors in maternal ART cohorts. 
The way engagement in HIV care is measured also varies widely and no gold standard 
measures of ART adherence or retention exist. Composite assessments of adherence and 
retention, including drug concentrations, longitudinal self-reported adherence, and interlinked 
routine electronic health data, have not been thoroughly evaluated among African women 
living with HIV. To address these gaps in knowledge, this thesis investigates novel measures 
of ART adherence, and evaluates interlinked routine electronic health data to measure 
retention in a South African maternal ART cohort. It describes maternal engagement in HIV 
care, and examines barriers to engagement that require consideration specific to maternal 
ART.  
Methods: This research included women who initiated ART during pregnancy in a large 
integrated antenatal care and ART clinic in Gugulethu, South Africa (2013-2014). Until July 
2013, only women who met certain clinical criteria (CD4 cell count <350 cells/µL or disease 
stage III or IV) were eligible for lifelong ART, thereafter guidelines changed to recommend 
lifelong ART for all pregnant women living with HIV. In this setting, all women receive 
ART and antenatal care in an integrated clinic during pregnancy and are required to transfer 
to a general ART clinic postpartum. Data were obtained from questionnaires (including 
demographics, self-reported ART adherence and self-reported side effects) and blood 
specimens (for HIV viral load) collected at study visits approximately every three months 
from pregnancy through 18 months postpartum. One additional visit took place 3-4 years 
postpartum where blood specimens for drug concentrations were also collected. In parallel, 
routine electronic data, linked across clinics and data sources including HIV clinical visits, 
laboratory testing and pharmacy dispensing data, were obtained through 30 months on ART. 
Findings: Substantial disengagement from care, both non-adherence and non-retention, was 
observed in all analyses. At least one ART side effect was reported by 97% of women during 
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pregnancy and high overall side effect burden was associated with reported missed ART 
doses. Retention worsened over the first two years on ART and 21% of women were lost 
immediately after transfer from the integrated clinic. Women who linked to care spread to 
multiple different ART clinics after transfer; 21% moved clinics two or more times. Using 
combined routine medical records, only 59% of women had evidence of accessing routine 
HIV care in consecutive 12-month windows through 24 months on ART. Among women 
with viral loads available, attending ≥2 clinics was associated with viraemia. 
In analyses of ART adherence, TFV-DP in DBS provided a more nuanced adherence measure 
but plasma efavirenz and tenofovir assays had similar ability to predict viral suppression. 
Areas under the Receiver Operating Curve were higher for all drug concentrations (all 
>0.850) compared to self-reported adherence using a cross-sectional three-item scale (0.756). 
Longitudinal measurement of the same self-reported adherence scale showed that reporting 
worse adherence on any of three items over consecutive visits could predict viremia (>50 and 
>1000 copies/mL), particularly among women who were suppressed at the initial visit.  
Measuring retention using routine interlinked electronic data facilitated tracing of women 
beyond transfer from the integrated clinic to any clinic where they accessed HIV care 
postpartum. Estimates of retention varied widely using different retention definitions and data 
sources. Overall, electronic primary health care data, linked across clinics, performed better 
than laboratory data alone and was a robust measure for monitoring retention in HIV care. 
Conclusions: Taken together, these findings underscore a concerning level of disengagement 
from HIV care during and after pregnancy. Potential ART side effects, required transfer of 
care, the potential challenges of mobility and the importance of sustained engagement in care 
beyond pregnancy and breastfeeding, should be emphasised in ART counselling. Drug 
concentrations in DBS and plasma strongly predict viral suppression, but these data on 
longitudinal self-reported adherence provide a proof of concept for a low resource interim 
adherence measure that warrants further investigation in routine care settings with limited 
resources for viral load or drug concentration testing. Transfer of care and postpartum 
mobility mean that interlinked data sources are essential to obtain accurate estimates of 
retention postpartum. Further evaluation of the optimal approaches to transferring maternal 
ART care and the development of interventions to support engagement both in and beyond 
the clinic of ART initiation will be critical to sustain maternal engagement in HIV care in the 
long term. 
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 Introduction 
1.1 Introduction 
1.1.1 The global HIV epidemic 
Almost 37 million people are living with human immunodeficiency virus (HIV) worldwide 
[1]. Despite substantial progress in HIV treatment and prevention, in 2017 there were still an 
estimated 1.8 million new infections globally and 940 000 deaths dues to acquired immune 
deficiency syndrome (AIDS) [2]. Since 2016, the World Health Organization (WHO) has 
recommended universal initiation of lifelong antiretroviral therapy (ART) for all people 
living with HIV [3]. The goal of ART is to suppress the level of virus in the body which in 
turn reduces HIV/AIDS related morbidity and mortality and minimizes the risk of HIV 
transmission [4–10].  
Alongside the scale up of universal ART are the Joint United Nations Program on HIV and 
AIDS (UNAIDS) 90-90-90 targets: 90% of people living with HIV must know their status, 
90% of those who know their status must be on ART, and 90% of those on ART must be 
virologically suppressed [11]. Modelling estimates have shown that reaching these targets by 
2020, and continuing to 95-95-95 by 2030, will enable the control of HIV transmission and 
the end of the AIDS epidemic. Sustained retention in care and adherence to ART are required 
to achieve and sustain viral suppression (Figure 1-1) [8,12,13] and to achieve the benefits of 
lifelong ART. However, sustained engagement in care – including both retention in HIV care 
and adherence to ART - remains a persistent challenge globally [1,14]. 
 
 
Figure 1-1 The association 
between adherence to 
antiretroviral therapy and 
sustained viral suppression, 
from Nachega et al [13]. 
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1.1.2 HIV in pregnant and postpartum women 
In Sub-Saharan Africa (SSA), women bear a disproportionate burden of the HIV epidemic. 
SSA home to approximately 70% of all people living with HIV and 56% of them are women 
[1]. In 2017, women accounted for 59% of new HIV infections in SSA and around 90% of all 
pregnancies among women living with HIV occur in this region [2,15]. “Test and treat” or 
universal treatment for all people living with HIV is included in the WHO recommendations 
for prevention of mother-to-child transmission of HIV (PMTCT) [3]. Encouragingly, over 
90% of pregnant women known to be living with HIV globally received antiretrovirals 
(ARVs) for prevention of mother-to-child transmission (PMTCT) of HIV in 2017 resulting in 
less than 10% transmission [2]. Even with this progress, there were still 92 000 new HIV 
infections in children and 160 000 AIDS-related deaths among women in SSA in 2017 [2].  
Among pregnant and postpartum women living with HIV, sustained engagement in HIV care 
has the potential to impact on individual-, family- and population-level health outcomes [3]. 
Firstly, just as in all people living with HIV, ART reduces morbidity and mortality for the 
individual [4,8]. This has obvious benefit for a woman’s quality of life but also means that 
she is more likely to live a long healthy life and to be able to care for herself and her family. 
Preventing perinatal and postnatal transmission in the incident pregnancy is often the 
immediate priority and with sustained ART, this benefit extends to all future pregnancies 
[10]. Lastly, remaining engaged in care and virologically suppressed will prevent 
transmission of HIV to HIV-uninfected sexual partners, a critical component for ending the 
HIV epidemic [5]. 
Despite the important benefits of sustained engagement in ART care, many women do not 
remain retained in care and adherent to ART. A 2018 systematic review of ART retention 
among pregnant and breastfeeding women living with HIV in Africa found retention ranged 
from 47% to 88% only six months after starting ART [16]. Data from Malawi showed that 
70% of women were retained after three years on ART [17], and only 70% of women had 
>90% drug coverage using pharmacy refill data through two years on ART [18]. 
1.1.3 HIV prophylaxis and treatment guidelines for pregnant and postpartum women 
Over the past 20 years there has been a paradigm shift in our approach to PMTCT services 
with increasing recognition of the value of HIV treatment for maternal health and population 
health outcomes [10]. Global guidelines have evolved from the first recommendation of 
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single-dose and short-course ARV prophylaxis for PMTCT in 2001 [19], through lifelong 
ART for those meeting strict disease stage criteria and short-term prophylaxis for those not 
eligible for ART [20–22], to lifelong ART for all pregnant and breastfeeding women 
regardless of disease stage [23] (Figure 1-2). This shift represents an evolution in our 
understanding of HIV transmission, the role of ARV drugs in HIV treatment and prevention, 
and the potential for PMTCT services as an entry into lifelong HIV care [24].  
YEAR 
Prevention of mother-to-child 
transmission prophylaxis 
Triple drug antiretroviral therapy 
(ART) 
2001 
Four weeks of zidovudine, zidovudine 
and lamivudine, or single dose nevirapine 
No recommendation for lifelong 
antiretroviral therapy 
2004 
Zidovudine from 28wks + single dose 
nevirapine in pregnancy 
If CD4 ≤ 200 
2006 
Zidovudine from 28wks + single dose 
nevirapine + zidovudine and lamivudine 
for 7 days 
If CD4 ≤ 200 
2010 
Option A  
Zidovudine from 14 weeks gestation 
or 
Option B 
ART during pregnancy and breastfeeding 
If CD4 ≤ 350 
2013 
Option B 
ART during pregnancy and breastfeeding 
If CD4 ≤ 500 
or 
Option B+ 
ART for all pregnant and breastfeeding women living with HIV 
2015 Option B+ 
ART for all pregnant and breastfeeding women living with HIV 
2016 
 
2018 
Universal ART 
ART for all people living with HIV 
Figure 1-2 Evolution of World Health Organization guidelines for antiretrovirals in pregnant 
and postpartum women 
Universal lifelong ART for pregnant and breastfeeding women was first implemented in 2011 
in Malawi [25]. Since then there has been an unprecedented scale-up with almost all 
countries adopting this approach by November 2017 [26]. This policy change has resulted in 
antenatal services, particularly in high HIV prevalence areas, becoming an important entry 
point into lifelong ART programmes for women [27]. HIV testing during pregnancy is the 
norm in high burden countries and, although barriers to ART uptake still exist, great advances 
have been made in ensuring women initiate ART following an HIV diagnosis in pregnancy. 
The removal of the need for CD4 cell count testing to establish ART eligibility and simplified 
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treatment guidelines have minimised delays in ART initiation during pregnancy and 
treatment initiation on the day of diagnosis is now common [10,28,29]. Despite the 
achievements with treatment uptake, the success of lifelong ART is threatened as major 
challenges persist with keeping women engaged in ART services in the long term. 
1.1.4 ART regimens for pregnant and postpartum women 
From the time this thesis was conceived, the first-line regimen recommended by the WHO 
and in the South African national treatment guidelines has been a fixed-dose, once-daily 
combination of efavirenz (EFV), emtricitabine/lamivudine and tenofovir (TFV) [30]. EFV 
and TFV have been found to be safe in pregnancy with no evidence of increased risk of birth 
defects [31,32], and this regimen is widely used across SSA. TFV can cause side effects such 
as nausea, headaches and dizziness, but is usually well tolerated [32–34]. The most worrying 
potential toxicity from TFV is renal disfunction and kidney function is routinely monitored 
through creatinine levels and glomerular filtration rates among patients on TFV containing 
regimens [3,35,36]. There are concerns about adverse effects of EFV, specifically central 
nervous system (CNS) effects such as dizziness, abnormal dreams and insomnia, as well as 
depression and suicidality [34,37,38]. In 2017, the WHO included recommendations for 
dolutegravir as an alternative to EFV in first-line regimens with many countries adopting this 
new regimen [26,39]. Dolutegravir has superior efficacy and tolerability compared to EFV, 
however concerns remain about dolutegravir safety in the first trimester of pregnancy. It is 
therefore not currently recommended for women planning to conceive or for women in the 
first eight weeks of pregnancy [40–42]. 
1.1.5 Providing ART for pregnant and postpartum women 
When triple drug ART was first recommended for the treatment of HIV it required specialist 
treatment services. ARV prophylaxis for PMTCT has almost always been provided by nurses 
within antenatal care (ANC) clinics, but lifelong ART has historically been provided in HIV 
clinics with treatment initiated and managed by doctors. Under this model of care many 
pregnant women who were eligible for ART did not successfully link to HIV treatment 
services from ANC and did not initiate treatment before delivery [43,44]. The need for 
specialist clinicians also hampered the potential to scale up ART programmes in many low- 
and middle-income countries [45]. Task-shifting, the process of delegating tasks to cadres of 
staff with lower-level qualifications, is one approach that has been widely used to expand 
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access to HIV services in SSA. A formal guideline on task-shifting and training nurses to 
provide primary HIV care services was released by the WHO in 2008 [46] and many ART 
services are now predominantly nurse led [47]. With task-shifting came the potential to 
integrate ART services into ANC settings run by nurses. Integration of antenatal and HIV 
services has substantially increased ART uptake during pregnancy and is now the standard of 
care in most high burden countries [48,49]. 
Models of care for providing ART to pregnant and postpartum women still vary. Van Lettow 
et al conducted a survey on implementing universal ART for pregnant and breastfeeding 
women in Malawi and identified three models of care: Model 1 provided integrated ANC and 
ART through 6 weeks postpartum with subsequent transfer to general ART clinics; Model 2 
provided immediate referral from ANC to a general ART clinic for ART initiation; and 
Model 3 provided the first dose of ART in the ANC clinic followed by immediate transfer to 
a general ART clinic [50]. Women who entered care in Model 1 or 3 were much more likely 
to initiate ART, however retention in care among women who successfully initiated ART was 
best in Model 2. These findings point to a potential delay in disengagement from care, fixing 
a vulnerable point in the cascade and shifting the loss to the next vulnerable point. Another 
study in Malawi reported similar results however they also presented a cumulative cascade 
[28]. This showed that, despite greater early losses among women successfully started on 
ART in the integrated care model (Model 1) compared to those who started ART in the 
referral model (Model 2), the impact of improved uptake of ART services resulted in lower 
overall loss from the care cascade by six months on ART (Figure 1-3). 
Even with the improved coverage of ART in pregnancy that resulted from integrating ART 
services into ANC, many settings still require women to transfer their ART care from 
integrated ANC and ART services to routine adult ART clinics after delivery. The timing of 
transfer varies across settings, ranging from six weeks to two years postpartum, but may also 
be a vulnerable point for disengagement from care [50–54]. Further extending integrated 
antenatal services to include maternal ART and routine child health services postpartum has 
been found to improve maternal retention and viral suppression, and to improve adherence to 
the early infant diagnosis cascade [55–57]. This has clear benefits for the periods of greatest 
risk for perinatal and postpartum HIV transmission, but it is not yet clear if the benefit for 
engagement in care is sustained following transfer to general adult care [55,56]. Taken 
together, this evidence suggests that integrated services improve ART uptake and outcomes 
as long as women are retained in the integrated services. They may not prevent 
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disengagement from care in the long-term, an idea that has also been posited in the context of 
universal ART [58]. 
Figure 1-3 The proportion of women starting and remaining in ART care when ART in 
integrated in antenatal care (Model 1) and when women are required to transfer from 
antenatal care to ART services (Model 2), from Chan et al [28]. 
1.1.6 The construct of engagement in HIV care: adherence and retention 
Throughout this thesis the term “engagement in HIV care” will be considered as an umbrella 
term for both retention in HIV care and adherence to ART [59]. The WHO define loss to 
follow-up (LTFU, or not retained on ART) as “patients receiving ART and not seen at the 
clinic, or pharmacy, >90 days after the date of their last missed appointment or last missed 
drug pick-up and who are not known to have transferred out or died” and ART adherence as 
“the extent to which a person’s behaviour corresponds with the agreed recommendations 
from a health care provider” [60,61]. Gardner et al described a spectrum of engagement 
based on the Health Resources and Services Administration (HRSA) continuum of 
engagement in ART care (Figure 1-4) [14]. Based on this spectrum, people living with HIV 
may lie anywhere between not knowing their HIV status, to being in care but not adherent to 
ART or to being fully engaged in HIV care.  
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The spectrum of engagement in HIV care 
Not engaged in care  Fully engaged in care  
Does not 
know HIV 
status 
Known HIV 
status but 
never linked 
to HIV/ART 
care 
Linked to 
HIV/ART 
care but 
never 
initiated 
ART 
Initiated 
ART but 
dropped out 
of care 
Moves in 
and out of 
HIV/ART 
care 
Retained in 
HIV/ART 
care with but 
not adherent 
to treatment 
Retained in 
HIV/ART 
care and 
adherent to 
treatment 
Figure 1-4 The spectrum of engagement in ART care (adapted from Gardner et al [14] and 
the Health Resources and Services Administration (HRSA) continuum of engagement in 
ART care [62]) 
Vrijens et al also proposed a definition of adherence which encompasses both adherence and 
retention as well as a time dimension [63]. The definition consists of initiation, 
implementation, persistence and discontinuation. Initiation includes the initial prescription 
and first ART dose, implementation speaks to adherence and non-adherence as defined 
above, and persistence is how long patients maintain being in care as prescribed without 
discontinuing care or being LTFU. This framework is useful in thinking about sustained 
engagement in HIV care in the long-term. Myer et al presented what this might look like for 
women starting ART in pregnancy, with many women engaged in care in the first few 
months on ART and gradually increasing proportions either in care but not adherent, or not 
retained in care, both of which are considered disengagement (Figure 1-5) [59]. 
Figure 1-5 Hypothetical depiction of engagement in HIV care (adherence and retention), 
from Myer et al [59]. 
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Another component of engagement in care is viral suppression. Viral suppression, driven by 
retention and adherence to ART, is the key factor in the success of ART for treatment and 
prevention of HIV and viral load monitoring is a core component of ART programs [23,64]. 
Currently the WHO recommends viral load testing at six and 12 months after ART initiation 
and annually thereafter, with additional testing following a high viral load (>1000 copies/mL) 
[65]. Some countries, including South Africa and Kenya, recommend more frequent viral 
load testing during pregnancy and breastfeeding due to the risk of transmission, although to 
date there are no global recommendations on optimal viral load monitoring for pregnant and 
breastfeeding women [36,66–68]. By the end of 2017, 58% of low- and middle-income 
countries were fully implementing WHO recommended viral load monitoring [26] but 
numerous barriers exist to the implementation of frequent viral load testing in low-resource 
settings [64,69]. Viral load measures near the time of delivery are important to help classify 
HIV-exposed children as low or high risk for transmission and to provide additional infant 
prophylaxis if needed. In SSA, many barriers persist to the implementation of viral load 
monitoring feedback of viral load results during pregnancy [67]. Viral load testing is also 
periodic and is not informative about patterns of adherence or gaps in care [70]. Although 
primarily driven by engagement in care, viral load is also affected by other factors such as 
ARV resistance, comorbidities and acute infection [71]. As such, even with full 
implementation of viral load monitoring, measures of retention and adherence are needed in 
order to assess and intervene on patient care real-time, to monitor ART programmes and to 
evaluate outcomes in research [72].  
In low-resource settings where frequent viral load testing is not possible, interim measures of 
adherence and retention are required to measure patterns of engagement in care and to flag 
patients requiring intervention. Methods used to measure retention and adherence are highly 
variable and no gold standard measures exist [73–75]. The common approaches to measuring 
these constructs and the challenges with each are discussed in detail in the literature review.  
1.2 Problem statement and rationale 
Despite the success in scaling up access to ART for pregnant and postpartum women, 
engagement in HIV care remains a persistent challenge. Without continued engagement in 
care, women are at risk of HIV-related morbidity and mortality, there is increased risk of 
perinatal and postnatal transmission of HIV in the incident pregnancy and subsequent 
pregnancies, and there is risk of transmission to sexual partners. There is a need to investigate 
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barriers to engagement in care that may have particular considerations in pregnant and 
postpartum women. There are also no gold standard measures of adherence and retention and 
approaches to measuring these constructs remain highly variable. Novel adherence 
measurement approaches need to be investigated for use in conjunction with viral load 
monitoring and for use in research. Given the frequent requirement for transfer of ART care 
from integrated ANC and ART services postpartum, there is also a need to understand the 
measurement of retention beyond the facility of ART initiation and potential for using routine 
interlinked data sources for this purpose. To monitor ART programmes, evaluate 
interventions and successfully intervene in patient care, further investigation into both the 
barriers to engagement and measurement approaches are required. 
1.3 Aim and objectives 
The overall aim of this research was to investigate barriers to engagement in HIV care with 
specific considerations among pregnant and postpartum women as well as to explore novel 
adherence measurement approaches and the use of routine interlinked data sources to 
measure retention in HIV care after ART initiation in pregnancy in South Africa. 
The specific objectives were: 
1. To review the literature on engagement in HIV care during and after pregnancy in 
SSA, including barriers, facilitators and methodological considerations for measuring 
adherence and retention in care. 
2. To describe engagement in care during and after pregnancy and to explore two known 
barriers to engagement in care that have specific considerations in the context of 
maternal ART: 
a. To examine the occurrence and patterns of self-reported ART side effects 
among women starting first-line EFV-based regimens in pregnancy, and to 
explore the relationship between self-reported ART side effects and missed 
ART doses. 
b. To explore the impact of postpartum transfer out of integrated antenatal and 
ART services on linkage, mobility to access HIV care and retention in care. 
3. To investigate and compare novel measures of ART adherence in a cohort of African 
women: 
10 
 
a. To compare the ability of self-reported adherence using a simple three-item 
scale and drug concentrations of plasma EFV, plasma TFV and tenofovir-
diphosphate (TFV-DP) in dried blood spots (DBS), to predict viral 
suppression. 
b. To explore the use of longitudinal change in self-reported ART adherence to 
predict viremia. 
4. To evaluate the use of routine interlinked electronic health data to measure retention 
in HIV care, specifically: 
a. To examine the impact of using different routine care data sources and 
different retention definitions on i) the estimate of retention in care, ii) the 
consistency of associations between selected covariates and estimated 
retention, and iii) the association between retention and viral load. 
b. To investigate the use of routine interlinked health data to measure linkage to 
care and mobility to access HIV care after transferring out of integrated 
antenatal and ART services. 
1.4 Data sources 
Data for this thesis were drawn from three sources: a prospective cohort study (the maternal 
and child health [MCH]-ART study, ClinicalTrials.gov NCT01933477); an additional cross-
sectional study including women who participated in the MCH-ART study (the long-term 
adherence and care engagement [LACE] study); and routine electronic medical records from 
the Provincial Health Data Centre (PHDC) of the Western Cape Department of Health, 
obtained retrospectively for all women who enrolled in the MCH-ART cohort.  
These data sources provided parallel study and routine health data for the same cohort of 
women as presented in Figure 1-6. Objectives 2, 3 and 4 used data collected during the MCH-
ART study, Objective 3a used data from the LACE study, and Objective 4 used data 
collected during the MCH-ART study combined with parallel routine programme data from 
the PHDC. These data sources and their contributions are described in detail below. 
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Figure 1-6. Time line of data sources include in this thesis: MCH-ART study visits (blue), the LACE study visit (green) and parallel routine 
medical record data (grey); ART – antiretroviral therapy. 
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1.4.1 The MCH-ART study 
Strategies to optimize antiretroviral therapy services for maternal & child health: the MCH-
ART study (HREC REF: 451/2012, appendix 9.1.1) was a multi-phase implementation 
science trial that began in March 2013, at the Gugulethu Midwife Obstetric Unit (MOU) in 
Cape Town, South Africa. The overall aim of the MCH-ART study was to evaluate two 
different strategies for delivering HIV care and treatment services during the postpartum 
period to women living with HIV who initiated ART during pregnancy and their HIV-
exposed infants. 
The study design had three interrelated phases: 
Phase 1: a cross-sectional evaluation of consecutive HIV-infected pregnant women seeking 
ANC at the study clinic (n=1554). 
Phase 2: an observational cohort of all women from Phase 1 who were eligible for initiation 
of ART (n=628), followed in three study measurement visits, from their second antenatal 
clinic visit until their first postpartum clinic visit. ART initiation and management were 
integrated into antenatal follow-up that took place at the Gugulethu MOU according to 
standard provincial protocols.  
Phase 3: a randomised trial of strategies for delivering ART to women during the postpartum 
period (n= up to 471). Women enrolled in Phase 2 who were breastfeeding their infants were 
approached to participate in the trial at the end of the first routine postpartum clinic visit. 
Women were randomised to one of two approaches to providing ART during the postpartum 
period to HIV-infected mothers who are breastfeeding: 
Arm A: referral of women to their nearest general ART services at approximately 4-8 
weeks postpartum (the current standard of care in this setting). 
Arm B: continued receipt of ART in the antenatal clinic, as part of an MCH-focused 
ART service at the Gugulethu MOU that only referred women to general ART 
services after cessation of breastfeeding and once the child’s final HIV status was 
determined. 
The two arms both employed standard provincial protocols for ART services and 
routine child health (with identical medications and routine monitoring); they differed 
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by the length of time women remained in the MCH-focused ART service at the 
Gugulethu MOU before they were referred to general ART clinics. 
All women participating in Phase 3 were followed through 18 months postpartum. The total 
length of participation in the study varied based on gestational age at enrolment into Phase 2, 
ranging from a minimum of approximately 52 weeks to a maximum of approximately 80 
weeks. Study measurement visits were conducted in a separate building on the Gugulethu 
clinic premises, away from routine antenatal, postnatal or ART services. All research 
activities were conducted by separate research staff and routine clinical care was managed as 
usual by the clinic. Measurements included questionnaires and HIV viral loads at each visit, 
as well as abstraction of clinical data on routine antenatal, postnatal and ART services 
received, for both mothers and infants. The study viral loads were batch tested at the end of 
each study phase by the National Health Laboratory Services (NHLS) using the same assays 
as routine care viral loads. Active participant follow-up ended in June 2016 and 87% of 
women enrolled into phase 3 were retained in the study through 12 months postpartum. 
Contribution of these data to the thesis 
Women who enrolled into phase 2 or phase 3 of the MCH-ART study were included in the 
analyses presented in this thesis. A detailed structured questionnaire on patient-perceived 
ART side effects during pregnancy, based on the Division of AIDS adverse event grading 
table [76], was used to examine patterns of side effects reported during pregnancy (Objective 
2a). Self-reported adherence, using a novel three-item scale developed in United States [77], 
was assessed at every study visit and provided the data for the longitudinal analyses of 
reported adherence in Objective 3b. Plasma HIV viral load was also measured at each study 
visit, independent of routine care. These study viral loads allowed ascertainment of viral 
suppression even if women were not retained in routine care and were used to examine the 
association between adherence and viral load for Objective 3, and retention and viral load to 
address Objectives 2b and 4. A limitation of the analyses for Objective 2a is that viral load 
data could not be included as the batched study viral load results were not available at the 
time. 
Important to note is that the impact of the postpartum trial arm was not the focus of this thesis 
and these results have been reported elsewhere [55]. The intervention arm resulted in 
significant improvement in maternal retention and viral suppression at 12 months postpartum. 
Therefore, where appropriate, an indicator of whether a woman was in only phase 2, in phase 
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3 in the standard of care arm, or in phase 3 in the intervention arm, was included in analyses 
to account for design effects.  
1.4.2 The LACE study 
Following completion of the MCH-ART study, further funding was obtained to conduct one 
additional study visit at a later postpartum time point. The primary aim of the study was to 
explore long-term adherence and care engagement and to examine whether there was any 
sustained impact of the MCH-ART intervention at this later time (HREC-REF 866/2016, 
appendix 9.1.2). Women who had enrolled in phase 3 of MCH-ART were recruited into the 
LACE study between 36 and 60 months postpartum; 75% of the original cohort was recruited 
between May 2017 and May 2018. Women who enrolled completed a face-to-face study visit 
equivalent to those in MCH-ART. Venous blood and DBS specimens were collected at the 
study visit to measure plasma HIV viral load, plasma EFV, plasma TFV and DBS TFV-DP 
concentrations.  
Contribution of these data to the thesis 
The drug concentration measures, viral load and self-reported adherence (using the same 
measure used in the MCH-ART study) collected during the LACE study were used to address 
Objective 3a of this thesis. 
1.4.3 Routine health data 
The PHDC is a patient-level interlinked health information exchange within the Western 
Cape Government Department of Health [78,79]. The information exchange combines a 
variety of routine electronic health data platforms from hospitals and primary care clinics 
across the province (Figure 1-7). These platforms include a combination of clinical, clerical 
and administrative data bases such as facility-captured HIV registers [80], birth registers, 
hospital and primary care patient information systems including visits and admissions, 
laboratory test data and electronic pharmacy dispensing data [78]. Deaths recorded in health 
facilities are also included. The Western Cape Province implemented a unique patient 
identifier in the early 2000s which now extends through all hospitals and primary care clinics 
in the province [79]. The PHDC uses the unique identifier, together with other captured 
identifiers, to link patients across facilities, with deduplicating algorithms to identify patients 
with more than one provincial identifier [78,79]. 
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Figure 1-7. A schematic of the Western Cape Provincial Health Data Centre (Courtesy of 
Andrew Boulle) 
In addition to data obtained from the PHDC, the NHLS database, including laboratory testing 
from all public health facilities in South Africa, was searched. Each woman enrolled in phase 
2 of the MCH-ART study was searched for in the databased using the identifiers she had 
provided at study enrolment and HIV-related laboratory test results were abstracted. 
Contribution of these data to the thesis 
Routine HIV care data were requested from the PHDC for all women who had enrolled into 
phase 2 of the MCH-ART study. This provided the routine care data from the time of 
presentation for ANC and ART initiation, through to 30 months on ART. Available data for 
HIV care contacts included ART clinic visits (routinely captured by clerks at each facility 
into the local clerical information systems and electronic registers) [80] and ART pharmacy 
dispensing data from the local pharmacy administrative databases. This provincial data was 
merged with the laboratory test data (CD4 cell counts and HIV viral loads) from the NHLS 
database to ascertain retention in HIV care. In both routine data sources, the source, data and 
place of care access was recorded. Attempt was made to remove acute health care contacts 
and contacts with non-routine services where possible. These data were used to investigate 
the use of interlinked routine data sources to measure retention in HIV care and addressed 
Objective 2b and Objective 4. 
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1.5 Ethics approvals 
The MCH-ART and LACE studies were approved by the University of Cape Town Human 
Research Ethics Committee and the Columbia University Institutional Review Board. Both 
studies only enrolled women aged 18 years and older due to the need for parental consent for 
younger women. All women enrolled in the MCH-ART study provided written informed 
consent which included consent to abstract routine medical records, including linkage to 
electronic databases. Identifying information including the unique provincial patient 
identification number as well as name, surname, date of birth and South African 
identification number if available, were collected during the study for purpose of abstracting 
medical records. Linked data for all available data sources were obtained from the PHDC for 
all women who enrolled in phase 2 of the MCH-ART study. Ethics approval for the analyses 
presented in this thesis was obtained from the University of Cape Town Human Research 
Ethics Committee (HREC-REF 117/2017, appendix 9.1.3). 
1.6 Overview and structure of the thesis 
This thesis consists of an introductory chapter, a literature review, five results chapters, a 
discussion chapter synthesising the findings of the overall thesis and supporting appendices. 
This introduction chapter places the issues of engagement in HIV care, specifically for 
pregnant and postpartum women in SSA, into context and describes the objectives of the 
thesis, which were conceptualised in 2016. 
Chapter 2, the literature review, presents a critical review of the barriers and facilitators 
related to women’s engagement in HIV care during pregnancy, breastfeeding and post-
breastfeeding motherhood, as well as a review of common approaches to measuring 
adherence and retention in care in this population. It is not intended to be an exhaustive 
review but rather to present key aspects of the engagement in HIV care literature pertinent to 
pregnant and postpartum women in SSA and to summarise the main methods of measuring 
ART adherence and retention in HIV care. To note, Part A of this review chapter is adapted 
from a narrative review, first-authored by the candidate, that is currently undergoing peer-
review at Expert Review of Anti-Infective Therapy (submitted 1 September 2018). 
Five results chapters are included. They present results from a cohort of women living with 
HIV who initiated ART during pregnancy in a large integrated ANC and ART clinic in 
Gugulethu, South Africa in 2013-2014. Eighty percent of the cohort started ART under the 
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policy of Option B+, universal ART for all pregnant and breastfeeding women. All results 
chapters are manuscripts that are either published, submitted or being prepared for 
submission (Table 1-1): 
• Objectives 2a and b are explored in Chapter 3 and Chapter 7, respectively. Chapter 3 
used data on self-reported ART side effects and missed ART doses during pregnancy. 
The chapter explores patterns of reported side effects, both system-specific and 
overall, and investigates the association between reported side effects and missed 
ART doses. Chapter 7 used interlinked routine electronic health data for the same 
cohort from ART initiation through 30 months on ART to describe linkage to care, 
mobility for HIV care access, and retention in care after women were transferred out 
of the integrated ANC and ART clinic postpartum. 
• Objective 3a is addressed in Chapter 4 where self-reported adherence, plasma EFV 
and plasma TFV concentrations are compared to TFV-DP in DBS in their ability to 
predict viral suppression in a sub-set of women 3-4 years postpartum. The findings of 
Chapter 4 provide novel data on the use of TFV-DP in DBS to measure adherence 
among African women living with HIV. Chapter 5, which addressed Objective 3b, 
goes on to present a proof of concept for using change in self-reported adherence 
across consecutive visits to improve the value of self-reported adherence to predict 
viral load. 
• Chapters 6 and 7 fulfil Objective 4 and focus on the measurement of maternal 
retention in HIV care using interlinked routine electronic data. The results of Chapter 
6 show how using different data sources and definitions of retention can result in a 
range of different retention estimates and explores the associations of covariates with 
retention estimates as well as associations between retention estimates and viral 
suppression. This is followed by a detailed analysis of the issues around clinic transfer 
of care from integrated ANC and ART services and where women continue their HIV 
care postpartum in Chapter 7. 
The findings of this combined body of work are discussed and synthesised in Chapter 8. A 
summary of the key contributions of this thesis are presented along with recommendations 
for policy and future research. Supplementary material, including a formative publication that 
presents a validation of the self-reported adherence scale used in Chapter 4 and 5, as well as 
supplementary inserts from each results chapter, follows in Chapter 9. 
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Table 1-1. Summary of thesis results chapters (Ch), objectives, manuscripts and data sources  
Chapter and objective Manuscript title and status Data source 
Ch 3 2a: To examine the occurrence and patterns of self-reported 
ART side effects among women starting first-line EFV-based 
regimens in pregnancy, and to explore the relationship between 
self-reported ART side effects and missed ART doses. 
Phillips TK, Cois A, Remien RH, et al. Self-reported side 
effects and adherence to antiretroviral therapy in HIV-
infected pregnant women under option B+: A prospective 
study. PLoS One 2016; 11:e0163079 
MCH-ART 
Ch 4 3a: To compare the ability of self-reported adherence using a 
simple three-item scale and drug concentrations of plasma EFV, 
plasma TFV and TFV-DP in DBS, to predict viral suppression. 
Phillips TK, Sinxadi P, Abrams EJ, et al. A comparison 
of plasma efavirenz and tenofovir, dried blood spot 
tenofovir-diphosphate, and self-reported adherence to 
predict virologic suppression among South African 
women. J Acquir Immune Defic Syndr 
2019;81(3):311-318. 
MCH-ART 
and LACE 
Ch 5 3b: To explore the use of longitudinal change in self-reported 
ART adherence to predict viremia. 
 
Phillips TK, Wilson IB, Brittain K, et al. Decreases in 
self-reported ART adherence predict HIV viremia in a 
longitudinal cohort of pregnant and postpartum women 
in Cape Town, South Africa. J Acquir Immune Defic 
Syndr 2018; 80(3):247-254. 
MCH-ART 
Ch 6 4a: To examine the impact of using different routine care data 
sources and different retention definitions on i) the estimate of 
retention in care, ii) the consistency of associations between 
selected covariates and estimated retention, and iii) the 
association between retention and viral load. 
Phillips TK, Orrell C, Brittain K, et al. Estimating 
retention in antiretroviral therapy services: the impact of 
definitions and data sources in a South African maternal 
cohort. Being prepared for submission 
MCH-ART 
and PHDC 
Ch 7 2b: To explore the impact of postpartum transfer out of 
integrated antenatal and ART services on linkage and retention 
in care. 
4b: To investigate the used of routine interlinked health data to 
measure linkage to care and mobility to access HIV care after 
transferring out of integrated antenatal and ART services 
Phillips TK, Clouse K, Zerbe A, et al. Linkage to care, 
mobility and retention of HIV-positive postpartum women 
in antiretroviral therapy services in South Africa. J Int AIDS 
Soc 2018; 21:e25114 
MCH-ART 
and PHDC 
Ch 9 Appendix supporting objective 3: This validation of the three-
item self-reported adherence scale for use in Xhosa speaking 
populations in South Africa provided the foundation for analyses 
included in this thesis using this measure (Chapters 3 and 4). 
Phillips TK, Brittain K, Mellins CA, et al. A self-
reported adherence measure to screen for elevated HIV 
viral load in pregnant and postpartum women on 
antiretroviral therapy. AIDS Behav 2017; 21:450–461. 
MCH-ART 
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 Literature review 
2.1 Overview 
This literature review consists of the following parts: Part A provides an overview of the 
engagement in HIV care literature specific to pregnant and postpartum women on 
antiretroviral therapy (ART), and Part B is a review of the methods used to measure 
adherence and retention in care in the Option B+ (universal ART for pregnant and 
breastfeeding women) literature. It is not intended to be an exhaustive review, but rather to 
present key aspects of the literature that are pertinent to understanding maternal engagement 
in HIV care.  
PubMed was searched for literature on adherence or retention under Option B+ in sub-
Saharan Africa (SSA). The search was restricted to articles published from January 2011, the 
earliest roll-out of Option B+ in Malawi, and the search was closed on 15 May 2018. The 
search terms used were: (HIV AND (pregnan* OR postpartum OR antenatal OR postnatal 
OR maternal) AND (antiretroviral therapy OR ART OR HAART OR "Option B+") AND 
(adherence OR non-adherence OR compliance OR non-compliance OR "medication taking" 
OR persistence OR retention OR non-retention OR LTFU OR engagement OR 
disengagement OR "loss to follow-up" OR default*)). Overall, the search yielded 595 articles 
of which 70 focused on retention and/or adherence under universal ART for pregnant and 
postpartum women in SSA and were reviewed in detail. Reference lists of identified studies 
were also screened and articles highlighting key aspects of maternal engagement in care were 
selected. Part A presents a framework to consider the engagement in care issues specific to 
pregnant and postpartum women and reviews the evidence on maternal engagement in care as 
well as the associated barriers and facilitators. The methodology used in articles with an 
outcome of adherence or retention in care is reviewed in Part B. Pertinent literature on 
approaches to measuring adherence or retention in adult ART cohorts is also included. 
Note: Part A of this review was adapted into a narrative review article published in the 
journal Expert Review of Anti-infective Therapy (Shifting to the long view: engagement of 
pregnant and postpartum women living with HIV in lifelong antiretroviral therapy services, 
Expert Review of Anti-infective Therapy, 2019; 17(5):349-361). The article was conceived 
of and written by the Candidate, with support from Professor Landon Myer. 
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2.2 Part A: Engagement in ART care during and after pregnancy 
2.2.1 What is unique about pregnant and postpartum women? 
Although engagement in lifelong ART is a concern in all populations living with HIV [1], 
particular concerns have been raised about pregnant and postpartum women. A number of 
studies have shown that pregnant and postpartum women have worse adherence to ART and 
poorer retention in care than men and non-pregnant women [2–5]. For all women, regardless 
of HIV-status, the periods of pregnancy and postpartum are times of change: there is the life 
transition into pregnancy and motherhood, which comes with its unique stressors, and there 
are changes in the structure and location of health services. The primary focus of health 
services is often the immediate health needs of the mother and the health of the baby with 
perhaps less recognition of the multitude of physiological, psychological, social and 
economic changes taking place for a woman during and after pregnancy [6,7].  
One of the central challenges in focusing on engagement in ART services for pregnant and 
postpartum women specifically is the absence of a conceptual framework that positions HIV 
and ART within the context of women’s lives. The Partnership for Maternal, Newborn and 
Child Health presented a framework for connecting care across the continuum of maternal, 
newborn and child health over time and place, moving from pre-pregnancy through childbirth 
and into ongoing maternal and child health [8,9]. Placing this framework in the context of 
maternal HIV and ART, the maternal treatment cycle could be conceptualized as parallel 
periods of life transitions and changes in HIV care as outlined below and depicted in Figure 
2-1. By considering some of the factors impacting women during the unique life stages of 
pregnancy, breastfeeding and post-breastfeeding motherhood, we can identify gaps and 
opportunities to optimize engagement in ART care in the long term. 
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Figure 2-1. The maternal ART cycle, connecting HIV care through pregnancy, breastfeeding 
and post-breastfeeding motherhood. Adapted from The Partnership for Maternal, Newborn 
and Child Health framework [8] and Kerber et al [9]. 
Pregnancy 
Coupled with the many benefits of early presentation for antenatal care (ANC) [10] is the 
need, among women living with HIV, for prompt ART initiation or rapid intervention on 
adherence or ART regimen to ensure virologic suppression by delivery. Many women face 
multiple concomitant barriers during this time. For women diagnosed with HIV during 
pregnancy, Stinson et al described a triple burden of transitioning into pregnancy, accepting 
an HIV diagnosis, and the urgent requirement to start lifelong ART as soon as possible [11]. 
Issues of reproductive healthcare, including contraceptive choices and safer conception 
practices, are beyond the scope of this review but are also critical for prevention of mother-
to-child transmission (PMTCT) and sustained maternal health [12–15]. Unplanned pregnancy 
is an important contributor to mother-to-child transmission (MTCT) and maternal 
engagement in ART care [16,17]. A “double disclosure bind” has been described for women 
dealing with disclosing a new HIV diagnosis and an unintended pregnancy with stigma 
associated with both events [18]. An estimated 44% of pregnancies between 2010 and 2014 
were estimated to be unintended [19] and in African cohorts living with HIV, cross-sectional 
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studies that took place between 2012 and 2016 found that 45-70% of women report 
unplanned pregnancies [20–22].  
During pregnancy, women commonly experience a number of pregnancy-related symptoms. 
Although the side effect profiles of ARV regimens have improved over time, many 
pregnancy-related symptoms, including nausea, fatigue and gastrointestinal disturbances, are 
very similar to the potential side effects of ART [23]. ART side effects are frequently 
reported as barriers to ART adherence and retention [24] and for women newly initiating 
ART in pregnancy it may be difficult to tell whether it is the pregnancy or the new treatment 
that is causing their symptoms.  
Despite these barriers, higher levels of ART adherence and viral suppression have been 
reported during pregnancy compared to postpartum [25–27] and several reasons have been 
suggested for this. Women report being strongly motivated to take ART to secure the health 
of their child [28–33]. Although women are starting lifelong treatment both for the health of 
their child and to optimize their own health, both adherence messaging and a mother’s 
interest during pregnancy may be focused on the health of the baby and preventing 
transmission [4,34]. During pregnancy women are also expected to attend health services 
regularly making it easier for women who have not disclosed their HIV status to explain why 
they are attending a health facility and why they need to take daily medication [31,32]. 
It is also important to consider that pregnancy can provide a unique opportunity to engage 
women in healthcare. The United Nations Children’s Fund reports that 86% of women access 
at least one ANC visit but only half attend the recommended four visits in pregnancy [35]. 
Although barriers to accessing ANC services still exist and are beyond the scope of this 
review, for women who do engage in ANC services there is an important opportunity to 
deliver interventions. These interventions may be HIV specific, including ART initiation or 
re-engaging women in HIV care, or they may address other concerns such as preparedness 
for ART and lifelong care, depression, substance use, partner violence or chronic conditions 
that can hinder HIV care and general maternal health in the short and long term [36–38]. 
Breastfeeding 
With the success of antenatal ART, an increasing proportion of HIV transmission from 
mother to child is now attributable to the postpartum period through breastfeeding [39]. With 
the use of lifelong ART, the risk of transmission through breastfeeding is very low and if a 
woman is virologically suppressed the risk of breastfeeding is far outweighed by the 
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overwhelming health benefits outside of the context of HIV [39]. Breastfeeding prevents 
infectious morbidity and improves short- and long-term child development and health 
outcomes which is particularly pertinent in low-resource settings where malnutrition, 
diarrhoea and pneumonia are common causes of childhood mortality [40]. The World Health 
Organisation (WHO) now recommends breastfeeding for up to 24 months postpartum 
regardless of HIV status in low-income settings [40]. Breastfeeding is also being considered 
as an option for women living with HIV in high-income countries where formula feeding is 
the norm [41].  
During this early postpartum period a mother is adjusting to her new baby, perhaps still 
coming to terms with her HIV status, and starting to return to her usual life. Psaros et al 
described a combined burden on women to adhere to infant feeding recommendations, to 
administer antiretroviral prophylaxis to their infant as prescribed, and to remain adherent to 
their own treatment [42]. The duration of breastfeeding will vary depending on local feeding 
preferences and guidelines, cultural norms and other factors such as employment [43]. If the 
risk of HIV transmission through breastfeeding is understood by a mother, motivation to 
remain engaged in HIV care to protect the health of the child may be similar to that during 
pregnancy, but a sense of relief if the child is healthy and tests negative after delivery may be 
a barrier to continued ART [32,44].  
The breastfeeding period is a time when women are still required to attend the clinic regularly 
for routine child care. Integrated maternal and child care provides an opportunity for a single 
visit for mother and child with continued counselling on MTCT and maternal ART, as well as 
reproductive health. Integrated postpartum services provide routine child health care 
alongside maternal services, perform early infant diagnosis and either provide care or 
appropriate referral for infants infected with HIV. Some countries provide integrated 
maternal and child care through 12 or 24 months postpartum, the WHO recommended 
breastfeeding duration, but not all do. Postpartum women may be required to transfer their 
ART care to an adult ART clinic, or a new provider in the same clinic, removed from the 
focused mother and child care received during pregnancy [45,46]. The impact that 
transferring care may have on engagement in maternal ART services, adherence to infant 
prophylaxis and to infant feeding practices is not yet well understood, yet it is likely that 
difficulty juggling multiple visits and fear of being recognised at the clinic with inadvertent 
HIV status disclosure may prevent some women from continuing their ART care after 
delivery [30,44].  
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Post-breastfeeding motherhood 
To date, almost all research and health programmes for pregnant and postpartum women 
living with HIV have been focused heavily on the periods of pregnancy and breastfeeding, 
with relatively little attention given to the ongoing care of mothers after the risk for MTCT 
has ended. This short-term view has in some regards undermined the goals of HIV 
programmes with many women disengaging from care after delivery or cessation of 
breastfeeding [42,47]. Transitioning out of the unique periods of pregnancy and breastfeeding 
and back into regular life presents a new set of challenges that will differ for each woman. 
Without the risk of MTCT there is a shift of focus from the short-term priority of PMTCT to 
a woman’s own long-term health. Even after the direct risk of transmission is removed, 
frequently women report that their motivation to stay on ART is to stay healthy for their 
children [29,48] and some women report feelings of hope for the future that ART can provide 
them [33]. 
The period following weaning involves a return to many usual life activities and their 
associated stressors. Studies have reported that women feel overwhelmed in this period and 
are often too busy with other things to continue their treatment [28,31,32]. Without the 
regular need to attend the clinic as they had to during pregnancy and early postpartum, 
women report finding it more difficult to continue ART and avoid disclosure of their HIV 
status to partners, family, friends and employers [32,33]. In some settings it is also not 
uncommon for a child to be left in the care of family or friends but the implications of this for 
maternal and child care engagement have not been described [49]. As mentioned above, 
transfer to adult ART services after delivery is usually inevitable, even if it is just to a new 
nurse or venue in the same facility [45,50–52], and this may present an additional barrier to 
engagement in care.  
Postpartum women also need to access additional services, such as continued reproductive 
health care and child health services. Continued parallel engagement in reproductive health 
services, including contraceptives when women do not desire a pregnancy, and counselling 
on safer conception when they do, is an equally important consideration for both PMTCT, 
maternal health and sexual transmission risk [13,15]. Again, integrated services may reduce 
the need to attend multiple appointments at different clinics and offer an opportunity to 
continually promote engagement in care [14]. Even in the absence of integration, these 
additional routine health services could be leveraged to identify and re-engage women who 
have disengaged from care. 
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Women may cycle in and out of the pregnancy, breastfeeding and post-breastfeeding periods 
and parallel HIV services over their reproductive years, particularly in regions with high 
fertility. Others may enter general adult ART care post-breastfeeding and not have a repeat 
pregnancy. Even in the latter case, there are likely to be further life transitions and movement 
between ART facilities over time due to mobility or preference [53]. In order to optimize 
maternal health, reduce sexual transmission and prevent perinatal and postnatal transmission 
of HIV in both the incident and all subsequent pregnancies, it is critical to focus on the long 
view of sustained engagement of pregnant and postpartum women in lifelong ART services. 
2.2.2 What do we know about maternal engagement in HIV care in sub-Saharan Africa? 
How often do women disengage? 
The scale-up of universal ART for all people living with HIV has raised concerns about long-
term engagement in routine ART care among pregnant or breastfeeding women. Most studies 
to date have focused on the short view, reporting outcomes up to 12 months on ART, but 
reports of retention in routine ART programmes three to four years following ART initiation 
in pregnancy are starting to emerge [54,55]. Estimates of maternal retention in routine ART 
care after 12 months on ART range from 58% in Rwanda [56] to over 90% in Uganda [55,57] 
and a recent meta-analysis reported a pooled retention estimate of 76% at 12 months [47]. 
This is slightly lower that the average retention estimated among adults at 12 months after 
ART start in Africa (81%), prior to the role out of universal ART [58]. In Malawi, 70% of 
women were estimated to be engaged in care three years following ART initiation in 
pregnancy or breastfeeding [54]. The authors highlight that this is above the roughly 50% 
norm for engagement in care for other chronic conditions, but it is still well below the 
UNAIDS targets of 90% of people living with HIV being on treatment [48]. Important to note 
is that the measures and definitions of retention in all these studies vary widely making direct 
comparisons difficult. 
ART adherence under Option B+ also varied across studies. Studies that reported on 
adherence during pregnancy found high levels of adherence using pill counts [59] and self-
report [60–62]. A South Africa study that measured the presence of ARVs in dried blood 
spots (DBS) found 74% of women had at least two detectable ARVs at 32 weeks gestation 
[63]. Similarly, using pharmacy refill measures, 73% of women in a study in Malawi had 
≥90% drug coverage during pregnancy [27]. This dropped to 66% in the first three months 
postpartum but increased again to 75% from 4-21 months postpartum; around 70% of women 
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had ≥90% drug coverage through two years on ART but only 30% were adherent at each visit 
in that time. Another study in Zimbabwe, also using pharmacy refill, found that only 39% of 
women had ≥95% drug coverage through to one year on ART and they observed a steady 
decline in adherence over time [64]. Looking at only postpartum women in Uganda, Decker 
et al found that only half of women were adequately adherent from six weeks to six months 
postpartum using a combination of pharmacy refill and self-report; no woman in the study 
was fully adherent through 18 months postpartum [65]. 
When do women disengage? 
There is overwhelming consistency in the finding that women starting ART during pregnancy 
more frequently exit care soon after ART initiation with decreasing proportions of women 
lost from care at later time points [4,66–70]. This loss has been observed either immediately 
after ART initiation with no return for further follow-up, or within the first year on ART, 
often shortly after delivery or following cessation of breastfeeding [31,66,69,70]. There are 
various possible explanations for the timing of loss from care. Some studies have suggested 
that rapid ART initiation following HIV diagnosis in pregnancy could result in patients being 
overwhelmed and underprepared and more likely not to return for any follow-up after ART 
initiation [52,70–74]. Two studies looking specifically at ART initiation on the same day of 
HIV diagnosis in pregnancy have reported mixed results [67,75] and a systematic review, not 
limited to pregnant women, found no adverse impact of rapid ART initiation [76]. Some 
women have reported that having a full appreciation of the benefits of ART and feeling the 
improvement in their health has helped them to stay adherent and in care while others report 
lack of understanding of HIV as a reason for stopping ART [48,77]. A change in motivation 
to continue ART after delivery or weaning is also a possible contributor to postpartum 
disengagement [28,31,32]. These findings link to the life transitions described above yet it is 
increasingly recognized that the factors associated with disengagement from ART care are 
often complex and interrelated. One recent study from eSwatini described discontinuing ART 
as “an inextricably interwoven chain of events” including numerous individual, social and 
structural barriers [78]. 
The dynamic nature of long-term engagement in care 
It is well documented that engagement in HIV care is not static and yet our care cascades are 
often presented as such. Engagement in care has been described as a spectrum along which 
patients may move throughout their time on treatment [79]. Nsanzimana et al used the term 
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“churning” to describe patients engaging, disengaging and re-engaging in HIV care [80], 
Powers et al presented a framework of “HIV states and transitions” to better capture the 
dynamic pathways in and out of HIV services [81], while a very recent publication called for 
thinking “beyond binary retention in HIV care” and described the dynamic processes of 
moving in and out of care in adult patients living with HIV in the United States [82]. This 
aligns with thinking on medication taking behaviours which are also dynamic, as changing 
adherence patterns have also been well documented among both people living with HIV and 
those with other chronic conditions [83–85]. 
Changes in engagement in care have the potential to impact on individual health outcomes as 
well population health, particularly for the treatment of a chronic infectious disease such as 
HIV [86,87]. Little is known about the long-term patterns of engagement in HIV care among 
women who initiate lifelong ART during their reproductive years or what the predictors of re-
engagement in care are. In adult ART cohorts, poor treatment by health providers, poverty, 
stigma and treatment fatigue have been identified as barriers to re-engagement in HIV care 
[88,89]. Acute illness or a repeat pregnancy may bring women back into care but 
opportunities to re-engage women before these events may exist. Women who disengage 
from HIV care may be accessing other non-HIV services such as reproductive health or care 
for other chronic conditions; many women will also be accessing routine child health services 
with their children. Finding interventions that can maximize periods of engagement and 
leverage opportunities to identify and re-engage those who do disengage will be critical 
approaches [90]. 
2.2.3 What influences engagement in lifelong ART in pregnant and postpartum women? 
The WHO considers five dimensions of adherence (Figure 2-2) that can help to conceptualise 
the numerous factors at play [91]. The factors influencing engagement in care are highly 
interconnected and do not fit neatly into these boxes, but this framework will be used here to 
structure the discussion on the various influences on engagement in HIV care for pregnant 
and postpartum women. 
36 
 
 
 
 
Figure 2-2 Five dimensions of 
adherence from the 2003 World Health 
Organization Adherence to long-term 
therapies: evidence for action [91]. 
 
 
 
Condition- and therapy-related factors 
Some barriers to engagement in HIV care stem directly from the HIV diagnosis, the condition 
itself or the treatment. Individuals who present to care at a more advanced disease stage will 
be experiencing condition-related factors including physical symptoms and opportunistic 
infections that may make them vulnerable to disengagement from care [24,69,92]. Over the 
past decade there has been a major decline in the proportion of individuals initiating ART at 
an advanced disease stage with around 27% of people living with HIV in South Africa 
starting ART with CD4 cell counts <50 cells/µL [93]. This proportion is higher in men than 
women and is likely to be lower among women starting ART in pregnancy who are generally 
healthier and perhaps more likely to access care early through antenatal services [93,94]. 
Most women are now initiating ART before they experience any symptoms of HIV infection 
yet feeling well and not feeling a need for treatment has also been reported as a barrier to 
remaining engaged in ART services [29,32,34].  
Therapy-related side effects are also frequently reported as barriers to treatment adherence 
and non-retention [34,47,95,96]. In qualitative studies among women starting ART in 
pregnancy, both fear of and the experience of side effects have been cited by women as 
reasons for disengaging from care [29,60,77]. Efavirenz, currently recommended for first-line 
regimens, has elicited particular concerns around neuropsychiatric or central nervous system 
(CNS) side effects including dizziness, insomnia, unusual dreams as well as depression and 
suicidality [97,98]. In 2018, dolutegravir was recommended as an alternative for first-line 
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regimens as it has superior efficacy and tolerance to most other regimens [99]. However, 
concerns still remain about the safety of dolutegravir in early pregnancy and efavirenz is still 
recommended for women planning to conceive and women in the first eight weeks of 
pregnancy [100,101]. To date, most of the literature on ART side effects and adherence has 
focused on clinician reported adverse events, mainly from clinical trials [102–104]. It is 
known that perceived side effects may differ from clinician-reported side effects and can 
influence adherence [95,105–107], yet this has not been quantitatively investigated among 
pregnant women. 
The impact of both condition-related and therapy-related factors is likely to be dependent on 
the individual’s perceptions about the disease and the treatment [91,108]. Pregnant women 
are unlikely to be able to separate out what symptoms are a result of their pregnancy, the HIV 
infection or the ARVs [108]. As such their response to remain in care or to disengage will be 
informed by their understanding of the disease, treatment and their health status. This is 
captured by the 2003 WHO report on Adherence to Long-Term Therapies that states “Unique 
characteristics of diseases and/or therapies do not outweigh the common factors affecting 
adherence, but rather modify their influence” [91]. Being pregnant or postpartum could 
modify the patient experience of condition- and therapy-related factors and may influence 
whether women remain in care despite these challenges. 
Patient-related factors 
Age is a basic consideration in thinking about health behaviours and their determinants, and 
young people encounter unique challenges when engaging in chronic healthcare [109]. 
Adolescents and young adults living with HIV have been found to have worse HIV treatment 
outcomes than adults [110–113]. Similarly, in the context of pregnancy and postpartum 
specifically, adolescents and young women have been found to be at higher risk of loss to 
follow-up (LTFU), poor ART adherence and MTCT [47,70,77,114,115]. Late presentation 
for ANC, which has been linked to younger age and could be a marker of general health 
seeking behaviours, is also associated with poor engagement in HIV care and increased risk 
of MTCT [64,68,116,117]. Overall trust in the health system and health providers can also 
influence engagement in HIV care and other health services [118,119]. This was highlighted 
in a recent study investigating maternal priorities for HIV care that found that trust in 
providers was the most highly prioritized factor both during and after pregnancy [120]. 
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Psychosocial concerns, including depression and alcohol or substance use, are prevalent 
among women living with HIV and known to be associated with poor adherence and 
retention [83,121,122]. Adverse events experienced during childhood are also prevalent 
among people living with HIV and can have a long-lasting impact on mental health and a 
woman’s ability to cope with a lifelong illness [123]. Current stressful life events - food and 
housing security, partner violence, crime, death of family or friends, loss of employment, 
migration and travel - can result in disruption of treatment [77,124–128].  
Social and economic factors 
There is also an intersection between patient-related and social factors. Lack of support from 
partners, family and the community is commonly cited as a barrier to engagement in HIV 
care in the literature [24,33,34,129]. Stigma, both perceived and experienced, can prevent 
women from disclosing their HIV status [34,130]. Disclosure can open the door to better 
support, but many women may fear violence, shunning or loss of social support if their HIV 
status is disclosed [66,74,131,132]. In many settings women are reliant on approval or 
financial support from their partner or family in order to attend health services [131,133]. 
Without the cover of frequent ANC or routine child health visits, women who have not 
disclosed or fear inadvertent disclosure may find it difficult to continue to remain engaged in 
ART care as their child gets older [28]. Stigma remains a significant barrier to long-term 
engagement in ART care despite the global focus on its eradication. Turan et al have 
presented a framework highlighting the mechanisms through which different dimensions of 
stigma may affect engagement in HIV care and health outcomes [134]. They stress the need 
for stigma interventions that are focused on specific mechanisms and that target the 
community level in order to influence stigmatization mechanisms [134]. For pregnant and 
postpartum women, strategies that build social support and safe disclosure, such as partner 
and family involvement in HIV testing and treatment as well as community-level 
engagement, will be needed to promote a supportive environment for lifelong maternal ART 
[130,134–137]. 
Women living in poverty and living with HIV may experience many of these factors more 
frequently and often simultaneously with negative impacts on engagement in HIV care [138–
140]. There is growing recognition that these risk factors can act in a syndemic nature, 
increasing the disease burden through their interactions [141,142]. Combination interventions 
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addressing these intersecting risk factors will be needed to promote long-term engagement in 
ART services.  
Health system factors 
Along with transitioning through the life stages of pregnancy and breastfeeding, the health 
system often also requires pregnant and postpartum women to transfer their health care. We 
know from the paediatric HIV literature that transitioning from paediatric to adult ART care 
can be a vulnerable time [143]. Similarly, transferring from maternal and child focused 
antenatal or postpartum care into general adult ART services can be a point of disengagement 
[46,144]. The structure of the health system, in parallel to life transitions, is also likely to 
impact the most vulnerable times for disengagement, although this aspect is frequently not 
well described in the literature.  
Integration of antenatal and ART care, compared to referring pregnant women to separate 
adult ART services, dramatically improves the uptake of ART during pregnancy and is the 
standard of care in many countries [144–148]. In some countries, integrated care for mothers 
and their children is continued postpartum and this approach has been shown to improve 
postpartum retention [149–151]. However, even with integrated antenatal, ART and child 
health services, many ANC clinics are not designed to keep adults in care indefinitely and 
there is often a need to transfer to general adult ART clinics at some time postpartum. The 
timing of this transfer is not consistent in different countries and regions: in South Africa 
women are often transferred to general adult ART care at 6-10 weeks postpartum [46]; in 
Malawi it ranges from 6 weeks to 12 months [45,77]; in Zimbabwe and Mozambique, women 
and children remain in integrated services for up to two years postpartum [51]. In other 
settings, all services (including antenatal and postnatal care, routine child health services and 
lifelong ART) are provided in one facility and there is no need to transfer location, but 
women may move to a different part of the same clinic [66,152]. Some studies of postpartum 
engagement in ART care mention the need to transfer postpartum but do not specify the 
timing while others do not describe where care is routinely received after delivery. The 
impact of transferring ART care postpartum is not yet well understood but, similar to referral 
to initiate ART during pregnancy or to the adolescent transition from paediatric to adult care, 
the transfer step may be a vulnerable point for disengagement [46,143].  
Other structural barriers such as transport costs, payment for services, long waiting times and 
poor patient-provider relationships also remain barriers to continued engagement in care in 
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many settings [24,34]. With the routinising of ART services globally and rapidly increasing 
access to treatment for all, people living with HIV will have more choices about where and 
how they access ART. The choice of health facility will be influenced by a combination of 
individual, societal and health systems factors. In some settings people must travel long 
distances to access ART services while in many urban settings there are multiple clinics 
offering ART services in one area. A study in South Africa showed how postpartum women 
who were thought to be lost from care had actually moved between multiple different clinics, 
even over a relatively short follow-up time [53]. A study in adults on ART highlighted that 
HIV disclosure, individual agency over their ART care and flexibility of ART providers in 
times of transition were key to ensuring continuity of lifelong ART [153]. Overall, 
interventions, health systems and healthcare providers must be able to adapt to support 
continued engagement in care through required and preferred health care transfers and 
through the life transitions of pregnancy, breastfeeding and beyond. 
2.3 Part B: Measurement of ART adherence and retention in Option B+ cohorts in 
sub-Saharan Africa  
In both research and routine care, ART adherence and retention in care are measured for a 
variety of reasons including: i) to monitor and intervene in patient care, ii) for programme 
monitoring, and iii) to measure outcomes and compare interventions in research. To date 
there is no standard method for measuring any component of these definitions, either in 
research or in routine programmes. As noted in Part A above, there is substantial variation in 
the methods used to measure adherence and retention. Here, the commonly used methods and 
considerations for measuring ART adherence and retention in care, with particular focus on 
Option B+ cohorts in SSA, are described. 
2.3.1 Adherence measures 
There is no single measure which encompasses all the components of medication adherence 
and there is no gold standard measure of adherence [154,155]. Each measure has drawbacks, 
and all are only estimates rather than direct measures of an individual’s medication taking 
practices [140,156–159]. Measures of treatment implementation, the extent to which a 
patient’s actual dosing corresponds to the prescribed dosing regimen and the adherence 
construct focused on in this thesis can be broadly divided into objective and subjective 
measures. The evidence for and use of each measure is discussed below. 
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Objective measures 
Directly observed therapy (DOT) involves supervised medication taking. Predominantly used 
as an adherence support method, DOT provides a direct measure of the exact dose and timing 
of dose taken. DOT is frequently used for tuberculosis treatment and has also been used for 
HIV [160]. One study under Option B+ that investigated a community-based DOT 
intervention, combined with short-text messaging service (SMS) support, to improve 
adherence found that women were willing to nominate a friend or family member to be their 
DOT supporter, but concerns were raised about time constraints and logistics [161] . 
Although this is an objective measure of adherence, it is impractical given the volumes of 
patients on ART and the resources required to implement DOT. Randomised trials in both 
high- and low- resource settings have found little evidence that DOT improves adherence or 
biological markers and DOT is not currently recommended to measure ART adherence 
[85,140].  
Drug concentrations in biological samples provide the closest measure of actual drug 
exposure in the body. They are frequently used to measure adherence in clinical trials, but 
they are expensive and require complex laboratory assays [162]. Drug concentrations usually 
only provide information on adherence in the short term, limited to the half-life of the ARV 
being measured. Measures of tenofovir-diphosphate (TFV-DP) in DBS have been 
successfully used to measure adherence to pre-exposure prophylaxis (PrEP) [162] but only 
two published studies have assessed TFV-DP in DBS as an adherence measure among people 
living with HIV [163,164]. Antiretroviral pharmacokinetics are known to vary by gender and 
ethnicity. In particular, data from the US has shown differences in therapeutic thresholds of 
TFV-DP in DBS among males and females [165] and among Black compared to White or 
Hispanic individuals [163]. However, there are no published studies on TFV-DP in DBS to 
measure adherence in African women living with HIV. TFV-DP in DBS provides 
information on ARV intake over the past 17 days [165], a major advantage in comparison to 
plasma efavirenz (EFV) and tenofovir (TFV) assays that are informative about drug intake in 
the past 4-5 days [166,167], but these methods have not been compared head-to-head. DBS 
specimens have the advantage of being easy to collect but TFV-DP assays in DBS are 
complex and expensive to run [162]. The use of hair to measure drug concentrations has also 
been successfully used and shows a strong correlation with HIV viral load. Hair may be 
easier to collect than other samples and is relatively easy to store and transport [168]. 
Although adherence thresholds are currently only established for TFV, hair can be used for 
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many antiretrovirals [162]. Hair samples still have the limitation of requiring laboratory 
testing and there may be individual and cultural concerns about hair sampling [169]. Using 
drug concentrations with short half-lives to measure adherence has raised concern about 
“white coat adherence” which occurs when people take their ARVs as prescribed only just 
before a clinic appointment [162,170]. Due to the cost and complexity, drug concentrations 
are not routinely recommended for adherence monitoring but are frequently used in research 
[85,140,164,171,172]. 
Pill counts by clinic staff are widely used to assess adherence in routine care settings, 
however there is conflicting evidence on the association between pill counts and treatment 
outcomes [140,173,174]. Three Option B+ studies used pill counts to measure adherence, but 
none correlated pill count to another adherence measure or clinical outcome [59,175,176]. 
Pill counts are time intensive and may be subject to manipulation by patients due to social 
desirability [140,159,177,178]. 
Pharmacy refill data are recommended for adherence monitoring in settings where patients 
must collect treatment from a pharmacy. Pharmacy refill does not measure medication taking 
behaviour but is a useful proxy under the assumption that if a patient has not been dispensed 
ARVs they cannot be taking their treatment as prescribed or at all. This is not true if patients 
are able to access treatment through another facility or avenue, making this most useful in 
interlinked systems where any dispensing of drug within the system would be known. 
Pharmacy refill data has been found to be a valid adherence measure [140,172,178–180] and 
is a frequently used measure in the Option B+ literature, usually using medication possession 
ratios or the proportion of time with drug in hand [27,64,181]. 
Electronic drug monitoring (EDM) devices have consistently been associated with treatment 
outcomes and provide a good measure of adherence. If the device is not used correctly it may 
underestimate adherence and it is also possible for the patient to manipulate the results by 
opening and closing the device but not necessarily taking the treatment. EDM devices are 
expensive and may be a burden to patients so use has mostly been limited to research settings 
[140,172,173,178]. No published articles using EDM in the context of Option B+ were 
located but EDM devices, such as the Wisepill, are being used in ongoing research in South 
Africa and Uganda both to measure adherence and to prompt real-time intervention among 
pregnant and postpartum women [182]. 
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Subjective measures 
Self-reported adherence measures are widely used in research and routine care and reported 
adherence has been recommended for use in routine ART services [140,159,183,184]. Self-
reported adherence has generally been found to have reasonable predictive value in relation 
to EDM devices and viral load [157,158]. There are numerous different tools to measure self-
reported adherence and although a lot of work has been done towards optimizing the response 
options and recall period, there is still substantial variability in self-reported adherence 
measures in use [184]. Self-report of ART doses taken or missed over a recall period ranging 
from 3-30 days is commonly used. Multi-item scales and visual analogue tools are also 
widely used to assess adherence. In the Option B+ literature, studies using self-reported 
adherence mostly reported on missed ART doses with recall periods ranging from three to 30 
days [62,65,185]. Others used combinations of self-reported adherence questions [60,185]. 
No single measure stood out as most frequently used. Despite frequent use, self-reported 
adherence measures can be subject to recall and social desirability bias and may result in 
overestimation of medication taking [178,183]. Results are often positively skewed towards 
good adherence (known as the “ceiling effect”) which increases the risk of patient 
misclassification and makes it difficult to measure meaningful differences in adherence 
[178,186]. 
2.3.2 Retention measures 
Various measures and definitions of retention in ART care have been described in the 
literature and it has been demonstrated in adult ART cohorts that changes in definitions and 
measurement strategies can substantially alter estimates of retention in HIV care [187–191]. 
Two studies have evaluated the ability of different retention measures to predict viral load 
and have found that all measures correlate with having a suppressed viral load, with similar 
moderate predictive ability across measures [190,192]. Some authors have stressed that there 
is no gold standard measure or standard definition of retention and LTFU and that the 
measurement of retention should be tailored to the local context [189,190]. Yet, given the 
wide variation in measures and difficulties comparing outcomes within and between cohorts, 
other authors have advocated for a universal approach to measuring retention, particularly for 
monitoring and comparing ART programme outcomes [187,188]. 
There is little literature specifically interrogating retention measures and definitions in 
pregnant and postpartum women. Rollins et al noted that women initiating ART under Option 
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B+ guidelines should be monitored in the same way as other adult ART patients following 
final ascertainment of vertical transmission as well as adherence and retention in care at the 
time of breastfeeding cessation [193]. However, during pregnancy and breastfeeding slightly 
different measurement intervals and strategies may be required. In the same paper they 
offered some guidance in approaching retention measurement and analysis, highlighting the 
need for measures of retention over time to assess continuity of care. In another paper 
discussing the INSPIRE network studies [194], all of which evaluated interventions to 
improve maternal retention in care, Rollins and colleagues discuss the difficulty in making 
comparisons across the six studies due to the heterogeneity in retention definitions adopted. 
They suggested a move towards standard definitions and approaches to measuring retention. 
Through the review of literature on retention under Option B+ in SSA, a wide variety of 
definitions and approaches to measuring retention were observed and the key methodological 
aspects of each study are displayed in Table 2-1. Retention measures differed in three main 
domains: i) the source of data, ii) the reference or follow-up period, iii) the retention 
definition. 
Data source 
The vast majority of studies estimating retention in the adult ART literature use facility-based 
data sources, either paper records and registers or electronic patient records [195]. In this 
review of the Option B+ literature, two thirds of studies used facility-specific data sources to 
estimate retention. An additional seven studies used facility-specific data but with active 
attempts to trace patients who were considered lost from care. Patients who were transferred 
out were usually excluded or censored at the time of transfer although one study assumed that 
transferred patients were retained in care [51]. This approach can result in either over or 
underestimating retention as patients who are formally transferred do not always link to care 
and patients who are considered lost are often in care elsewhere [46,53,196]. As discussed in 
part A above, mobility and transfer of ART care are key considerations in measures of 
engagement in all ART cohorts, but quite uniquely among pregnant and postpartum women. 
Transfer from ANC to ART services is often required, either at the time of presentation for 
ANC if services are separated, or at some time postpartum if ART services are integrated into 
ANC [45,46]. This makes it important to consider retention beyond just the facility of ART 
initiation. 
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The WHO recommends interlinked patient monitoring systems to “link a single patient across 
his or her records (patient cards or registers) through identifying data elements such as name, 
date of birth, sex or unique ID to ensure de-duplication of record-keeping and continuity of 
care across service delivery points (both programme and facility) and time” [197]. Currently 
these data systems are rarely available. Only two studies appeared to use interlinked data 
sources to estimate retention across clinics in a region, both were conducted in South Africa 
[53,150]. 
Follow-up period 
The follow-up period considered in the articles reviewed ranged from six months to over 
three years on ART. Some studies measured time from ART start while others measured time 
from delivery. Counting studies through one year postpartum as more than one year on ART, 
ten studies reported on outcomes beyond one year on ART; only three studies reported 
outcomes beyond two years on ART. This is in part due to the recency of the Option B+ roll 
out with longer term outcomes available from countries such as Malawi, where Option B+ 
was first implemented [27,54]. 
Retention definitions 
The retention definitions used in the Option B+ literature, and in the adult ART literature, can 
be broadly grouped into cross sectional, longitudinal and gap in care definitions (Table 2-1) 
[191]. Cross-sectional definitions estimate retention at a single instant or window of time. 
These definitions do not consider care access prior to the timepoint of interest. Longitudinal 
definitions use estimates in multiple windows of time to measure consistent retention over a 
longer time period. This is often an accumulation of cross-sectional estimates of retention or 
visit constancy. Lastly, gaps in care are often used to estimate retention. These could be gaps 
in time with no visits or a gap in time after the last scheduled visit (time with no ARVs in 
hand). Gap in care definitions are usually analysed as time to first gap in care using time-to-
event methods.  
Even within definitions there is variation in the length of windows of time, thresholds for loss 
and how definitions are used in analyses. For gap in care definitions, Grimsrud et al found 
different ways of implementing the definition in analyses, for example which date was 
assigned to being lost, could result in substantial variation of estimates [187]. Some studies 
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use combinations of definitions to try to capture both retention at a particular instant as well 
as sustained retention or adherence to scheduled visits over time [117,198,199]. 
2.3.3 Viral load 
Viral load, the most common biomarker of HIV treatment success, is frequently used as a 
proxy marker of treatment adherence and retention. Although viral load can be influenced by 
other factors including resistance, comorbidities and adverse effects, adherence to ART is a 
major driver of viral load [200]. Viral load monitoring for detection of treatment failure and 
as an adherence monitoring tool is strongly advocated for by the WHO and is being scaled up 
globally [201–204]. Despite the advocacy for increased viral load monitoring, particularly 
during pregnancy and breastfeeding, viral load measures remain infrequent in many low- and 
middle-income countries [202,203]. Some studies do report on viral load in conjunction with 
adherence and retention measures [61,150], but viral load measures are often not available. 
2.4 Summary 
These multiple potential domains of variation make it very difficult to compare results, either 
in a single programme over time, across ART programmes or when comparing interventions 
or research studies [187,190,194]. Which measures of engagement are optimal likely depend 
on the purpose and the availability of different data sources. Review of paper or electronic 
medical records is frequently used but these are often not linked across facilities. Laboratory 
databases may be more likely to be centralised but without unique patient identifiers may not 
be interlinked across facilities. Laboratory results can also provide some indication of a 
patient’s health status, but they only provide high-level evidence that a patient has touched 
the health care system. Although studies have compared retention outcomes using different 
definitions, few have focused on the impact of different data sources and most studies do not 
used interlinked data to account for outcomes beyond the facility of interest. 
2.4.1 Summary and gaps in the literature 
Poor engagement in care after ART initiation in pregnancy is a major concern and 
considerable methodological challenges exist in the measurement of both ART adherence and 
retention in care. Numerous gaps exist in our understanding of the predictors and appropriate 
measures of maternal engagement in care, all of which hamper efforts to monitor ART 
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programmes as well as to design, evaluate and implement acceptable and effective 
interventions to improve patient care. Four specific gaps will be addressed in this thesis. 
What is the impact of patient-reported ART side effects on ART adherence during pregnancy? 
Although ART side effects are frequently reported in both the quantitative and qualitative 
literature as a reason for poor ART adherence, no quantitative analyses exist on system-
specific or overall patterns of patient-perceived ART side effects following ART initiation in 
pregnancy and their associations with ART adherence. 
How do plasma and dried blood spot antiretroviral concentrations compare to self-reported 
adherence to predict viral suppression among African women? 
Although there is a push towards more frequent viral load monitoring to ensure prompt 
intervention when needed, some countries only implement viral load testing every 1-2 years. 
No gold standard measure of adherence exists but interim adherence measures, in conjunction 
with viral load monitoring, are needed. Measuring ARV concentrations is the most direct way 
of measuring ARV exposure and thus adherence to ART, but no data exist on the use of DBS 
TFV-DP assays to measure adherence to ART in African women. Nor do data exist 
comparing the relatively less expensive plasma EFV and TFV assays to TFV-DP in DBS and 
even more simple and less expensive self-reported adherence.  
What is the potential of longitudinal self-reported adherence measures? 
Self-report adherence is known to be subject to bias and other more objective measures are 
recommended, but self-reported adherence is still widely used in research and routine care 
settings. Most studies have assessed cross-sectional self-reported adherence. Longitudinal 
methods have the potential to overcome some of the weaknesses of self-reported adherence 
data, yet they remain relatively unexplored. 
How can interlinked data sources be used to improve the measurement of retention in care? 
Measuring retention in HIV care is a key component of monitoring HIV programmes, 
informing clinical care and measuring outcomes in research. As with adherence, no gold 
standard measure of retention in care exists. Despite the recommendation by the WHO and 
known issues of transfer and mobility, few studies use interlinked data sources to assess 
retention beyond the facility of ART initiation. Postpartum transfer of ART care is often 
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required for women who start ART in pregnancy yet there are no data characterising linkage 
to care and mobility for HIV care from ART initiation in pregnancy through the transfer into 
general ART care. 
Summary 
A lot of work is being done to develop and evaluate interventions to support maternal 
engagement in HIV care, yet the evidence is largely weak, and methods are highly variable 
making comparisons difficult. By contributing to these gaps in the literature, the work of this 
thesis will improve our understanding of the issues influencing engagement in HIV care 
during and after pregnancy and will inform robust measures to evaluate engagement in care. 
The ultimate aim of this work is to inform the development, evaluation and implementation 
of interventions to improve long-term engagement in HIV care among pregnant and 
postpartum women.
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Table 2-1. Summary of retention time reference periods, data sources and definitions used in the Option B+ literature 
Author, year [ref] 
Trial name if 
applicable 
Country Study design Reference period Source of 
retention data 
Facility-specific/ 
interlinked 
Retention outcome definition 
Cross-sectional 
Clouse, 2017 [53] South Africa Observational 
cohort 
Up to 3.5 years on 
ART 
National laboratory 
database 
Interlinked For evidence of engagement: At 
least one CD4 or viral load or a 
laboratory record from a named 
ART facility after being 
considered lost from clinic 
Foster, 2017 [205]  
EPAZ 
Zimbabwe Cluster 
randomised 
trial 
One year 
postpartum 
Record review of 
facility registers 
and patient files 
Included PMTCT, 
ART as well as 
family planning 
and illness visits 
Facility-specific Visited the clinic at 12 months 
postpartum ±1 month 
Koss, 2017 [55] 
PROMOTE-PIs 
Uganda Cross-sectional 
follow-up of a 
random sample 
of women in a 
randomised 
trial 
Median 4 years 
since ART start 
Review of patient 
records combined 
with patient 
interviews 
Traced 
regardless of 
clinic 
Attended the clinic in the 90 days 
preceding the interview 
Miller, 2017 [206] Uganda Retrospective 
cohort 
One year after 
pregnancy 
detection 
Record review of 
facility registers 
and patient records 
Facility-specific At least one clinic visit ≥12 
months after pregnancy detection 
Myer, 2016 [207] 
MCH-ART 
South Africa Randomised 
control trial 
One year 
postpartum 
Combination of 
routine electronic 
HIV databases 
Interlinked Evidence of any HIV-care 
contact between 9 and 18 months 
postpartum 
Longitudinal 
Woelk, 2016 [56] Rwanda Retrospective 
cohort 
One year 
postpartum 
Record review of 
facility registers 
and patient files 
Facility-specific At least one visit (any indication 
of ART dispensed) in each 
period 6wk, 3, 6, 9, 12 months 
postpartum 
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Author, year [ref] 
Trial name if 
applicable 
Country Study design Reference period Source of 
retention data 
Facility-specific/ 
interlinked 
Retention outcome definition 
Kiweewa, 2013 
[176] 
Uganda Randomised 
control trial 
One year on ART Record review of 
facility registers 
and patient files? 
Facility-specific Attendance of all scheduled 
visits in first 12 months on ART  
Sam-agudu, 2017 
[208] 
MoMent 
Nigeria Prospective 
cohort 
Six months 
postpartum 
Record review of 
facility registers 
and patient files 
Facility-specific ≥3 (of expected 6) 30-day 
periods between delivery and 
180 days postpartum with at least 
one clinical visit 
Gaps after scheduled visit or with no drug in hand 
Atanga, 2017 [66] Cameroon Prospective 
cohort 
Up to one year 
from ANC 
registration 
Study collected 
facility level data 
on refill 
appointments 
Facility-specific 
with active 
tracing of lost 
patients 
No gap of ≥90 days after 
scheduled appointment missed  
Schwartz, 2015 [209] South Africa Pilot 
intervention 
One year 
postpartum 
Record review of 
facility registers 
and patient files 
Facility-specific No gap of >6 weeks after 
scheduled appointment missed 
[210] 
Van Lettow, 2014 
[45] 
Malawi Observational 
cohort 
Six and 12 months 
on ART 
Routine facility 
cohort reports 
Facility-specific No gap with no ART for ≥2 
months 
Haas, 2016 [54] Malawi Observational 
cohort 
One, two and three 
years on ART 
Routine electronic 
medical records 
Facility-specific No gap of >60 days after 
scheduled appointment missed 
Phiri, 2017 [211] 
PURE 
Malawi Randomised 
control trial 
Two years on ART Record review of 
facility registers 
and patient files 
Facility-specific No gap of ≥60 days after 
scheduled appointment missed 
Auld, 2016 [212] Mozambique Observational 
cohort  
Six months on ART Routine electronic 
programme data 
Facility-specific 
with active 
tracing of lost 
patients 
≥60 days late for their next 
scheduled 
medication pick-up appointment 
Chan, 2016 [67] Malawi Retrospective 
cohort 
Six months on ART Record review of 
facility registers 
and patient records 
Facility-specific Attending clinic within two 
months after the date that last 
dispensed antiretroviral drugs 
would run out 
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Author, year [ref] 
Trial name if 
applicable 
Country Study design Reference period Source of 
retention data 
Facility-specific/ 
interlinked 
Retention outcome definition 
Kamuyango, 2014 
[181] 
Malawi Retrospective 
cohort 
One year on ART Record review of 
facility registers 
and patient records 
Facility-specific No gap of ≥60 days after 
scheduled appointment missed 
Koole, 2014 [213] Malawi Retrospective 
cohort 
Six months on ART Record review of 
facility registers 
and patient records 
plus patient 
interviews 
Attempt to link 
to other clinics 
No gap of ≥60 days after 
scheduled appointment missed 
Landes, 2016 [69] Malawi Retrospective 
cohort 
One year on ART Review of standard 
ART monitoring 
tools captured 
through an ongoing 
observational 
cohort 
Facility-specific No gap of ≥60 days after 
scheduled appointment missed 
Tenthani, 2014 [71] Malawi Retrospective 
cohort 
Six months on ART Review of facility 
records aggregated 
for routine 
monitoring and 
evaluation 
 
Routine electronic 
medical records 
Facility-specific No gap of ≥60 days after 
scheduled appointment missed 
Tweya, 2014 [77] Malawi Retrospective 
cohort 
Up to two years on 
ART 
Routine electronic 
medical records 
Facility-specific 
with active 
tracing of lost 
patients 
No gap of ≥3 weeks after 
scheduled appointment missed 
Gamell, 2017 [214] 
One-Stop clinic 
model 
Tanzania Prospective 
cohort 
Median 17 months 
on ART 
Routine electronic 
medical records 
Facility-specific No gap of ≥60 days after 
scheduled appointment missed 
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Author, year [ref] 
Trial name if 
applicable 
Country Study design Reference period Source of 
retention data 
Facility-specific/ 
interlinked 
Retention outcome definition 
Hoffman, 2017 [215] Malawi Case-control One year on ART Review of facility 
records 
Facility-specific 
with active 
tracing of lost 
patients 
No gap of ≥60 days after 
scheduled appointment missed 
Gaps with no visits 
Llenas-Garcia, 2016 
[216] 
Mozambique Observational 
cohort 
Up to one year on 
ART 
Routine HIV 
programme data 
Facility-specific No gap in visits ≥180 days 
Ford, 2017 [3] 
Lablite project 
Zimbabwe Retrospective 
cohort 
One year on ART Record review of 
facility registers 
and patient records 
Facility-specific No gap >90 days with no visit 
Etoori, 2018 [68] eSwatini Prospective 
cohort 
Up to two years on 
ART 
Review of facility 
registers and 
patient records 
Facility-specific 
with active 
tracing of lost 
patients 
No gap in visits ≥4.5 months 
Musomba, 2017 [57] Uganda Retrospective 
cohort 
Up to two years on 
ART 
Routine electronic 
medical records 
Facility-specific No gap in visits ≥3 months 
Mitiku, 2016 [70] Ethiopia Retrospective 
cohort 
From three months 
to two years on 
ART 
Record review of 
facility registers 
and patient files 
Facility-specific No gap of ≥90 days with no visit 
Combined 
Oyeledun, 2017 
[198] 
Nigeria Cluster 
randomised 
trial 
Six months 
postpartum 
Record review of 
facility registers 
and patient files 
Facility-specific Full: Attended six-month 
postpartum visit (±30 days) and 
did not missed any previous 
scheduled visit by more than 30 
days  
Partial: Attended six-month 
postpartum visit (±30 days) but 
missed ≥1 previous scheduled 
visit by more than 30 days 
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Author, year [ref] 
Trial name if 
applicable 
Country Study design Reference period Source of 
retention data 
Facility-specific/ 
interlinked 
Retention outcome definition 
Mwapasa, 2017 
[117] PRIME 
Malawi Cluster 
randomised 
trial 
One year 
postpartum 
Record review of 
facility registers 
and patient files 
Facility-specific Attends 12-month postpartum 
visit and all ARV drug refills no 
more than 14 days late 
Attends 12-month postpartum 
Joseph, 2017 [73]  
E4E 
Zimbabwe Cluster 
randomised 
trial 
One year on ART Record review of 
facility registers 
and patient files 
Facility-specific Having had an ART refill visit a 
minimum of 335 days post-ART 
initiation and on-time attendance 
(before, on or up to 14 days after 
the next scheduled date) for at 
least 75% of scheduled ART 
refill visits, up to and including 
the 12-month visit AND no gap 
in care >90 days. 
Not defined 
Dzangare, 2016 [51] Zimbabwe Retrospective 
cohort 
Six months on ART Record review of 
facility registers 
and patient records 
Facility-specific 
(transfers out 
assumed 
retained) 
Retention/LTF not defined in the 
paper (or in national guidelines) 
Price, 2014 [217] Malawi Retrospective 
cohort 
Median four 
months postpartum 
Review of facility 
records and self-
report 
Searched across 
facilities 
“on ART” at the time of the 
interview. Not further defined. 
Abbreviations: ART – antiretroviral therapy
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Relevance of this paper to the thesis: 
Side effects from antiretroviral therapy (ART) are frequently reported as barrier to 
adherence soon after starting ART and there are particular concerns about side effects with 
efavirenz-based regimens. However, little is known about patient perceived side effects to 
first-line efavirenz-based regimens and the association with treatment adherence during 
pregnancy. This paper presents a detailed analysis of the patterns of system-specific and 
overall self-reported side effects among women who started ART during pregnancy and 
explores the association between reported side effects and reported missed ART doses.  
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3.1 Abstract 
Antiretroviral therapy (ART) regimens containing efavirenz (EFV) are recommended as part 
of universal ART for pregnant and breastfeeding women. EFV may have appreciable side 
effects, and ART adherence in pregnancy is a major concern, but little is known about ART 
side effects and associations with adherence in pregnancy.  
We investigated the distribution of patient-reported side effects (based on Division of AIDS 
categories) and the association of side effects with missed ART doses in a cohort of 517 
women starting EFV+3TC/FTC+TDF during pregnancy. In analysis, side effects were 
considered in terms of their overall frequency, by systems category, and by latent classes. 
Overall 97% of women reported experiencing at least one side effect after ART initiation, 
with 48% experiencing more than five side effects. Gastrointestinal, central nervous system, 
systemic and skin side effects were reported by 81%, 85%, 79% and 31% of women, 
respectively, with considerable overlap across groups. At least one missed dose was reported 
by 32% of women. In multivariable models, ART non-adherence was associated with 
systemic side effects compared to other systems categories, and measures of the overall 
burden of side effects experienced were most strongly associated with missed ART doses.  
These data demonstrate very high levels of side effects in pregnant women initiating EFV-
based ART and a strong association between side effect burden and ART adherence. ART 
regimens with reduced side effect profiles may enhance adherence, and as countries expand 
universal ART for all adult patients, counselling must include preparation for ART side 
effects. 
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3.2 Introduction 
With the recent adoption of Option B+ for prevention to mother-to-child HIV transmission 
(PMTCT) there have been rapid increases globally in the use of antiretroviral therapy (ART) 
by HIV-infected pregnant and breastfeeding women [1]. Following initiation of ART, 
successful treatment implementation and continued adherence to lifelong therapy is a 
widespread concern, emerging as a particular issue for women initiating ART during the 
perinatal period [2,3]. In turn, understanding adherence under Option B+ and the 
determinants of non-adherence, is a major priority both for individual and programme level 
PMTCT outcomes. 
Medication side effects are commonly thought to influence treatment adherence [4-6]. 
Efavirenz (EFV)-containing ART regimens are currently recommended by the World Health 
Organization (WHO) as first-line treatment. They are widely used in resource-limited settings 
and are generally considered to be better tolerated than previous Non-nucleoside reverse 
transcriptase inhibitor (NNRTI) regimens [7-10]. However, specific side effects associated 
with EFV are well known, particularly neuropsychiatric side effects such as dizziness and 
vivid dreams [11,12]. In general, side effects from current first-line therapy are thought to be 
relatively short lived and improve as patients continue on ART. However, these early side 
effects may disrupt initial implementation of the regimen, and there is some evidence that 
early treatment adherence is important to set the course of long-term adherence and treatment 
success [13]. Early adherence, particularly during pregnancy, is required to ensure rapid viral 
suppression, reduced transmission risk and improved maternal health outcomes.  
Experience of side effects has been associated with non-adherence and discontinuation of 
ART in general adult populations using various regimens [12,15-20]. However, few studies 
focus specifically on EFV-containing regimens and treatment adherence. One study in a 
small general adult cohort in South Africa, the majority on EFV-based regimens, found that 
experience of symptoms was associated with lower self-reported adherence scores [18]. Fear 
and experiences of side effects have been mooted as threats to ART adherence and continued 
ART use both in general adult patients as well as in pregnant and postpartum women 
[3,16,21-26]. 
The role of side effects in ART adherence warrants special attention in pregnant and 
postpartum women. To date evaluations of side effects in pregnant populations have been 
mostly limited to clinician-reported adverse events, primarily in trial settings [27-30]. Yet 
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patients’ experiences of side effects may differ from clinician-reported adverse events 
[7,19,31]. While data on side effects under Option B+ are few, country-level data show high 
rates of early loss to follow-up under Option B+, particularly among women with higher 
baseline CD4 cell counts, which may be attributable in part to ART side effects [32,33]. The 
experience and tolerance of ART side effects in relatively healthy individuals, commonly the 
case in pregnant women initiating ART under Option B+, may differ from that of individuals 
with more advanced HIV disease [31,34-36]. Also, in the context of pregnancy, ART 
initiation is frequently fast-tracked to maximize the chances of reaching viral suppression by 
delivery. There may be limited time to counsel patients on common side effects and their 
management, and lack of preparation for side effects has been suggested as a risk factor for 
poor adherence in the context of Option B+ [24].  
Despite the importance of these issues, little is known about experience of side effects and the 
relationship with adherence after ART initiation in pregnancy, particularly with first-line 
EFV-containing regimens in the context of Option B+. We examined the occurrence and 
patterns of side effects during pregnancy among women initiating EFV-based ART and 
investigated the relationship between reported side effects and reported missed ART doses. 
3.3 Methods 
 Population 
This analysis draws on data from a large multi-phase trial evaluating strategies for delivering 
HIV care and treatment services during pregnancy and the postpartum period (The MCH-
ART study, https://clinicaltrials.gov/ct2/show/NCT01933477) [37]. The study took place in a 
large public sector antenatal clinic in Gugulethu, Cape Town, South Africa. This setting is 
characterized by high levels of poverty and HIV with a local antenatal HIV seroprevalence of 
33% [38]. Local public-sector health services have provided free ART services since 2004 
and from 2012 ART was delivered together with antenatal care (ANC). From July 2013, all 
HIV-infected pregnant women were eligible to start lifelong ART regardless of CD4 cell 
count or clinical stage (Option B+).  
Consecutive HIV-infected, ART-eligible pregnant women 18 years and older making their 
first ANC visit during the current pregnancy were enrolled into the MCH-ART study 
between April 2013 and June 2014. Overall, 526 women were enrolled under Option B+ 
which started on 1 July 2013. Women started a first-line regimen of EFV (600mg), 
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emtricitabine (FTC)/ lamivudine (3TC) (300mg) and tenofovir (TDF) (300mg) 
(EFV+FTC/3TC+TDF), provided as a fixed dose combination. ART initiation and follow-up 
was conducted by nurse-midwives within the ANC clinic. ART was usually initiated on the 
day of the first antenatal visit or within two weeks, with routine follow-up visits occurring 
monthly for the first four months on treatment and one to two monthly thereafter. ART 
counselling was provided by trained counsellors before initiation and at each follow-up visit. 
The cohort was followed through study assessments conducted separately from routine care. 
Participants completed an interviewer-administered questionnaire at the time of enrolment, 
up to twice more during pregnancy, and once immediately after delivery. Each study 
assessment included structured questionnaires on ART use, and at the first postpartum study 
visit self-reported side effects experienced since ART initiation were assessed. This study 
was conducted in accordance with the ethical standards of the 1964 Helsinki declaration and 
its later amendments and was approved and conducted in accordance with the standards of 
the Human Research Ethics Committee of the University of Cape Town and the Columbia 
University Medical Centre Institutional Review Board. All participants provided written 
informed consent. 
Measures 
A structured questionnaire based on Division of AIDS (DAIDS) Tables for grading adverse 
events [39] was used to collect information on side effects experienced, including 
gastrointestinal tract (GIT) (nausea/vomiting, appetite change, diarrhoea, other GIT), central 
nervous system (CNS) (headache, dizziness, unusual dreaming, other CNS), skin (rash, other 
skin), systemic (fatigue, fever/sweats, non-specific pain, other systemic) side effects. The 
collected information was codified using a set of 14 binary variables for the reporting of each 
side effect from ART initiation through to the first postpartum study visit. 
Missed doses in the preceding 30 days were reported at each visit. The average number of 
missed ART doses was calculated by summing the reported missed doses across all study 
visits between ART start and the first postpartum visit. The sum of missed doses was divided 
by the sum of the reference period (the maximum number of visits on ART completed was 
three, resulting in a maximum reference period of 90 days) and multiplied by 30 to obtain the 
average number of missed doses in a 30-day period. This was analysed as both a continuous 
and binary variable (any vs. no missed doses). A secondary outcome of a reported period of 
no treatment for 30 days or more at the time of the last assessment was also evaluated. 
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Analysis 
This secondary analysis of data from the MCH-ART study excluded women enrolled under 
the Option A policy as well as women who did not have data available on side effects in 
pregnancy (n=9). Women were included regardless of mode of delivery. Data were analysed 
using Stata Version 12.0 (Stata Corporation, College Station, Texas, USA) and MPlus 
Version 7.3 (Muthén & Muthén, Los Angeles, CA). Variables were described using medians 
(with interquartile ranges, IQR) and proportions with (95% confidence intervals, CI). We 
used rank-sum and chi-square (replaced in the case of sparse data by Fisher’s exact) tests to 
examine differences in central tendencies and proportions, respectively. Three different 
constructs were used to examine the patterns of side effects reported by participants and the 
associations with missed ART doses:  
a) Systems categories: A classification based on DAIDS categories [39] was used to 
divide reported side effects into groups of GIT, CNS, skin and systemic side effects. 
Assignment to these categories was not mutually exclusive.  
b) Cumulative number of side effects: Subjects were grouped according to the number of 
different types of side effects experienced since ART initiation (from no side effects 
reported to up to 14 different side effects). 
c) Latent side effects class: Latent Class Analysis (LCA) was used to classify individuals 
into mutually exclusive groups (latent classes) characterized by different pattern of 
side effects, allowing for patterns that may not be solely systems-based (as assumed in 
[a] above). LCA, a statistical method for inferring unmeasured class membership 
using a set of measured variables as imperfect class indicators, has been used to 
identify underlying patterns of signs and symptoms in other contexts [40-43]. Here 
the binary variables representing presence/absence of different side effects since ART 
initiation were used as indicators, and the optimal number of latent classes was 
determined by comparing the fit of models with different number of classes according 
to statistical information criteria together with the results of the bootstrap likelihood 
ratio test [44]. Individuals were assigned to each class according to the maximum 
posterior probability. The LCA process is described in Supplementary Table 9-3-1 
and Supplementary Table 9-3-2. 
Multiple logistic regression was used to investigate adjusted associations between reported 
side effects (according to the three different classifications described above) and reported 
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missed ART doses. Covariates with associations at p≤0.10 in the bivariate models were 
included in the multivariable models. When analysing predictors of latent class membership, 
the probability of misclassification of individuals was taken into account in the estimation, 
using the three-step approach described by Asparouhov and Muthén [45]. 
3.4 Results 
Overall, 517 women who initiated ART in pregnancy under Option B+ were included in this 
analysis (Table 3-1). The median age was 28 years, 74% of women had not completed 
secondary school and 63% were unemployed. At ART initiation, the median CD4 cell count 
was 361 cells/µL (IQR 244-539 cells/µL) and the median gestational age was 21 weeks (IQR 
16-27 weeks). HIV diagnosis occurred during the current pregnancy for 55% of women and 
28% had used some form of antiretroviral (ARV) previously (predominantly short-course 
PMTCT regimens). All women received folic acid, calcium carbonate and iron supplements 
during ANC, and 6 women were treated for tuberculosis during pregnancy. At the time of the 
side effects assessment postpartum (median, 7 days after delivery) the median duration of 
ART use was 19 weeks (IQR 12-23 weeks).  
Prevalence of side effects 
Overall, 97% of women (n=502) reported experiencing at least one side effect on ART during 
pregnancy. Only median duration on ART differed between women who did and did not 
report side effects (19 and 9 weeks, respectively; p=0.012) (Table 3-1). The median number 
of different side effects experienced was five (IQR 3-7; max 12) and 91% of women reported 
two or more different side effects. GIT, CNS, systemic and skin side effects were reported by 
81%, 85%, 79% and 31% of women, respectively. There was considerable overlap in side 
effect reporting (Figure 3-1) with 22% of women (n=112) experiencing at least one side 
effect from all four categories, and 40% (n=208) reporting GIT, CNS and systemic side 
effects. The distributions of each SE construct by socio-demographic sub- groups are 
displayed in Supplementary Table 9-3-3. 
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Table 3-1 Demographic characteristics of 517 women initiating ART during pregnancy 
included in the study, by reported side effects. All cells are N (%) unless otherwise specified. 
 
 
All women 
Any side 
effects 
>5 side effects 
1-5 side 
effects 
No side 
effects 
p-value 
(any vs 
none) 
Number of women 517 502 (97) 250 (48) 252 (49) 15 (3) - 
Median age (IQR) 28 (24-32) 28 (25-32) 28 (24-32) 28 (25-32) 33 (23-34) 0.364 
Socioeconomic status        
Lowest 197 (38) 190 (38) 103 (41) 87 (35) 7 (47) 0.758 
Medium 152 (29) 149 (30) 68 (27) 81 (32) 3 (20)  
Highest 168 (33) 163 (32) 79 (32) 84 (33) 5 (33)  
Education level                      
Finished secondary 
school 
134 (26) 130 (26) 59 (24) 71 (28) 4 (27) 1.000 
Did not finish 
secondary school 
383 (74) 372 (74) 191 (76) 181 (72) 11 (73)  
Employment status                                    
Employed 193 (37) 187 (37) 91 (36) 96 (38) 6 (40) 0.794 
Not employed 324 (63) 315 (63) 159 (64) 156 (62) 9 (60)  
Relationship status                    
Married/cohabiting 198 (38) 194 (39) 88 (35) 106 (42) 4 (27) 0.427 
Not 
married/cohabiting 
319 (62) 308 (61) 164 (65) 144 (58) 11 (73)  
Median gravidity 
(IQR) 
2 (2-3) 2 (2-3) 2 (2-3) 2 (2-3) 3 (2-3) 0.183 
Primigravida 93 (18) 91 (18) 50 (20) 41 (16) 2 (13) 1.000 
Multigravida 424 (82) 411 (82) 200 (80) 211 (84) 13 (87)  
Timing of HIV 
diagnosis 
      
In the current 
pregnancy 
286 (55) 278 (55) 135 (54) 143 (57) 8 (53) 1.000 
Prior to this 
pregnancy 
231 (45) 224 (45) 115 (46) 109 (43) 7 (47)  
ARV history                                                  
ARV naïve 374 (72) 365 (73) 186 (74) 179 (71) 9 (60) 0.386 
Previous PMTCT 126 (24) 120 (24) 53 (21) 67 (27) 6 (40)  
Previous ART 17 (3) 17 (3) 11 (4) 6 (2) 0 (0)  
Median CD4 cell 
count at ART 
initiation (IQR) § 
361 (244-
539) 
359 (242-536) 337 (225-507) 390 (271-553) 502 (294-635) 0.104 
CD4<200 85 (17) 85 (18) 52 (21) 33 (14) 0 (0) 0.200 
CD4 200 - 349 150 (30) 145 (30) 76 (31) 69 (29) 5 (33)  
CD4≥350 265 (53) 255 (53) 115 (47) 140 (58) 10 (67)  
Median 
gestation(weeks) at 
ART initiation (IQR) 
21 (16-27) 21 (16-27) 20 (15-25) 22 (17-29) 23 (13-21) 0.360 
Median weeks on 
ART (IQR) 
19 (12-23) 19 (12-23) 19 (15-24) 17 (10-23) 9 (4-21) 0.012 
§17 missing CD4 count; ARV - antiretroviral 
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Figure 3-1 Venn diagram of number of women reporting each side effect by system category. 
(CNS – central nervous system; GIT – gastrointestinal tract). 
 
Latent side effect classes 
Four distinct patterns of side effects identified using LCA are shown in Figure 3-2 and 
described in Table 3-2. One group of women, comprising 26% of the cohort, reported 
experiencing most of the assessed side effects (here referred to as Class 1). A second group 
(Class 2, 17% of the cohort) frequently reported experiencing systemic side effects but 
reported experiencing CNS, GIT and skin side effects less commonly. Class 3 (30% of 
women) reported experiencing all types of side effects less commonly (including systemic 
side effects), while a fourth class (27% of women) reported experiencing few side effects.  
In a multinomial logistic regression adjusted for age and number of weeks on ART, 
education, CD4 count and gestation at ART initiation were significantly associated with class 
membership (Supplementary Table 9-3-4). Women with lower CD4 counts at ART initiation 
were more likely to belong to Class 1 than other classes. Increased education predicted 
membership to Class 3, experiencing moderate levels of all side effects, compared to Class 1, 
experiencing most or all types of side effects. In addition, starting ART earlier in pregnancy 
was associated with higher probability of belonging to latent classes characterized by higher 
levels of side effects (Classes 1 and 2).  
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Figure 3-2 Proportion of women reporting each side effect by latent side effect classes; 
systems-based side effects categories are shown in green (systemic side effects), yellow (skin 
side effects), red (central nervous system [CNS] side effects) and blue (gastrointestinal tract 
[GIT] side effects). 
Side effects and ART adherence 
At least one missed ART dose during pregnancy was reported by 32% of women (n=166). 
Among these women, 87% (n=145) reported between one and three missed doses, and the 
remaining 13% (n=21) reported four or more missed doses, per 30 days on ART, respectively 
(Table 3-2). Women who experienced any side effects were significantly more likely to 
report any missed ART dose compared to those who reported no side effects (100% versus 
96%, p=0.003). Women with any missed dose reported a marginally higher number of 
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individual side effects compared to women reporting no missed doses (median 5 versus 6 
reported side effects, p<0.001).  
Figure 3-3 shows the proportions of women reporting individual side effects grouped by 
reporting any versus no missed doses. For all systems side effects groups, the proportion of 
women reporting side effects was higher among those who missed any dose compared to 
those who reported no missed doses. These differences were statistically significant for all 
GIT, systemic and skin side effects, except for the “other” categories which were reported at 
very low frequencies. Of the CNS side effects, only dizziness was associated with reporting 
any missed ART doses. In the analysis of side effects as latent classes, missed doses were 
reported more frequently in classes where side effects reporting was more common: 36%, 
21%, 31% and 13% of women who reported any missed ART during pregnancy were in 
Classes 1, 2, 3 and 4, respectively (p<0.001, Table 3-2). 
The associations between each side effect construct (including frequency of side effects, 
systems classification and latent classes) and missed ART doses were considered separately 
in multivariable logistic regression models adjusted for participant age, marital status, parity 
and time on ART. In all models, side effects were consistently associated with missed ART 
doses (Supplementary Table 9-3-4). CD4 cell count, although associated with reporting side 
effects, was not associated with missed doses and did not appear to confound the association 
between reported side effects and missed ART doses. Higher numbers of different reported 
side effects were associated with increasing odds of a missed dose (OR 1.20, CI 1.12-1.29, 
for each additional type of side effects reported). Using systems side effects categories, 
having any GIT or any systemic side effects was associated with increased odds of reporting 
missed doses (OR 1.78 [CI 1.00-3.17] and OR 2.65 [CI 1.46-4.81], respectively). However, 
CNS and skin side effects were not associated with self-reported adherence. Compared to 
women in Class 1, women in Class 4 (with the lowest side effect profile) had significantly 
lower odds of reporting any missed dose (OR 0.25, CI 0.14-0.45). These associations did not 
change appreciably when mode of delivery was included in the final model. 
Six women (1%) reported missing 30 or more ART doses and the time off ART at assessment 
ranged from 43 to 156 days. The reasons reported for missing more than 30 days of ART are 
shown in Supplementary Table 9-3-5. Five out of six women were in Classes 1 or 2 where the 
experience of side effects was highest, and four of the six women cited side effects among the 
reasons for stopping to take their treatment.  
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Figure 3-3 Proportions of women reporting each side effect with 95% confidence intervals, 
by any or no missed doses reported. 
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Table 3-2 Reported side effects among 517 women following ART initiation during pregnancy in Cape Town, South Africa. All cells are N (%) 
unless otherwise specified. 
 
All women 
Missed doses in 30 days (on average) Discontinued ART p-value 
None 1-3 4 or more 
Any 
missed 
on ART 
Stopped 
ART 
(any vs. no 
missed dose) 
Number of women 517 351 145 21 166 511 6  
Any side effect reported  502 (97) 336 (96) 145 (100) 21 (100) 166 (100) 496 (97) 6 (100) 0.003 
Median number of reported side effects (IQR) 5 (3-7) 5 (2-7) 6 (4-8) 8 (5-9) 6 (4-8) 5 (3-7) 8 (7-9) <0.001 
No reported side effects 15 (3) 15 (4) 0 (0) 0 (0) 0 (0) 15 (3) 0 <0.001 
Only 1 reported side effects 32 (6) 28 (8) 3 (2) 1 (5) 4 (2) 31 (6) 1 (17)  
More than 1 reported side effects 470 (91) 308 (88) 142 (98) 20 (95) 162 (98) 465 (91) 5 (83)  
Any GIT side effects 417 (81) 269 (77) 131 (90) 17 (81) 148 (89) 412 (81) 5 (83) 0.001 
Nausea or vomiting 337 (65) 215 (61) 107 (74) 15 (71) 122 (73) 332 (65) 5 (83) 0.006 
Diarrhoea 204 (39) 122 (35) 73 (50) 9 (43) 82 (49) 202 (40) 2 (33) 0.001 
Appetite change 247 (48) 147 (42) 89 (61) 11 (52) 100 (60) 244 (48) 3 (50) <0.001 
Other GIT  11 (2) 6 (2) 4 (3) 1 (5) 5 (3) 11 (2) 0 0.272 
Any CNS side effects 437 (85) 289 (82) 128 (88) 20 (95) 148 (89) 431 (84) 6 (100) 0.045 
Dizziness 327 (63) 208 (59) 101 (70) 18 (86) 119 (72) 321 (63) 6 (100) 0.006 
Unusual dreaming  250 (48) 160 (46) 75 (52) 15 (71) 90 (54) 246 (48) 4 (67) 0.067 
Headache 278 (54) 182 (52) 82 (57) 14 (67) 96 (58) 273 (53) 5 (83) 0.203 
All other CNS side effects 20 (4) 10 (3) 9 (6) 1 (5) 10 (6) 19 (4) 1 (17) 0.080 
Any skin side effects 161 (31) 102 (29) 48 (33) 11 (52) 59 (36) 158 (31) 3 (50) 0.137 
Rash 154 (30) 95 (27) 48 (33) 11 (52) 59 (36) 151 (30) 3 (50) 0.049 
All other skin side effects 11 (2) 8 (2) 2 (1) 1 (5) 3 (2) 11 (2) 0 0.728 
Any systemic side effects 406 (79) 256 (73) 131 (90) 19 (91) 150 (90) 401 (78) 5 (83) <0.001 
Fever or sweats 303 (59) 191 (54) 96 (66) 16 (76) 112 (67) 299 (59) 4 (67) 0.005 
Other nonspecific pain 215 (42) 126 (36) 75 (52) 14 (67) 89 (54) 210 (41) 5 (83) <0.001 
Fatigue  310 (60) 190 (54) 104 (72) 16 (76) 120 (72) 305 (60) 5 (83) <0.001 
All other systemic side effects 48 (9) 30 (9) 14 (10) 4 (19) 18 (11) 48 (9) 0 0.401 
Class 1 (high side effects) 133 (26) 74 (21) 31 (28) 28 (51) 59 (36) 130 (25) 3 (50) <0.001 
Class 2 (moderate side effects, high systemic) 89 (17) 55 (16) 26 (23) 8 (15) 34 (20) 87 (17) 2 (33)  
Class 3 (moderate side effects) 156 (30) 105 (30) 37 (33) 14 (25) 51 (31) 156 (31) 0 (0)  
Class 4 (low side effects) 139 (27) 117 (33) 17 (15) 5 (9) 22 (13) 138 (27) 1 (17)  
(GIT – gastrointestinal tract; CNS – central nervous system) 
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3.5 Discussion 
Our study is the first to document very high levels of side effects experienced by women 
initiating efavirenz-based ART during pregnancy in sub-Saharan Africa and an association 
with self-reported missed ART doses. Missed doses were reported frequently. However, we 
found no persistent associations between specific side effects and missed doses; instead, the 
strongest associations with missed doses involved measures of the overall burden of side 
effects experienced by women. This finding adds an important new perspective to ART 
adherence in pregnancy under Option B+. 
Overall, 97% of women reported at least one side effect and the vast majority of women 
reported multiple side effects. While there are few data on ART side effects reporting in 
pregnancy and methods of measurement vary, these levels appear substantially higher than in 
other studies of first-line, EFV-containing regimens in non-pregnant adults [7,18,46]. As in 
other analyses of medication side effects in pregnant women, it is not clear if the side effects 
reported here were related to the ARVs, routine supplements given in pregnancy (iron, folate 
and calcium), symptoms of pregnancy, or symptoms of HIV disease. Unfortunately, we did 
not collect data on additional supplements however, use of over the counter supplements in 
this setting is not common. Concurrent tuberculosis medication may also impact reported side 
effects however less than 1% of this cohort had a tuberculosis episode during pregnancy. GIT 
and systemic side effects may be related to physiologic changes of pregnancy, many of which 
typically occur early in pregnancy. The median gestation at ART start in this cohort was 21 
weeks, meaning most women were well into the second trimester when they initiated ART. 
The finding that women with lower CD4 cell counts appeared to experience more diverse 
side effects in both the absolute count and latent class analysis suggests that some of this 
reporting may be linked to HIV disease rather than ART use directly. There are concerns that 
healthier individuals starting ART may have more adherence problems. However, our 
findings show that individuals with lower CD4 cell counts are likely to experience more side 
effects and therefore may also be at risk for poor adherence. These findings may have 
important implications for universal ART initiation in pregnancy as well as for adult “test and 
treat” approaches. Appropriate counselling and support for side effect management is 
required both to prepare healthy individuals for the effects of ART, as well as to prepare the 
individuals with more advanced disease for the effects of their HIV and ART. 
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In general, EFV side effects are thought to be relatively short-lived and improve over time. 
However, early side effects on ART have not been well documented in the literature. Our 
findings suggest that women who booked for ANC earlier, and therefore had a longer 
duration on ART, report more side effects than women with less time on ART. Further 
research on the timing and severity of ART side effects during pregnancy and in non-
pregnant women and healthy adults will be valuable to better understand these side effect 
profiles and provide appropriate support in the early time on treatment. 
Regardless of the underlying cause, all three constructs of reported side effects (number of 
different side effects reported, systems-based side effects categories, and latent side effects 
classes) were associated with reported missed ART doses. There was more imprecision 
around some associations between any side effects or specific side effects and missed doses 
observed in the logistic regression estimates in Supplementary Table 9-3-4, likely due to the 
very high proportions of women reporting side effects in this cohort. In all three of the side 
effects constructs used, effect sizes were relatively small and no specific side effects appeared 
to be driving missed doses in any of the analyses. Although this may in part be due to 
inability to detect small differences with relatively homogenous reports of side effects 
overall, this finding suggests that non-adherence may not be related to any one specific type 
or cluster of side effects (for example nausea or dizziness), but rather to the overall side 
effects burden. 
This finding has several possible interpretations. The experience of multiple side effects may 
present a cumulative burden of physical symptoms, any one of which may not contribute to 
non-adherence in isolation. There is evidence that the experience of side effects is related to 
plasma ARV levels, including EFV, which in turn may be moderated by genetic 
polymorphisms influencing drug metabolism [47]. The polymorphism resulting in increased 
plasma EFV levels has been found to be relatively common in patients of African descent, 
and high EFV concentrations have been associated with experiencing EFV related side 
effects [47,48]. In addition to this physiologic explanation, it is important to note that the 
reporting of larger numbers of side effects may be more common in individuals with specific 
personality traits, such as neuroticism [49]. In this context it is plausible that mental health 
concerns may contribute to side effects reporting as well as to non-adherence. These and 
other possible interpretations warrant additional attention. 
This is the first report of side effects experienced by pregnant women starting ART under 
Option B+ in South Africa. The data provide novel insights but are subject to important 
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limitations. All women in this analysis were on a regimen of EFV+FTC/3TC+TDF, the 
regimen initiated by the majority of HIV-infected pregnant women under current global 
policy. However, we were unable to examine how this regimen compares to others with 
respect to reported side effects and adherence. As individual ARV agents have different side 
effects profiles, the possibility that different ART regimens may have less side effects and 
contribute to better adherence in pregnancy is a pertinent consideration. The prevalence of 
reported CNS side effects, a specific concern in EFV-containing regimens, was very high and 
limited our ability to examine associations with non-adherence in this analysis [11]. More 
generally, all side effects and adherence data were based on patient self-report, and social 
desirability may have led to misreports of ART adherence and/or reported side effects, 
though we note the relatively high levels of missed dose reporting in this sample. 
Despite these limitations, these findings have important implications for health services 
providing ART to pregnant women. Experiences of side effects and fear of side effects have 
been reported as barriers to adherence to ART in pregnancy [3,21,23,24]. The high level of 
reported side effects and the association with missed doses found in this cohort supports 
previous calls for specific counselling on ART side effects [6,50]. Antenatal ART initiation is 
often rapid to ensure maximum time on ART prior to delivery. Time for pre-ART counselling 
may be limited, however counselling to address possible ART side effects, as well as 
pregnancy symptoms which may be perceived as ART related, should be a focus both at 
treatment initiation as well as subsequent follow up visits. More generally, the high burden of 
side effects experienced in this cohort using EFV+FTC/3TC+TDF points to the ongoing need 
both to understand the causes of side effects in context of pregnancy, and to identify new 
agents that minimize experience of side effects. 
3.6 Conclusion 
In summary, these novel data are important in demonstrating a high level of side effects 
experienced in this population of pregnant women initiating a first-line EFV-containing 
regimen under Option B+. The overall burden of side effects experience, rather than specific 
side effects, appears persistently associated with self-reported missed ART doses. Although 
the reported side effects may not be directly related to ARV regimen, these data highlight that 
patient reported side effects in the early time on ART may impact treatment adherence and 
there is a clear need to include counselling on expected ART side effects at ART initiation 
and follow-up visits. In this analysis we did not find an association between CD4 cell count 
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and missed ART doses which is reassuring for universal ART policies. As many countries 
move towards a “test and treat” approach, providing ART for all HIV-infected adults, the 
lessons we have learned from rapid universal ART initiation in pregnancy should be carefully 
considered. Managing experience and perception of ART side effects may play an important 
role in optimizing adherence behaviour during this early treatment period, which could in 
turn improve long term treatment outcomes. 
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Relevance of this paper to the thesis: 
There is an urgent need for robust measures of ART adherence to flag patients at risk for 
treatment failure and prompt appropriate intervention, particularly in the high risk periods 
of pregnancy and breastfeeding. Tenofovir-Diphosphate in dried blood spots is one 
possible measure but it has not been evaluated among African women living with HIV. 
There are also no data comparing this measure to other less expensive and more simple 
adherence measures that may be more appropriate for settings with limited resources. This 
paper compares the performance of self-reported adherence, plasma efavirenz, plasma 
tenofovir and tenofovir-diphosphate in dried blood spots to predict virologic suppression. 
A limitation of this chapter is that these data were only available at a single postpartum 
time point. These results therefore cannot speak directly to the utility of these measures 
during pregnancy, a time when pharmacokinetics may shift considerably. 
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4.1 Abstract 
Background: Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective 
long-term adherence measure but data are limited on its ability to predict virologic 
suppression (VS) among people on antiretroviral (ARV) treatment. There are also no data 
comparing DBS TFV-DP with plasma ARV concentrations as predictors of VS. 
Methods: Women who were on a first-line regimen of tenofovir, emtricitabine, and efavirenz 
(EFV) were enrolled in a cross-sectional study. Plasma EFV and tenofovir (TFV), DBS TFV-
DP assays, and 30-day self-reported adherence were evaluated as predictors of VS (<50 
copies/mL) with area under the curve (AUC) of receiver operating characteristics (ROC) and 
logistic regression. 
Results: We enrolled 137 women; mean age 33 years; median 4 years on ART; 88 (64%) had 
VS. In ROC analyses: DBS TFV-DP (0.926 [95%CI 0.876-0.976]) had a higher AUC than 
plasma TFV (0.864 [0.797-0.932]; p=0.006), while plasma EFV (0.903 [0.839-0.967]) was 
not significantly different from DBS TFV-DP (p=0.138) or plasma TFV (p=0.140); all ARV 
assays performed better than self-report. The association of TFV-DP in DBS with VS 
strengthened with increasing concentrations (reference <350 fmol/punch: 350-699 
fmol/punch aOR 37 [8-178]; 700-1249 fmol/punch aOR 47 [13-175]; ≥1250 fmol/punch aOR 
175 [20-1539]). “White coat adherence” (defined as DBS TFV-DP <350 fmol/punch with 
detectable plasma TFV) was only detected in 4 women. 
Conclusions: Plasma EFV, TFV and DBS TFV-DP were all strong predictors of VS. Plasma 
EFV and TFV concentrations, which are much simpler and cheaper than DBS TFV-DP, may 
warrant consideration as adherence measures in low-resource settings.  
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4.2 Introduction 
Good adherence to antiretroviral therapy (ART) is required to achieve and sustain virologic 
suppression [1]. A multitude of adherence measures exist but there is no gold standard and 
measuring ART adherence in both routine care and research settings is a major challenge [2]. 
Self-reported adherence frequently overestimates actual treatment adherence [3] while HIV 
viral load, which is often used as a marker of ART adherence, does not capture patterns of 
adherence or discriminate between poor adherence and resistance as causes of virologic 
failure [2].  
Measuring antiretroviral (ARV) drug concentrations has limitations but is an objective way to 
assess ART adherence [2]. Plasma concentrations of the ARVs tenofovir (TFV) and efavirenz 
(EFV), which are used in first-line ART regimens, are only informative about dosing in the 
past 4-5 days [4,5]. Plasma TFV has a half-life of approximately 14 hours [6] while EFV 
concentrations and half-life vary with CYP2B6 metaboliser genotype making interpretation of 
plasma EFV concentrations as an adherence measure difficult [4,7,8]. Recently, an assay has 
been developed to measure tenofovir-diphosphate (TFV-DP) concentrations in dried blood 
spots (DBS) [9]. TFV-DP in DBS has a half-life of 17 days and can be detected for up to 12 
weeks after stopping, a major benefit for assessing long-term adherence [10–12]. However, 
TFV-DP in DBS is measured using a complex and expensive laboratory assay that is not 
feasible outside of the context of clinical trials, and certainly not possible for routine care in 
resource limited settings.  
To date, most data on DBS TFV-DP as an adherence measure have been obtained from HIV-
negative individuals in pre-exposure prophylaxis (PrEP) studies. There are very few studies 
reporting TFV-DP DBS concentrations or therapeutic thresholds for ART adherence among 
people living with HIV (PLWH). Two small studies compared DBS TFV-DP with other 
adherence measures: pharmacy refill adherence among 35 women in the United States [10] 
and electronic drug monitoring in South Africa (n=29) [13]. Only one study has reported on 
the ability of TFV-DP in DBS to predict virologic suppression [11]. In addition, little is 
known about how TFV-DP in DBS compares with plasma ARV drug concentrations or other 
more affordable adherence measures that could be used in low-resource settings. Existing 
data on TFV-DP concentrations in DBS indicate that concentrations are up to 19% lower in 
males than females [12] and that there appear to be differences across populations with lower 
concentrations among Black compared with White or Hispanic individuals [11]. African 
women bear the largest burden of the HIV epidemic but to date there is just one unpublished 
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report on TFV-DP in DBS in an African cohort on ART [13] and there are no data on the 
ability of TFV-DP in DBS to predict virologic suppression among African women. Here we 
describe plasma EFV, plasma TFV and DBS TFV-DP concentrations, and self-reported 
adherence, in a cohort of women living with HIV who are on ART in Cape Town, South 
Africa, and assess their relationship with HIV viral load.  
4.3 Methods 
Design, participants and setting 
Women who were enrolled during pregnancy in a large implementation science study (the 
MCH-ART study) in Gugulethu, Cape Town were approached between 36 and 60 months 
postpartum and invited to participate in this cross-sectional sub-study. The MCH-ART study 
methods and results have been described previously [14,15]. All women had initiated the 
first-line regimen of tenofovir disoproxil fumarate (TDF) 300mg, emtricitabine 200mg or 
lamivudine 300mg (XTC), and EFV 600mg, provided as a once daily fixed-dose 
combination. For this sub study, the first 150 women who agreed to participate were recruited 
and had blood drawn for ARV assays. Women who were pregnant or had switched to second 
line ART were excluded. 
Procedures 
During the study visit, all women completed structured face-to-face interviews in the 
predominant local language, isiXhosa. Self-reported medication adherence in the past 30 days 
was measured using a simple, three-item scale that has been described previously [16,17]. 
Women reported on their current ART use and which regimens they were taking. ART 
regimen history was reviewed using the provincial electronic pharmacy records. Women 
were asked to report their current pregnancy status and their height and weight were 
measured by study staff who were trained in anthropometric techniques. Weight was 
measured using a standing scale and height using a stadiometer with equipment calibrated 
regularly. 
Antiretroviral drug assays and viral loads 
Venous EDTA blood samples were drawn from each participant and kept cold until 
processing. The majority of specimens were collected in the mid-dose interval (12-18 hours 
post-dose). For the TFV-DP DBS assay, 50 µL of whole blood was pipetted onto Whatman 
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903 Proteinsaver® cards, allowed to dry overnight at room temperature and then stored 
desiccated in airtight freezer-safe bags at -80°C. Samples were then centrifuged at 3500 rpm 
and plasma decanted into cryovials, before being frozen at -80°C. 
EFV, TFV and TFV-DP were analysed with validated liquid chromatography tandem mass 
spectrometry assays by the Clinical PK Laboratory, Division of Clinical Pharmacology, 
University of Cape Town. EFV plasma concentrations were determined as described by 
Bienczak et al [18]. TFV concentrations were determined using a protein precipitation 
extraction method, with tenofovir-d6 as internal standard, followed by high performance 
liquid chromatography with MS/MS detection using an AB SCIEX API 3000 instrument. 
Gradient chromatography was performed on a Waters Atlantis T3 (C18, 3µm, 100 X 2.1 mm) 
analytical column. The mobile phase consisted of 0.1% formic acid in water and 0.1% formic 
acid in acetonitrile and was delivered at a flow-rate of 300 µl per minute. The analyte and 
internal standard were monitored at mass transitions of the protonated precursor ions m/z 
288.1 and m/z 294.1 to the product ions m/z 176.2 and m/z 182.2 for tenofovir and tenofovir-
d6, respectively. The calibration curve fitted a quadratic (weighted by 1/concentration) 
regression over the ranges 10 to 1600 ng/ml. TFV-DP in DBS was indirectly measured using 
a slightly modified LC-MS/MS assay as described by Castillo-Mancilla et al [9]. 
An additional venous sample was sent to the National Health Laboratory Services (NHLS) 
for viral load testing (Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assay; Roche 
Diagnostics, Branchburg, New Jersey, US). 
Routine medical records 
In addition to data collected from participants during the study visit, routine electronic health 
records were requested from the Western Cape Provincial Health Data Centre. This included 
data from the NHLS (for serum creatine and CD4 cell count measures) and pharmacy 
databases (to validate ARV regimens), all of which are linked by a unique patient identifier 
and include all public health facilities in the Western Cape Province. Serum creatinine 
concentrations and CD4 cell counts measured within six months before or after the study visit 
were abstracted from the laboratory records. Less than 25% of women had CD4 cell counts 
available so these data were not included. 
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Analysis 
All analyses were performed in Stata (Stata Corporation, College Station, TX). Means with 
standard deviations, medians with interquartile ranges, or proportions were used to describe 
the characteristics of the cohort and the adherence measures. Drug concentrations were also 
log-transformed and back-transformed to report geometric means with 95% confidence 
intervals (CI). Concentrations below the lower limit of quantification for each assay (LLOQ; 
0.0195 µg/mL for plasma EFV, 10 ng/mL for plasma TFV and 16.6 fmol/punch for DBS 
TFV-DP) were assigned a value half that of the LLOQ (0.00975 µg/mL for plasma EFV, 5 
ng/mL for plasma TFV and 8.3 fmol/punch for DBS TFV-DP) [10].  
Logistic regression models were used to evaluate the relationship between continuous 
adherence measures and virologic suppression. Virologic suppression was defined as viral 
load <50 copies/mL with sensitivity analyses using thresholds of <400 and <1000 copies/mL. 
Area under the curves (AUC) of receiver operating characteristics (ROC) were used to assess 
discrimination of the adherence measures to predict virologic suppression. ROC AUCs for 
each drug concentration and self-reported adherence were compared in STATA using chi-
squared tests for equality of AUCs proposed by De Long et al [19]. We estimated sensitivity, 
specificity and positive and negative predictive values (PPV and NPV) using established drug 
concentration thresholds: ≥0.7µg/mL for plasma EFV [20,21], ≥35.5ng/mL for plasma TFV 
[22], and five adherence thresholds (<350, 350-699, 700-1249, 1250-1849 and ≥1850 
fmol/punch) for TFV-DP from DBS that were determined in a healthy volunteer study 
[11,12]. We also examined which thresholds of each of the continuous drug concentrations 
would maximise both sensitivity and specificity to detect women with and without virologic 
suppression. Sensitivity analyses were conducted excluding women who reported taking no 
ART in the past 30 days, a group in whom drug concentrations may not be measured in a 
routine care setting. 
Ethics 
All participants completed written informed consent, including consent for specimen storage 
and drug assays, prior to completing any study procedures. This study was reviewed and 
approved by the University of Cape Town Human Research Ethics Committee and the 
Columbia University Institutional Review Board.  
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4.4 Results 
Thirteen of the 150 consecutive women screened were excluded (seven were pregnant [23] 
and six had switched to second line ART regimens). The characteristics of 137 women 
enrolled into the study are displayed in Table 4-1. At the study visit the median time on ART 
was 3.9 years (IQR 3.7-4.0) and 88 women (64%) were virologically suppressed (<50 
copies/mL).  
Table 4-1 Characteristics of 137 non-pregnant women on first-line ART at the time of the 
study visit. 
 All women 
Mean age (SD) 33 (5) 
Median (IQR) years on ART 3.9 (3.7-4.0) 
Median (IQR) weight (kg) 81 (65-93) 
Median (IQR) body mass index (BMI, kg/m2) 32 (26-36) 
BMI <18.5 kg/m2 3 (2) 
BMI ≥18.5 and <25 kg/m2 26 (19) 
BMI ≥25 and <30 kg/m2 33 (24) 
BMI ≥30 kg/m2 75 (56) 
Serum creatinine available, n (%) 74 (54) 
Median (IQR) serum creatinine1 (n=74) 55 (51-60) 
Median (IQR) log10 viral load 1.30 (1.30-3.56) 
Viral load <50 copies/mL, n (%) 88 (64) 
Viral load ≥50 and <400 copies/mL, n (%) 8 (6) 
Viral load ≥400 and <1000 copies/mL, n (%) 2 (1) 
Viral load ≥1000 copies/mL, n (%) 39 (28) 
1Creatine measures were abstracted from routine laboratory records within six months before or after the study visit 
The distribution of plasma EFV, TFV and DBS TFV-DP concentrations are presented in 
Table 4-2 and Supplementary Figure 9-4-1. Specimens were collected at a median of 15 
hours after last dosing (IQR 14-16). In total, 84%, 76% and 86% of women had any 
detectable plasma EFV, plasma TFV and DBS TFV-DP, respectively. There were 38 women 
(28%) who had drug concentrations below the LLOQ for all three ARV assays; two of these 
38 women were virologically suppressed. These two women both reported that they were no 
longer taking ART, which was confirmed in medical records, and their HIV diagnosis was 
confirmed on ELISA. Both were thought to be elite controllers. Most women had high self-
reported adherence scores with 56% of women (n=77) reporting 100% adherence in the last 
30 days on the three-item scale; 62 of whom (81%) were virologically suppressed.
106 
 
Table 4-2 Concentrations of TFV-DP in DBS, TFV plasma and EFV plasma as well as self-reported adherence among 137 women, grouped by 
viral load <50, <400 and <1000 copies/mL. Results presented as n (%) unless specified. 
 
 Viral load <50 
copies/mL 
Viral load ≥50 
copies/mL 
Viral load <400 
copies/mL 
Viral load ≥400 
copies/mL 
Viral load <1000 
copies/mL 
Viral load ≥1000 
copies/mL 
All women 
Number of women 88 (64) 49 (36) 96 (70) 41 (30) 98 (72) 39 (28) 137 
EFV plasma (µg/mL) 
Median  
(range) 
1.9  
(0.00975, 19.5) 
0.00975  
(0.00975, 4.8) 
1.91 
(0.00975, 19.5) 
0.00975 
(0.00975, 4.8) 
1.87  
(0.00975, 19.5) 
0.00975  
(0.00975, 4.8) 
1.52 
(0.00975, 19.5) 
Geometric mean (95% CI) 1.8 (1.4-2.3) 0.03 (0.02-0.06) 1.6 (1.2-2.1) 0.02 (0.01-0.03) 1.5 (1.1-2.0) 0.02 (0.01-0.03) 0.4 (0.3-0.6) 
LLOQ to <0.7 9 (10) 39 (80) 11 (11) 37 (90) 13 (13) 35 (90) 48 (35) 
0.7 to <4 66 (75) 8 (16) 71 (74) 3 (7) 71 (72) 3 (8) 74 (54) 
≥4 13 (15) 2 (4) 14 (15) 1 (2) 14 (14) 1 (3) 15 (11) 
TFV plasma (ng/mL) 
Median (range) 44.3  
(5.0, 120) 
5.0  
(5.0, 90.1) 
44.2  
(5.0, 120) 
5.0  
(5.0, 90.1) 
44.0  
(5.0, 120) 
5.0  
(5.0, 90.1) 
32.90  
(5.0, 120) 
Geometric mean (95% CI) 35 (30-42) 8 (6-11) 34 (29-41) 7 (5-8) 33 (28-39) 7 (5-9) 21 (17-25) 
LLOQ to <35.5 31 (35) 42 (86) 35 (36) 38 (93) 37 (38) 36 (92) 73 (53) 
≥35.5 57 (65) 7 (14) 61 (64) 3 (7) 61 (62) 3 (8) 64 (47) 
TFV-DP DBS (fmol/punch) 
Median (range) 961.5 
(8.3, 2402) 
8.3 
(8.3, 1359) 
952.5 
(8.3, 2402) 
8.3 
(8.3, 930) 
940.5  
(8.3, 2402) 
8.3 
(8.3, 930) 
701 
(8.3, 2402) 
Geometric mean (95% CI) 815 (670-992) 25 (14-43) 740 (591-926) 16 (10-25) 700 (551-889) 15 (9-24) 241 (163-336) 
LLOQ to <350 7 (8) 40 (81) 10 (10) 37 (90) 12 (12) 35 (90) 47 (35) 
350 to <700 16 (18) 3 (6) 17 (18) 2 (5) 17 (17) 2 (5) 19 (14) 
700 to <1250 36 (41) 5 (10) 39 (41) 2 (5) 39 (40) 2 (5) 41 (30) 
1250 to <1850 23 (26) 1 (3) 24 (25) 0 (0) 24 (24) 0 (0) 24 (18) 
≥1850 6 (7) 0 (0) 6 (6) 0 (0) 6 (6) 0 (0) 6 (4) 
Self-reported adherence in past 30 days 
Median 
(range) 
100 (0-100) 92 (0-100) 100 (0-100) 83 (0-100) 100 (0-100) 83 (0-100) 100 (0-100) 
Score ≤80 3 (3) 20 (41) 4 (4) 19 (46) 5 (5) 18 (46) 23 (17) 
Score >80 and ≤100 23 (26) 14 (29) 27 (28) 10 (24) 28 (29) 9 (23) 37 (27) 
Score=100 62 (70) 15 (31) 65 (68) 12 (29) 65 (66) 12 (31) 77 (56) 
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In ROC analyses to evaluate how well each adherence marker predicted virologic 
suppression, DBS TFV-DP had the highest AUC of 0.926 (95% CI 0.876-0.976) after 
adjusting for age and duration on ART (Figure 4-1; unadjusted ROC curves shown in 
Supplementary Figure 9-4-2). This was significantly better than plasma TFV (AUC=0.864 
95% CI 0.797-0.932, p=0.006) but not significantly different from plasma EFV (AUC=0.903 
95% CI 0.839-0.967, p=0.138). All drug concentrations performed better than 30-day self-
reported adherence (AUC=0.756 95% CI 0.660-0.852, p<0.05 for each assay). 
Figure 4-1 Adjusted area under the receiver operating characteristics (ROC) curves of DBS 
TFV-DP (grey), plasma EFV (green), plasma TFV (maroon), and self-reported adherence 
(blue) to predict viral suppression; n=137 (adjusted for age and duration on ART). 
 
Using drug concentrations to predict virologic suppression, we used ROC analyses to 
examine the diagnostic characteristics of different drug concentration cut-off points, 
including established thresholds for TFV-DP in DBS [11], plasma TFV [22] and plasma EFV 
[20,21] (Table 4-3). Having any detectable drug concentration on any of the three assays was 
highly predictive of virologic suppression. Almost 90% of the cohort were correctly 
classified based on any detectable TFV-DP in DBS or any plasma EFV; 85% were correctly 
classified by any detectable plasma TFV. Higher drug concentration cut-offs resulted in 
higher positive predictive values.  
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Table 4-3 Diagnostic characteristics of different binary drug concentration thresholds to 
predict virologic suppression (<50 copies/mL) using both established drug concentration cut-
off values and alternative cut-off values (indicated by *) that maximised sensitivity and 
specificity in ROC analyses. 
Tenofovir-diphosphate (TFV-DP) in DBS 
Select TFV-DP 
cut-off values 
Probability of 
virologic 
suppression1 
Sensitivity2 
(%) 
Specificity3 
(%) 
PPV4 
(%) 
NPV5 
(%) 
Correctly 
classified6 (%) 
>LLOQ >0.190 97.7 73.5 86.9 94.7 89.1 
≥350 ≥0.464 92.1 81.6 90.0 85.1 88.3 
≥399* ≥0.515 92.1 83.7 91.0 85.4 89.1 
≥700 ≥0.787 73.9 87.8 91.5 65.2 78.8 
≥1250 ≥0.975 33.0 98.0 96.7 44.9 56.2 
≥1850 ≥0.998 6.8 100.0 100.0 37.4 40.2 
Plasma tenofovir (TFV) 
Select plasma 
TFV cut-off 
values 
Probability of 
virologic 
suppression1 
Sensitivity2 
(%) 
Specificity3 
(%) 
PPV4 
(%) 
NPV5 
(%) 
Correctly 
classified6 (%) 
>LLOQ ≥0.411 88.6 77.6 87.6 79.2 84.7 
≥23.5* ≥0.586 78.4 79.6 87.3 67.2 78.8 
≥35.5 ≥0.750 64.8 85.7 89.1 57.5 72.3 
Plasma efavirenz (EFV) 
Select plasma 
EFV cut-off 
values 
Probability of 
virologic 
suppression1 
Sensitivity2 
(%) 
Specificity3 
(%) 
PPV4 
(%) 
NPV5 
(%) 
Correctly 
classified6 (%) 
>LLOQ ≥0.253 97.7 75.5 87.8 94.9 89.8 
≥0.70 ≥0.483 89.8 79.6 88.8 81.3 86.1 
≥1.00 ≥0.605 85.2 81.6 89.3 75.5 83.9 
≥1.13* ≥0.636 81.8 83.7 90.0 71.9 82.5 
≥4.00 ≥0.995 14.8 95.9 86.7 38.5 43.8 
1Probability estimated from logistic regression models. 
2Proportion of subjects with a viral load <50 copies/mL who were detected using this cut-off 
3Proportion of subjects with a viral load ≥50 copies/mL who were detected using this cut-off 
4Positive Predictive Value: proportion of those who were detected with this drug concentration cut-off who had a viral load 
<50 copies/mL 
5Negative Predictive Value: proportion of those who were not detected with this drug concentration cut-off who had a viral 
load ≥50 copies/mL 
6Overall proportion of those above and below the cut-off who were correctly classified. Note that this proportion is always 
biased towards the larger group. 
 
Thresholds of DBS TFV-DP have been shown to relate back to doses taken per week in 
healthy volunteers [11]. Table 4-4 examines in more detail the viral load distribution and 
association between virologic suppression and DBS TFV-DP in our cohort within these 
established thresholds. In our cohort 97% of women (n=29) who had a DBS TFV-DP 
concentration ≥1250 fmol/punch were virologically suppressed (defined as <50 copies/mL). 
This threshold also perfectly predicted viral loads <400 and <1000 copies/mL. Seven of the 
47 women (15%) in the lowest TFV-DP category, <350 fmol/punch, remained suppressed 
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despite none or very low drug concentrations. A dose-response relationship was observed 
between virologic suppression and increasing concentrations of TFV-DP in DBS; this was 
not observed for increasing concentrations of plasma EFV or TFV (data not shown). Similar 
associations were observed in sensitivity analyses excluding women who self-reported not 
taking any ART in the past 30 days (Supplementary Table 9-4-1). Increasing years of age 
(aOR 1.12 95% CI 1.01-1.25) and increasing years on ART (aOR 1.56 95% CI 0.13-18.07) 
were associated with virologic suppression, although the association with duration on ART 
was not statistically significant (crude models in Supplementary Table 9-4-2). Serum 
creatinine concentrations were not measured at the time of the drug concentration testing and 
only 74 women had available serum creatinine concentrations in the six months before or 
after the study visit. In this group, serum creatinine was not associated with virologic 
suppression. Neither serum creatinine nor body mass index (BMI) changed the associations 
between drug concentrations and viral load and were therefore not included in adjusted 
models. 
To examine improved short-term ART adherence related to the study visit among participants 
(so called “white coat” adherence [2,24]), we compared adherence in plasma TFV (half-life 
approximately 14 hours [6]) with TFV-DP (half-life of up to 17 days [12]). Concentrations of 
TFV-DP in DBS correlated well with plasma TFV concentrations (r=0.700, Supplementary 
Figure 9-4-3). There were four women with any detectable plasma TFV but DBS TFV-DP 
concentrations below 350 fmol/punch. All four women also had detectable plasma EFV 
concentrations and only two women had viral loads above 50 copies/mL (Supplementary 
Table 9-4-3). 
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Table 4-4 Viral load characteristics within established DBS TFV-DP thresholds among 137 
women. Odds ratios (OR) predicting viral load <50, <400 and <1000 copies/mL are 
presented. 
 TFV-DP threshold 
(approximate doses per 
week1) 
<350 (<2) 350-699 (2-3) 700-1249 (4-6) ≥1250 (7) 
Total number of women 47 19 41 30 
Median viral load log10 
copies/mL (IQR) 
3.7 (2.8-4.6) 1.3 (1.3-1.3) 1.3 (1.3-1.3) 1.3 (1.3-1.3) 
Median viral load 
copies/mL (IQR) 
12200  
(618-40027) 
20 (20-20) 20 (20-20) 20 (20-20) 
Viral load <50 copies/mL 
Viral load <50 
copies/mL, n (%) 
7 (15) 16 (84) 36 (88) 29 (97) 
OR (95% CI) Ref 30 (7-133) 41 (12-141) 166 (19-1421) 
aOR2 (95% CI) Ref 37 (8-178) 47 (13-175) 175 (20-1539) 
Viral load <400 copies/mL 
Viral load <400 
copies/mL, n (%) 
12 (26) 17 (89) 39 (95) 30 (100) 
OR (95% CI) Ref 31 (6-159) 72 (15-352) Omitted 
aOR2 (95% CI) Ref 47 (8-287) 100 (17-579) Omitted 
Viral load <1000 copies/mL 
Viral load <1000 
copies/mL, n (%) 
10 (21) 17 (89) 39 (95) 30 (100) 
OR (95% CI) Ref 25 (5-123) 57 (12-272) Omitted 
aOR2 (95% CI) Ref 31 (6-167) 64 (12-330) Omitted 
1As previously described by Castillo-Mancilla et al (CID, 2018) 
2Adjusted for age and duration on ART 
 
4.5 Discussion 
Our findings from a cohort of South African women show that concentrations of TFV-DP in 
DBS, plasma EFV and plasma TFV were all strongly associated with virologic suppression 
and all performed better than self-reported adherence. The strength of association between 
DBS TFV-DP and virologic suppression increased with increasing drug concentrations and 
remained consistent after adjustment for covariates and in sensitivity analyses, confirming 
recent findings in a US cohort [11]. This study is the first to compare TFV-DP in DBS with 
plasma ARV concentrations and HIV viral load for measuring ART adherence in an African 
population and adds novel insights for the potential use of TFV-DP in DBS and plasma EFV 
or TFV to measure adherence among PLWH. 
Plasma EFV and DBS TFV-DP concentrations above the LLOQ both had sensitivities 
approaching 100% and correctly identified 89% of women with virologic suppression. We 
found a stronger association between plasma EFV concentrations and virologic suppression 
than previously reported in a similar population up to one year on ART [7]. Adherence is 
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known to change over time and there may be less intermittent adherence in our cohort at 3-4 
years after ART start compared with the first year on ART. However, there are mixed results 
in the literature regarding the association between increasing duration on ART and adherence 
[25]. Although we were not able to measure the genes relevant to EFV metabolism in this 
study, it is likely that women with EFV concentrations above 4 µg/mL (11% of our cohort) 
possess the CYP2B6 slow metaboliser genotype resulting in a longer EFV half-life [8]. The 
longer DBS TFV-DP half-life and possibly longer EFV half-life compared to plasma TFV 
may explain why, even when administered in a fixed dose combination, plasma TFV 
concentrations performed slightly worse than plasma EFV and TFV-DP in DBS at predicting 
virologic suppression. 
TFV-DP concentrations in DBS among suppressed women in our cohort (geometric mean 
815 fmol/punch, median 961 fmol/punch) were equivalent to values reported in another South 
African cohort of predominantly women (median 939 fmol/punch) [13]. However, they were 
lower than observed among suppressed Black PLWH in the US (geometric mean 1453 
fmol/punch) [11] and higher than observed among non-pregnant HIV-negative women on 
PrEP in Uganda and Kenya (mean 637 fmol/punch) [23]. This supports recent findings that 
virologically suppressed PLWH have higher DBS TFV-DP concentrations than HIV-negative 
individuals [11] and suggests therapeutic thresholds of DBS TFV-DP may be lower among 
Black African PLWH. Although we observed lower TFV-DP concentrations in DBS than 
Castillo-Mancilla and colleagues [11], we found a similar dose-response relationship between 
virologic suppression and increasing TFV-DP concentrations in DBS. In contrast to their 
findings, we found no association between TFV-DP in DBS and BMI which may be due to 
most women in our cohort having BMI ≥25kg/m2. Other individual characteristics such as 
comorbidities and concomitant medication may also influence TFV-DP concentrations in 
DBS [11] but we were not able to evaluate these in our study. We were also unable to assess 
variability in TFV-DP concentrations in DBS due to ARV regimen, race or gender as our 
cohort was restricted to non-pregnant women on a first-line fixed-dose combination regimen 
of TDF+XTC+EFV. Pregnancy status has also recently been shown to influence TFV-DP 
concentrations in DBS among African women on PrEP [23] and this requires further 
evaluation in the context of HIV infection. 
Our findings should be interpreted with the following additional limitations in mind. Previous 
studies have accounted for CD4 cell count and kidney function in their analyses, however 
these data were not collected by the study and, although effort was made to abstract 
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information from routine medical records, few women had available measures within six 
months before or after the study visit. We ascertained ART regimen by self-report and 
through triangulation with routine pharmacy dispensing data, but errors may have occurred. 
In this cross-sectional study, we were also unable to assess daily dosing or to match drug 
concentration thresholds to actual ART dosing prior to the study visit as the last dose was not 
observed. Given the observed differences in TFV-DP concentrations in DBS among people 
living with and without HIV, as well as the lower concentrations reported among Black 
individuals, further research is needed to evaluate adherence thresholds in African 
populations living with HIV. 
In both research and routine care there is often concern about improved adherence shortly 
before a scheduled research or clinical visit, or “white coat” adherence [2,24]. We found little 
evidence of this in our cohort with only four women with therapeutic plasma TFV but TFV-
DP in DBS below 350 fmol/punch. The long half-life of TFV-DP in DBS and the dose-
response relationship with virologic suppression show that measuring TFV-DP in DBS 
provides a more nuanced measure of adherence than plasma EFV or TFV concentrations. 
However, our findings suggest that plasma EFV and TFV, both less expensive and complex 
assays, can also be strong predictors of virologic suppression and these assays may warrant 
consideration as adherence measures in resource-limited settings.  
4.6 Conclusion 
In summary, our data add to the evidence on the use of TFV-DP in DBS for monitoring ART 
adherence in PLWH, providing new insights from a cohort of African women. TFV-DP in 
DBS and plasma EFV and TFV concentrations were strongly associated with virologic 
suppression and are superior to self-reported adherence. Further research is needed to assess 
the added value of these drug concentration assays in the context of viral load monitoring and 
screening for ART resistance. 
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 Decreases in self-reported antiretroviral therapy adherence predict 
HIV viremia among pregnant and postpartum South African women 
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cohort of pregnant and postpartum women in Cape Town, South Africa. J Acquir Immune 
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Relevance of this paper to the thesis: 
Following on from Chapter 4, where drug concentration assays all outperformed the cross-
sectional self-reported adherence measure, this paper presents a novel approach to the use 
of self-reported adherence. Self-report is known to be prone to bias and frequently 
overestimates adherence but is still a widely used in routine care and research. This paper 
examine whether decreases in self-reported adherence over consecutive measurement 
times is associated with risk of viremia and provides a proof of concept for future work 
using longitudinal self-reported adherence in low-resource settings. 
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analyses and wrote the initial manuscript draft. All co-authors reviewed the manuscript 
and provided conceptual and intellectual comment. All authors were involved in the final 
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5.1 Abstract 
Introduction: Routine HIV viral load (VL) monitoring is recommended for patients on 
antiretroviral therapy (ART) but frequent VL testing, required in pregnant and postpartum 
women, is often not feasible. Self-reported adherence can be valuable, but little is known 
about its longitudinal characteristics.  
Methods: We followed women living with HIV from ART initiation in pregnancy through 
18 months postpartum in Cape Town, South Africa, with repeated measurement of VL and 
self-reported adherence using a three-item scale. We used generalized estimating equations 
(with results presented as odds ratios [OR] with 95% confidence intervals [CI]) to investigate 
the association between viremia and change in adherence over pairs of consecutive visits. 
Results: Among 2085 visit pairs from 433 women, a decrease in self-reported adherence 
relative to the previous visit on any of three self-report items, or the combined scale, was 
associated with VL >50 and >1000 copies/mL. The best performing thresholds to predict VL 
>50 copies/mL were a single level decrease on the Likert response item “how good a job did 
you do at taking your HIV medicines in the way that you were supposed to?” (OR 2.08 95% 
CI 1.48-2.91), and a decrease equivalent to ≥5 missed doses or a one level decrease in score 
on either of two Likert items (OR 1.34 95% CI 1.06-1.69). 
Conclusion: Longitudinal changes in self-reported adherence can help identify patients with 
viremia. This approach warrants consideration in settings where frequent viral load 
monitoring or other objective adherence measures are not possible. 
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5.2 Introduction 
Antiretroviral therapy (ART) is the cornerstone of HIV treatment and prevention efforts. 
Current global guidelines recommend that all individuals living with HIV start lifelong ART 
as soon as they are diagnosed, thereby improving their long-term health outcomes [1]. HIV 
transmission during pregnancy, labour and delivery, and breastfeeding can be reduced to 
below 1% in the presence of suppressive ART [2]. However, optimal ART adherence is 
essential to achieve sustained viral suppression and to realize the treatment and prevention 
benefits. 
Routine HIV viral load monitoring is being rolled out globally [3]. Viral load offers an 
objective marker of treatment success and a signal for poor adherence and antiretroviral 
resistance but, even with the push to scale up routine viral load monitoring, numerous 
challenges persist [3,4]. During pregnancy and postpartum, ART adherence is a particular 
concern due to the added risk of vertical HIV transmission [5,6]. An increased frequency of 
viral load testing is recommended during these periods, but this is not always feasible [7,8]. 
In low-resource settings where viral loads are infrequent or unavailable, other methods of 
assessing ART adherence are still required [9]. 
Self-reported adherence – which is inexpensive, immediate and easy to administer – is often 
used to assess ART adherence in both routine care and research settings. Although validated 
self-reported adherence measures exist, finding an optimal measure has been a focus of much 
research [10–13]. Self-reported adherence, which can often overestimate individual 
medication taking behaviour, measures an individual’s perception of their treatment 
adherence [10]. It may be influenced by various biases such as social desirability or recall 
bias, and this may vary between individuals depending on their own reference points 
regarding their medication-taking practices [11,14,15]. Despite these issues, self-reported 
adherence has often shown a reasonable correlation with viral load and other objective 
markers of adherence, including in low-resource settings [9,11,16].  
Although there have been calls for longitudinal adherence measures to assess changes in 
ART adherence [17,18], the vast majority of studies have only evaluated the association 
between adherence and viral load at a single time point. Longitudinal measures provide an 
opportunity to examine relative changes in reported adherence which could help to account 
for individual reporting patterns. Predictors of changes in reported adherence have been 
explored but few studies have assessed whether changes in reported adherence are associated 
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with an objective marker such as viral load [19–24]. Here we examined self-reported 
adherence and viral load among women living with HIV over multiple measurement points 
during and after pregnancy and investigate the association between changes in self-reported 
adherence and viremia. 
5.3 Methods 
We conducted a longitudinal analysis of women enrolled into a multi-phase implementation 
science study (the MCH-ART study, ClinicalTrials.gov NCT01933477) which has been 
described previously [25]. Women were followed from ART initiation during pregnancy for 
up to 18 months postpartum. Study visits occurred 2-3 times during pregnancy (depending on 
gestational age), once shortly after delivery and approximately every three months thereafter. 
Setting 
Women were recruited into the parent study between April 2013 and June 2014 when they 
presented for antenatal care (ANC) at a large primary care antenatal and obstetric care clinic 
in Gugulethu, Cape Town, with follow-up through January 2016. This setting is characterized 
by high levels of poverty and unemployment, and a very high burden of HIV [26]. The local 
antenatal HIV prevalence was estimated to be 22% in 2015 [27] and all women starting ART 
received a fixed dose combination of efavirenz, tenofovir and emtricitabine [28].  
Measures 
Data were collected at study visits which occurred independently of routine HIV and ANC. 
Interviews were conducted by trained interviewers in the predominant local language, 
isiXhosa. Demographic characteristics including age, marital status, employment and timing 
of HIV diagnosis were collected at the time of enrolment. CD4 cell count and gestational age 
at presentation for ANC were abstracted from routine medical records. 
Self-reported adherence was measured using a simple three-item adherence scale that was 
developed through a process of rigorous cognitive interviewing and has been validated in the 
United States [29–31]. It was translated into isiXhosa for use in South Africa and the cross-
sectional validity of the translated individual scale items and the overall scale score were 
evaluated previously in this setting (Cronbach α=0.79) [32]. The three items in the scale 
(Table 5-1) include a quantification of missed doses as well as two Likert response scales that 
ask patients “how good a job did you do taking your medications in the way you were 
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supposed to” and “how often did you take your medications in the way that you were 
supposed to,” all with reference to the past 30 days. To analyse the combined scale score, 
these three items were aggregated based on a re-coding of each item with equal weighting, to 
create a score ranging from 0 to 100, with the latter representing the best possible self-
reported adherence. 
HIV RNA viral load, the “gold standard” in our analyses, was measured at each study visit on 
the same day as the self-reported adherence scale was administered. Separate from routine 
HIV care services, venous blood was collected, and batch tested by the National Health 
Laboratory Services (Abbott RealTime HIV-1 assay, Abbott Laboratories, Illinois, USA), 
with results only available at the end of the study period. 
Table 5-1 Description of items in the three-item self-reported adherence scale and the 
thresholds used to assess change in adherence across visits. 
Item Threshold 
1. E: In the last 30 days, on how many 
days did you miss at least one dose of 
any of your HIV medicines? 
X: Kwintsuku ezi-30 ezidlulileyo, 
zimini ezingaphi okhe walibala ukutya 
amchiza akho entsholongwana? 
Range 0-30 
Stayed the same 
Increased by ≥1 missed dose  
Decreased by ≥1 missed dose  
2. E: In the last 30 days, how good a job 
did you do at taking your HIV 
medicines in the way that you were 
supposed to? 
X: Kwezi ntsuku zi-30 zidlulileyo 
uwatye kakuhle kanjani amachiza 
akho entsholongwane njengohlobo 
omele ukuwatya ngalo? 
Range “very poor” to “excellent” (1-6) 
Stayed the same 
Increased by ≥1 level  
Decreased by ≥1 level  
3. E: In the last 30 days how often did 
you take your HIV medicines in the 
way that you were supposed to? 
X: Kwezi ntsuku zi-30 
zidlulileyo,kukangaphi usitya 
amachiza akho entsholongwane 
ngendlela omele kuwatya ngayo? 
Range “never” to “always” (1-6) 
Stayed the same  
Increased by ≥1 level  
Decreased by ≥1 level  
Combined three-item scale 
Range 0-100 
Change ≤1 missed dose, both Likert items stayed the same 
Score increased ≥2 missed doses  
Score decreased ≥2 missed doses 
 
Change ≤4 missed doses, both Likert items stayed the same 
Increased by ≥1 level or ≥5 missed doses on any item  
Decreased by ≥1 level or ≥5 missed doses on any item  
 
Change ≤9 missed doses or 1 level change in either Likert item 
Increased by ≥2 levels or ≥10 missed doses on any item 
Decreased by ≥2 levels or ≥10 missed doses on any item 
E – English; X – isiXhosa 
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Visits 
Women were included in analyses from their first suppressed viral load after ART initiation 
(V0). To minimize potential bias introduced by attrition from the study, we included only 
women who had at least four consecutive study visits after V0 in primary analyses of self-
reported adherence and viral load over time (n=363). Data on trends over time for all women 
where at least one visit with both an adherence and a viral load measure was available after 
V0 are presented in supplementary material (n=434). We examined changes in self-reported 
adherence from each visit (Vi) to the next visit (Vi+1) among all available visit pairs from 
initial viral suppression (or from 16 weeks on ART in sensitivity analyses). Vi+1 was defined 
as the first visit occurring 1-6 months after Vi. Figure 5-1 summarizes A) the women and 
visits included in each analysis and B) the visit pair structure. 
 
Figure 5-1 A) Flow diagram of patient and visit inclusion and B) schematic of visit pairs 
where the first visit (V0) is the first suppressed visit after ART initiation in pregnancy. 
Adherence and viral load thresholds 
To describe the adherence scale score over time, thresholds of 100 versus <100 and ≥80 
versus <80 were used. In prior work these cut-offs produced a reasonable balance between 
sensitivity and specificity [32]. To analyse changes in adherence score from Vi to Vi+1, we 
used a simple approach that could potentially be applied in routine care. We determined 
thresholds based on the minimum possible change in each self-reported adherence item. For 
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item 1, reporting missed doses during the past 30 days, we examined a change of a single 
missed dose. For the other two items, 6-level Likert-type responses, a one-level change in 
response was examined. Larger changes in reported adherence were explored in sensitivity 
analyses, however there were very few visit pairs with larger changes and thus these data are 
not presented. For the combined scale score, we examined changes ranging from a single 
missed dose change in item 1 or a one level change in either of the Likert rating items, 
through to a change of ≥10 missed doses or ≥2 level change in either of the Likert rating 
items. All the change thresholds are outlined in Table 5-1. Viral load thresholds of >50 and 
>1000 copies/mL were examined based on the South African National ART guideline 
definitions of suppression and flags for treatment failure [33]. 
Analyses 
Data were analysed in Stata v14.0 (Stata Corporation, College Station, Texas, USA). Means 
with standard deviation (SD) or medians with interquartile ranges (IQR) were used to 
describe continuous variables. Frequencies and proportions were used to describe categorical 
variables. Regression coefficients (as slopes) with standard error (SE) and chi-squared tests 
for trend were used to assess trends in reported adherence and viral load over time. 
Generalized estimating equations (GEE) with robust SE and exchangeable correlation 
structures were used to explore the association between changes in reported adherence from 
Vi to Vi+1 and viral load at Vi+1 [13,34]. Quasi-likelihood under the independence model 
criterion (QIC), a modification of the Akaike information criterion (AIC), was used for model 
selection [35]. We included baseline self-reported adherence, viral load at Vi and time 
between Vi and Vi+1 in all models and examined additional baseline covariates (maternal 
age, marital status, education, employment, gravidity, gestational age at presentation for 
ANC, timing of diagnosis and CD4 cell count) that are often available in routine care and 
have previously been found to be associated with poor adherence or loss to follow-up [36]. 
We then selected the final adjusted model based on the lowest QIC. Model results were 
reported as crude (OR) and adjusted odds ratios (aOR) with 95% confidence intervals (CI).  
Primary analyses included all women who achieved viral suppression after ART initiation 
and who had at least one visit with both adherence and viral load data available following 
initial suppression (n=434; 92% of the total cohort of 471). Sensitivity analyses were 
conducted including an additional 17 women who did not achieve viral suppression but had 
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adherence and viral load measurements after 16 weeks on ART. These results were very 
similar and are presented in supplementary material. 
Ethics 
All women included in this analysis provided written informed consent on enrolment into the 
parent study. This study was conducted in accordance with the Declaration of Helsinki and 
was approved by the Columbia University Institutional Review Board and the University of 
Cape Town Human Research Ethics Committee. 
5.4 Results 
Among 471 women followed in the parent cohort, 37 women were excluded from analyses 
either because they were never observed to reach viral suppression (n=24) or they did not 
have at least one visit with adherence and viral load measured after achieving suppression 
(n=13). A total of 2828 visits were available from 434 included women (mean 4 visits per 
woman after initial viral suppression [range 1-9]). The median age was 28 years (IQR 25-33), 
41% were married or cohabiting and 56% had been diagnosed with HIV in the incident 
pregnancy (Table 5-2). Only 18% were in their first pregnancy and median gestational age at 
presentation for ANC was 21 weeks (IQR 16-26). Adherence and viral load over time were 
examined among women who had at least four consecutive visits after initial suppression 
(n=363) to minimize the impact of attrition, as well as among all 434 women. Women 
excluded were younger, more likely to be in their first pregnancy, presented later for ANC 
and had slightly lower baseline CD4 cell counts compared to the women included (Table 
5-2). 
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Table 5-2 Descriptive characteristics of women at the time of presentation for antenatal care, 
presented as n (%) unless otherwise stated. 
 ≥4 consecutive visits after 
first viral suppression 
≥1 visit after first viral 
suppression 
All women in 
the parent 
cohort  Included  Excluded Included  Excluded 
Number of women 363 (77) 108 (33) 434 (92) 37 (8) 471 
Median age (IQR) 28 (25-33) 27 (23-31) 28 (25-33) 26 (23-30) 28 (24-32) 
Age ≤25 95 (26) 42 (39) 121 (28) 16 (43) 137 (29) 
Married/cohabiting 152 (42) 41 (38) 178 (41) 15 (41) 193 (41) 
Completed secondary 
school 
87 (24) 30 (28) 104 (24) 13 (35) 117 (25) 
Employed 143 (39) 41 (38) 169 (39) 15 (41) 184 (39) 
First pregnancy 60 (17) 27 (25) 78 (18) 9 (24) 87 (18) 
Diagnosed with HIV in 
this pregnancy 
199 (55) 69 (64) 245 (56) 23 (62) 268 (57) 
Median CD4 (IQR) 355 (254-544) 327 (214-469) 354 (251-534) 284 (173-456) 354 (248-517) 
Median weeks gestation 
(IQR) 
20 (16-25) 24 (19-30) 21 (16-26) 25 (21-31) 21 (16-26) 
Median adherence 
score at first visit on 
ART 
89 (78-94) 89 (78-94) 89 (78-94) 93 (78-94)  
 
Self-reported adherence and viral load over time 
Among women with at least four visits after initial suppression (n=363), the proportion 
reporting adherence scores ≥80 increased slightly over time (slope 0.024, SE 0.004; chi-
squared for trend p<0.001) while the proportion with viral loads ≤1000 copies/mL decreased 
(slope -0.028, SE 0.003; chi-squared for trend p<0.001) (Figure 5-2). These patterns were 
consistent when including all 434 women (Supplementary Figure 9-5-1) and in sensitivity 
analyses including women who did not suppress after ART initiation (Supplementary Figure 
9-5-2). Although individual fluctuations in reported adherence were observed 
(Supplementary Figure 9-5-3), the median reported adherence remained stable over time 
(Supplementary Table 9-5-1). 
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Figure 5-2 Proportion of women with adherence scores ≥80 and HIV viral loads ≤1000 
copies/mL among 363 women with at least four study visits after V0 (first visit with a viral 
load ≤50 copies/mL after ART initiation during pregnancy). Data are shown from V0 through 
4 additional visits (V1-V4). 
Association between changes in self-reported adherence score and viral load 
To analyse changes in reported adherence, 2085 visit pairs were available for 433 women 
(mean 3 visit pairs per woman [range 1-8]). The average time between Vi and Vi+1 was 2.4 
months (SD 1.1). An adherence score ≥80 was reported at Vi in 81% and at Vi+1 in 83% of 
visit pairs. Viral load at Vi and Vi+1 was ≤50 copies/mL in 89% and 84% of visit pairs, and 
≤1000 copies/mL in 93% and 89% of visit pairs, respectively. Overall, viral load remained 
below 50 copies/mL in most visit pairs. Viral load declined from >50 to ≤50 copies/mL in 
only 1% of visit pairs and increased from ≤50 to >50 copies/mL in 5% of pairs 
(Supplementary Table 9-5-2). 
The results of univariable GEE models predicting viral load >50 and >1000 copies/mL at 
Vi+1, independent of the viral load measure at Vi, are presented in Table 5-3. Using the 
change thresholds outlined in Table 5-1 for a minimum change in each individual item and 
three different change thresholds on the combined scale score, a decrease in score was 
associated with viral load >50 and >1000 copies/mL. These results persisted in sensitivity 
analyses that included women who had never suppressed but who had at least 16 weeks on 
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ART (Supplementary Table 9-5-3). In stratified analyses restricted to visit pairs where the 
viral load at the first visit of the pair (Vi) was ≤50 copies/mL (1852 visit pairs), the strength 
of association increased. However, when restricted to women who already had a raised viral 
load at Vi (126 visit pairs), a change in reported adherence was no longer predictive of 
having a raised viral load at Vi+1 (Table 5-3). 
Multivariable models were examined for the two thresholds with the strongest associations: 
Item 2 “How good a job did you do at taking your HIV medicines in the way that you were 
supposed to?”, and the combined three-item scale threshold of a change of one level on either 
of the Likert items or ≥5 missed doses. A single level decrease in reported adherence on item 
2 remained predictive of having a viral load >50 and >1000 copies/mL (aOR 2.62 95% CI 
1.57-4.30 and aOR 1.91 95% CI 1.15-3.17, respectively) in adjusted models (Supplementary 
Table 9-5-4). Similarly, a decrease in self-reported adherence score equivalent to ≥5 missed 
doses or a one level decrease in score on either item 2 or 3 also remained predictive of viral 
load >50 and >1000 copies/mL (aOR 1.62 95% CI 1.11-2.38 and aOR 1.42 95% CI 1.00-
2.03, respectively). Again, these results were consistent in sensitivity analyses 
(Supplementary Table 9-5-5). In all analyses, there was no association between an 
improvement in reported adherence and odds of viral suppression at Vi+1. Increasing age, 
being married/cohabiting and being employed all independently reduced the odds of having a 
raised viral load, while increasing months on ART, presenting later for ANC, having a viral 
load >50 or >1000 copies/mL at Vi, and increasing time between Vi and Vi+1, increased the 
odds of having a viral load >50 and >1000 copies/mL at Vi+1 (Supplementary Table 9-5-4; 
univariable associations presented in Supplementary Table 9-5-6). 
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Table 5-3 Univariable GEE models for change in each reported adherence from Vi to Vi+1 to predict viremia >50 and >1000 copies/mL at Vi+1 in 
all visit pairs and stratified by viral load ≤50 or >50 copies/mL at Vi. Results are presented as odds ratios with 95% confidence intervals; 
statistically significant associations are in bold. 
 All visit pairs Pairs with Vi viral load ≤50 
copies/mL 
Pairs with Vi viral load >50 
copies/mL 
Number of women 433 428 126 
Number of visit pairs 2085 1852 233 
 Number of 
visit pairs, 
N (%) 
To predict 
viral load >50 
copies/mL 
To predict viral 
load >1000 
copies/mL 
To predict 
viral load >50 
copies/mL 
To predict viral 
load >1000 
copies/mL 
To predict viral 
load >50 
copies/mL 
To predict viral 
load >1000 
copies/mL 
Change in item 1 (missed dose)         
No change in missed doses 1621 (78) Ref Ref Ref Ref Ref Ref 
Increased ≥1 missed dose 223 (11) 0.95 (0.65-1.40) 0.97 (0.62-1.23) 0.96 (0.54-1.71) 1.37 (0.71-2.65) 1.28 (0.51-3.21) 0.85 (0.41-1.76) 
Decreased ≥1 missed dose 241 (12) 1.45 (1.07-1.97) 1.41 (1.04-1.93) 1.72 (1.11-2.66) 1.54 (0.84-2.81) 1.87 (0.71-4.92) 1.64 (0.87-3.07) 
Change in item 2 (good job)         
No change 1824 (87) Ref Ref Ref Ref Ref Ref 
Increased ≥1 level 139 (7) 1.07 (0.70-1.64) 0.93 (0.55-1.58) 0.98 (0.49-1.94) 0.72 (0.26-1.97) 2.36 (0.53-10.52) 1.83 (0.88-3.78) 
Decreased ≥1 level 122 (6) 2.08 (1.48-2.91) 1.89 (1.33-2.68) 2.30 (1.32-3.99) 2.09 (1.03-4.25) 5.57 (0.80-38.64) 1.85 (0.67-3.93) 
Change in item 3 (how often)        
No change 1600 (77) Ref Ref Ref Ref Ref Ref 
Increased ≥1 level 240 (12) 0.98 (0.72-1.33) 0.76 (0.51-1.34) 1.23 (0.75-2.00) 1.09 (0.55-2.16) 0.83 (0.33-2.12) 0.61 (0.30-1.23) 
Decreased ≥1 level 245 (12) 1.34 (0.98-1.83) 1.10 (0.79-1.54) 1.72 (1.09-2.71) 1.73 (0.97-3.09) 1.73 (0.63-4.75) 0.82 (0.43-1.57) 
Change in combined score        
No change in missed doses 565 (27) Ref Ref Ref Ref Ref Ref 
Increased ≥1 missed dose 784 (38) 1.00 (0.78-1.27) 0.96 (0.73-1.25) 1.08 (0.70-0.66) 1.05 (0.58-1.89) 1.04 (0.45-2.40) 0.94 (0.51-1.76) 
Decreased ≥1 missed dose 736 (35) 1.23 (0.98-1.54) 1.22 (0.96-1.55) 1.53 (1.01-2.31) 1.72 (0.99-2.97) 1.00 (0.43-2.32) 1.03 (0.57-1.87) 
Change ≤4 missed doses 1209 (58) Ref Ref Ref Ref Ref Ref 
Increased ≥1 level or ≥5 missed doses 447 (21) 1.02 (0.78-1.34) 0.95 (0.69-1.30) 1.19 (0.78-1.81) 1.23 (0.42-2.12) 1.21 (0.54-2.72) 1.08 (0.60-1.93) 
Decreased ≥1 level or ≥5 missed doses 429 (21) 1.34 (1.06-1.69) 1.32 (1.05-1.68) 1.69 (1.16-2.47) 1.71 (1.05-2.78) 1.19 (0.55-2.57) 1.37 (0.79-2.36) 
Change ≤9 missed doses or 1 level 1321 (63) Ref Ref Ref Ref Ref Ref 
Increased ≥2 levels or ≥10 missed doses 387 (19) 0.94 (0.72-1.24) 0.87 (0.63-1.21) 1.19 (0.78-1.82) 1.24 (0.71-2.16) 1.28 (0.53-3.11) 1.09 (0.61-1.92) 
Decreased ≥2 levels or ≥10 missed doses 377 (18) 1.29 (1.02-1.63) 1.28 (0.99-1.65) 1.65 (1.11-2.45) 1.76 (1.07-2.90) 1.25 (0.56-2.77) 1.22 (0.66-2.24) 
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5.5 Discussion 
In this cohort of women living with HIV who were followed from ART initiation during 
pregnancy through 18 months postpartum, decreases in self-reported adherence relative to the 
previous visit were independently predictive of raised viral load. Self-reported adherence 
remained high over repeated follow-up visits and, despite decreases in the proportion of 
women with viral suppression over time, over 80% of women attending each visit were 
virally suppressed. 
With a rapidly growing population on ART, routine viral load monitoring is recommended at 
least annually with increased frequency during pregnancy and breastfeeding, but not all 
settings are able to implement such frequent viral load testing [3,8]. Assessing change in 
reported adherence may provide an interim assessment to flag patients requiring additional 
intervention between viral load measures. The association between reporting decreased 
adherence and having a raised viral load in our cohort was most marked when restricted to 
visits where the viral load at the previous visit was suppressed. When participants had an 
unsuppressed viral load at the first visit of the pair, a decline in reported adherence did not 
predict viremia. However, in this adherent cohort there were relatively few such cases, which 
reduced statistical power to detect these differences. In routine practice this may be less of a 
concern as women with any raised viral loads should already be flagged for further 
intervention. One possible application may be to measure change in reported adherence 
following a suppressed viral load as an interim screening tool to prompt adherence 
counselling or viral load testing only among women reporting worse adherence. Further 
exploration of the utility and application of this approach is warranted in routine care settings 
where resources limit the frequency of viral load testing or other objective adherence 
measures. 
Self-reported adherence measures, although subject to well-documented biases, present the 
patient’s perception of their own adherence behaviour, e.g. some patients may miss a few 
doses and report excellent adherence while others may miss the same number of doses and 
report very poor adherence. Assessing a change in reported adherence in an individual over 
two consecutive visits could be a straightforward way for providers to flag emerging 
adherence problems, relative to each patient’s individual reporting. We found that, on 
average, women with viremia >50 or >1000 copies/mL, had increased odds of reporting 
worsening adherence across two visits on one or more of the three adherence scale items. 
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These findings persisted after adjusting for duration between visits, viral load at the previous 
visit, and other covariates. Previous studies have used similar methods to assess the 
predictors of changes in reported adherence, but few have linked this change to a biological 
or objective adherence marker [21,22,24]. The three individual scale items examined 
independently did not all perform equally. The second item, a Likert rating scale of how good 
a job you did taking your medication in the last 30 days, had the highest point estimates (OR 
2.08 95% CI 1.48-2.91 to detect viral load >50 copies/mL). An additional benefit of this 
change in adherence approach is that no adherence score conversions would be required. A 
provider could, for example, plot a patient’s response to each of the three questions at each 
visit. A patient reporting a poorer score on any or a combination of the questions could be 
flagged for further evaluation and appropriate interventions. Whether longitudinal changes in 
adherence could be assessed in this way, or even using a single item, merits testing in other 
populations and in routine care settings. 
Although a strength of this study is the very well-characterized cohort contributing over 2800 
visits, it is important to note that there was attrition over time. Women excluded from these 
analyses were younger, more likely to be in their first pregnancy, presented later for ANC 
and had lower CD4 cell counts compared to the overall cohort. These characteristics are all 
potential risk factors for loss to follow-up and poor ART adherence [36]. In pregnant and 
postpartum women, younger age in particular has been consistently found to predict loss to 
follow-up and poor adherence [36,37]. By including only the available data, selection bias 
was introduced and women at higher risk of poor adherence or viremia are likely to have 
been excluded. While this is a limitation, it is equivalent to the selection bias that would be 
present in the monitoring of ART services in routine care settings. This emphasizes the 
importance of comprehensive efforts to retain all people living with HIV in ART services. 
The longitudinal relationships between changes in self-reported adherence and viral load will 
likely vary depending on the distribution of reported adherence and viral load levels in the 
population being examined, the population sampled (e.g. pregnant and postpartum women), 
and other contextual factors. Here we studied pregnant and postpartum women from a single 
site in Cape Town, South Africa. This is likely representative of other urban sites in South 
Africa and sub-Saharan Africa but generalizability to other settings and populations should be 
considered with caution. All adherence and viral load measures were taken as part of research 
study visits, independent of routine HIV care, which may have reduced socially desirable 
response bias. Language and context translation are complex issues that may have impacted 
130 
 
these results. The self-report scale was translated into isiXhosa directly from the questions 
designed and validated in the United States and translation could partly explain the 
differences observed between the individual adherence items. Results may be strengthened by 
exploring cognitive interviewing approaches in the local language. We studied a population 
with excellent adherence and high rates of viral suppression for whom, in most cases, 
adherence could only decrease. It would be important to repeat this analysis in less adherent 
populations for whom adherence could both increase and decrease. Lastly, we were unable to 
assess the association between changes in self-reported adherence and an objective adherence 
marker, such as electronic drug monitoring or drug-level monitoring, which may be better 
“gold standard” measures of adherence behaviours than viral load. 
5.6 Conclusion 
In this cohort of South African women who initiated ART during pregnancy as part of routine 
care, self-reporting worse adherence relative to the previous visit on any of three simple 
adherence questions, and specifically the Likert item asking how good a job you did taking 
your medications in the way you were supposed to, was consistently associated with viremia. 
These results show that changes in self-reported adherence could provide a simple flag for 
women at risk for raised viral loads. This approach warrants further consideration in the 
context of monitoring ART adherence in settings with limited access to viral load and 
objective adherence monitoring. 
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Relevance of this paper to the thesis: 
This thesis focuses on engagement in maternal ART care which includes both adherence to 
ART (the focus of Chapters 3 through 5) as well as retention in HIV care. In the general 
adult ART literature, as well as among pregnant and postpartum women, there is major 
variability in definitions and approaches to measuring retention and most studies use 
facility-specific data sources. This paper focuses on the use of interlinked routine 
electronic medical records to measure retention in HIV care and explores the impact of 
using different definitions and routine data sources to estimate retention. 
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6.1 Abstract 
Retention in HIV care is required to achieve viral suppression and is measured to support 
patient care and to monitor HIV programs. A variety of data sources and definitions are used 
to estimate retention and most estimates are facility-specific. We examined the impact of 
different definitions and routine data sources (clinic visit, laboratory test and pharmacy 
dispensing data), linked across facilities, on estimates of retention, consistency of 
associations with risk factors for non-retention, and associations between retention and viral 
load, in a cohort of women who started antiretroviral therapy (ART) in pregnancy in South 
Africa. Different data sources and definitions yielded markedly different retention estimates. 
However, regardless of data source or definition, the proportion of women retained declined 
through 24 months on ART and associations with known risk factors for non-retention 
remained consistent. Clinic visit data identified over 80% of women considered retained in all 
definitions and provided a robust data source for measuring retention. Researchers must 
carefully consider the most appropriate retention definition depending on the available data 
sources and presentation of more than one approach may be warranted to obtain both context-
appropriate and comparable estimates. Unique patient identifiers and linking existing data 
sources should be prioritised to improve retention estimates for patient care and program 
monitoring. 
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6.2 Introduction 
Sustained retention on lifelong antiretroviral therapy (ART) for all people living with HIV, 
the second 90 in the UNAIDS 90-90-90 targets [1] remains a significant challenge globally 
[1,2]. Pregnant and postpartum women were the first to receive universal ART and over 80% 
of women with known HIV infection in sub-Saharan Africa received antiretrovirals during 
pregnancy in 2017 [3,4]. However, almost a quarter of women starting ART during 
pregnancy in Africa are estimated to be lost from HIV care by 12 months on treatment [5] 
and concerns about retention in care abound [6,7]. Retention in care is a necessary precursor 
to viral suppression and treatment success, thus monitoring postpartum retention in care, as 
well as developing and evaluating interventions to improve postpartum retention, has been a 
focus of much research [5,8–10]. 
Over the past decade there have been a number of calls for a more standardized approach to 
measuring retention in HIV care [11–13]. Despite this, the methods used to estimate retention 
in HIV care remain variable. In the existing literature reporting on postpartum retention since 
the start of universal ART for pregnant and breastfeeding women, a variety of data sources 
and many different definitions have been used [5,8,9,13]. Most studies use facility-specific 
clinic visit data, sometimes including pharmacy dispensing, either from physical record 
review of patient folders and clinic registers or from electronic records. In addition, a few 
studies of postpartum women and adult ART cohorts have used laboratory test data to 
estimate retention [14,15]. There is also variation in the literature on definitions of retention. 
Commonly used definitions can be grouped broadly into cross-sectional (evidence of 
accessing care in one specified window of time [16–18]), longitudinal (evidence of accessing 
care in multiple windows of time [19–21]), and gaps in care (assessing time between attended 
visits [22–26] or time with no ART in hand [27–30]), or a combination of the three [31–33]. 
The need for longitudinal definitions that can capture continuity of care, particularly in the 
context of pregnancy and postpartum, was raised by Rollins et al [13]. Visit constancy is one 
commonly used longitudinal measure while the Health Resources and Services 
Administration (HRSA) HIV/AIDS Bureau (HAB) definition is frequently used in the United 
States [34,35]. Both measures use an accumulation of cross-sectional retention measures over 
multiple time points to estimate continuity of care. 
Another key element of estimating retention is whether attempts are made to ascertain care 
engagement beyond a single facility of interest. Pregnant and postpartum women are often 
required to transfer care, either to start ART during pregnancy or to continue treatment at a 
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general ART clinic postpartum [36,37]. It is well documented that patients who transfer out 
of one facility do not always link to care at a new facility, while many patients who are 
considered lost are accessing care elsewhere [14,37,38]. To successfully monitor outcomes 
on ART among pregnant and postpartum women who are required to transfer, and to 
intervene when women have been lost from care, there is a need to ascertain retention beyond 
the facility of ART initiation. Interlinked routine health information systems are currently 
recommended by the World Health Organisation (WHO) for patient monitoring to allow 
assessment of continuity of care across programs and facilities [39], yet much of the retention 
literature, in both maternal and adult ART cohorts, relies on single facility-specific data 
sources. 
To systematically investigate the impact of variation in data sources and definitions used to 
estimate retention using interlinked data, we used routine electronic clinic visit, pharmacy 
refill and laboratory test data, linked across clinics, for an existing cohort of women who 
initiated ART in pregnancy in South Africa. First, we examined the impact of data sources 
and retention definitions on estimates of retention in care through 24 months on ART. 
Second, we explored the contribution of individual and combined data sources to retention 
estimates. Third, we investigated the consistency of associations between known risk factors 
and different retention estimates, and lastly, we compared the association between different 
estimates of retention and HIV viral load, a key biological marker of treatment success. 
6.3 Methods 
Study participants  
This is a secondary analysis of data collected during the MCH-ART study, a large 
implementation science trial that aimed to optimize ART services for postpartum women in 
Gugulethu, Cape Town, South Africa. The full study methods and the primary results have 
been reported [18,40]. Briefly, the study consecutively enrolled 628 pregnant women living 
with HIV who were eligible to initiate ART (April 2013-April 2014). All women were 
prospectively followed through delivery; a subset of breastfeeding women were followed 
through 18 months postpartum. Study data included demographics, date and gestation at ART 
initiation, delivery details and batched study viral load measures roughly every three months. 
Routinely collected electronic health data were obtained retrospectively for all women from 
presentation for antenatal care (ANC) through 30 months on ART. 
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Setting 
Gugulethu is characterised by high levels of poverty and the antenatal HIV seroprevalence in 
2015 was approximately 30% [41]. Health services are provided free of charge at all public 
primary health care facilities. In this setting, women receive integrated ANC and ART 
services during pregnancy and are required to transfer to general ART clinics to continue care 
postpartum. During the MCH-ART trial, women were randomly assigned to be transferred 
our per standard of care (6-10 weeks postpartum) or at cessation of breastfeeding [18]. 
During the study period, 1-4 months of ART was dispensed at each clinic visit depending on 
the facility and model of care. Routine viral load tests were expected every 3-6 months during 
pregnancy and breastfeeding and annually thereafter [42,43]. 
Routine data sources 
Routine electronic health data (summarised in Supplementary Table 9-6-1) were obtained 
from the Provincial Health Data Centre (PHDC) of the Western Cape Department of Health 
and the National Health Laboratory Services (NHLS) database. The PHDC structure has been 
described in detail elsewhere [44]. In brief, the PHDC receives data from all public health 
facilities in the Western Cape including clinic visits (routinely captured by clerks at each 
facility into the local clerical information systems and electronic registers) [45] and pharmacy 
dispensing data from the local pharmacy administrative databases. All patients receiving care 
in the province are allocated a unique patient identifier which is used to link records for 
patients across facilities. Data on HIV-related laboratory testing (CD4 cell counts and HIV 
viral loads) were abstracted from the NHLS database using patient identifiers collected at 
study enrolment. Where possible to differentiate, acute health care contacts and contacts with 
non-routine services were excluded. Although data on ART refills were frequently available 
within the clinic visit data, the data directly from the pharmacy dispensing databases was less 
consistently available across facilities, thus this data source was not considered alone but only 
as an additional source. 
Retention definitions 
Definitions of retention that have been frequently used in the adult or maternal ART literature 
were compared (Table 6-1). These included cross-sections, 6- and 12-month visit constancy 
(binarized at 100% visit constancy over all 6-month windows in the 24-month period), the 
HRSA-HAB definition and gaps in care. Data on next appointments and quantity of ART 
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dispensed were not reliably available and thus definitions using gaps without treatment and 
missed visits were not considered. We examined retention from ART initiation to 24 months 
on ART. All databases were closed on 31 December 2016, allowing a minimum of 30 months 
on ART for all women. This provided 180 days after the primary point of interest, 24 months 
on ART, so all women had the potential to experience the outcome of interest by 24 months 
when using the definition of a 180-day gap in care [12].  
Table 6-1 Retention definitions included in analyses and examples from the literature. 
Retention definition Description of retention Examples from the literature 
Cross-sections    
6-month window Any single HIV-specific contact 
within a 6-month window (e.g. 
0-6 months on ART) 
- Visited the clinic at 12 
months postpartum ±1 
month [16] 
- Evidence of any HIV-care 
contact between 9 and 18 
months postpartum [18] 
12-month window Any single HIV-specific contact 
within a 12-month window (e.g. 
0-12 months on ART) 
Longitudinal   
100% 6-month visit 
constancy 
At least one HIV-specific 
contact in each 6-month period: 
0-6, 6-12, 12-18 and 18-24 
months on ART 
- Visit constancy example:  
At least one visit within one 
month of 6 weeks, 3, 6, 9 
and 12 months [19] 
- HRSA-HAB example: 
Whether a patient had 2 kept 
visits separated by >90 days 
during the 12-month 
observation period [35] 
100% 12-month visit 
constancy 
At least one HIV-specific 
contact in each 12-month 
period: 0-12 and 12-24 months 
on ART 
100% HRSA-HAB Two HIV-specific contacts 
separated by 90 days or more 
within each 12-month period: 0-
12 and 12-24 months on ART 
Gap in care   
180-day visit gap  No gap of >180 days without a 
visit through 30 months after 
ART start 
- No gap in visits ≥180 days 
[22] 
- No gap in visits ≥3 months 
[26] 150-day visit gap No gap of >150 days without a 
visit through 30 months after 
ART start 
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Covariates associated with retention estimates 
Using a combination of all data sources, we examined the consistency of associations 
between different estimates of retention 0-24 months on ART and three covariates. The 
covariates were based on consistent risk factors for non-retention reported in a recent 
systematic review of postpartum retention [5]: younger age (<25 years), being newly 
diagnosed with HIV at ART start, and late gestation at presentation for ANC (≥20 weeks 
gestation).  
Association of retention estimates with viral load 
Lastly, we examined the association between retention estimates and viral load ≥1000 
copies/mL, in line with the initial flag for treatment failure in the South African National 
ART Guidelines [46]. Viral load is a key marker of treatment success, thus we wanted to 
investigate the impact of differences in retention estimates on the association between 
retention in the first 24 months on ART and viral suppression near the end of this period. We 
combined viral load results from the routine laboratory data with viral loads taken as part of 
the parent MCH-ART study and selected the viral load nearest to 18 months on ART within a 
window of 12 to 24 months on ART. Viral loads conducted during the study were batch 
tested by the NHLS using the same assays as routine care viral loads (Roche COBAS 
AmpliPrep/COBAS TaqMan HIV-1 assay; Roche Diagnostics, Branchburg, New Jersey, 
US). Study viral loads were conducted independently from routine HIV care and therefore 
allow insight into viral loads among women retained and not retained in HIV care.  
Statistical analyses 
All analyses were conducted in Stata (StataCorp, College Station, Texas, US) or R (R 
Foundation for Statistical Computing, Vienna, Austria). Characteristics of the cohort are 
described using frequencies and proportions, means with standard deviations (SD) and 
medians with interquartile ranges (IQR) as appropriate. Retention estimates for each data 
source and definition were described as proportions with 95% confidence intervals (CI). Chi-
squared tests were used to compare estimates using different data sources and definitions and 
chi-squared tests for trend were used to assess change in retention estimates over time. Venn 
diagrams created using BioVenn [47] were used to describe the contribution of each data 
source to retention estimates using all sources. Associations between covariates at the time of 
ART initiation and each retention estimate were examined using univariable logistic 
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regression models presented as odds ratios (OR) with 95% confidence intervals (CI). Among 
women with a viral load available between 12-24 months on ART, diagnostic characteristics 
including sensitivity, specificity, positive (PPV) and negative predictive values (NPV), 
positive and negative likelihood ratios (LR) as well as area under the curve (AUC) from 
Receiver Operating Characteristics (ROC) analyses were used to describe the ability of each 
retention estimate to discriminate between women with and without viral load ≥1000 
copies/mL. Sensitivity analyses were conducted assuming women with no available viral load 
were ≥1000 copies/mL. 
Ethical considerations 
The parent study was approved by the Columbia University Institutional Review Board and 
the University of Cape Town Human Research Ethics Committee (UCT HREC). All women 
completed written informed consent prior to enrolment which included consent to link to and 
abstract their paper and electronic routine medical records. This secondary analysis was 
approved by UCT HREC. 
6.4 Results 
Of 628 ART eligible pregnant women enrolled in the MCH-ART study, eight were known to 
have died and three relocated out of South Africa, thus 617 were included (Supplementary 
Table 9-6-2). Follow-up data were included for all women up to 30 months on ART (median 
26 [IQR 25-27] months postpartum at database closure). At the time of presentation for ANC, 
the mean age was 29 years (SD 5), 54% of women were newly diagnosed with HIV and 48% 
presented for ANC before 20 weeks gestation. 
Data sources and definitions 
Estimates of retention in care varied substantially by data source and definition (Figure 6-1). 
The lowest estimates for all definitions were observed when using only the laboratory test 
data: using a 12-month constancy definition and only laboratory data, 55% of women had 
100% constancy compared to 62% using the clinic visit data alone and 72% combining all 
sources (p<0.001). Combining the clinic visit and laboratory test data slightly increased the 
proportion of women considered retained compared to clinic visit data alone, as did the 
addition of data from pharmacy dispensing databases, but all confidence intervals overlapped. 
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Using a combination of all available data sources through 24 months on ART, retention 
estimates ranged from 41% (no gap of >180 days) to 72% (100% 12-month visit constancy, 
described above). Retention declined over time in all definitions. Using a 100% 6-month 
constancy definition and all data sources, retention estimates decreased from 100% in the first 
6 months to 77%, 65% and 58% in months 6-12, 12-18 and 18-24, respectively (chi-squared 
for trend p<0.001). There were similar significant declines in retention from 0-12 to 12-24 
months on ART in both the 12-month constancy and HRSA-HAB definitions (both p<0.001 
on chi-squared for trend). 
The contribution of each data source to retention estimates 
The contribution of each data source to the estimate of retention using a combination of all 
data sources was investigated for each definition of retention from 0-24 months on ART 
(Figure 6-2). Over 80% of women considered retained in each definition were identified in 
the clinic visit data. Of the 72% of women who were estimated as retained using the 100% 
12-month constancy definition, 87% had evidence of retention using the clinic visit data 
alone. An additional 12% were identified using the laboratory test data and only 1% of 
women were identified in the pharmacy databases alone. The laboratory and pharmacy 
databases alone contributed a very small proportion of the women considered retained using 
all databases and the 6-month constancy or HRSA-HAB definitions. When using a retention 
definition of experiencing no gap in care >180 days, the pharmacy databases made a slightly 
larger contribution, accounting for 17% of the estimated retention using all data sources.  
Covariaties associated with estimates of retention in HIV care using different definitions 
Using univariable logistic regression models, we examined crude associations between 
different definitions of retention 0-24 months on ART (using a combination of all available 
data sources) and three simple covariates [5]. Although point estimates varied slightly, there 
were consistent associations with all three covariates (Figure 6-3). Retained women had 
lower odds of being <25 years old and being newly diagnosed with HIV. They also had 
consistently higher odds of having presented for ANC before 20 weeks gestation.  
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Figure 6-1 The proportion of 617 women considered fully retained in HIV care using different individual and combination data sources across 
retention definitions in the first 24 months on ART.
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Figure 6-2 Overlap of retention in HIV care using each of laboratory tests, clinic visit data or 
pharmacy databases. Retention was measured from ART initiation through 24 months on 
ART using the following definitions: A) 100% 6-month visit constancy (n=298 retained 
using all data sources), B) 100% 12-month visit constancy (n=446 retained using all data 
sources),C) 100% HRSA-HAB definition (n=378 retained using all data sources) and D) 
never experiencing a 180-day gap in care (n=256 retained using all data sources). 
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Figure 6-3 Univariable associations of characteristics at ART start with retention in care 
through 24 months on ART using different definitions based on all available data sources. 
Results are presented as odds ratios (OR) with 95% confidence intervals (CI); n=617 except 
for C where n=613. (ANC – antenatal care). 
 
Relationship between retention estimates and viral load 
Of the 617 women included, 475 (77%) had a viral load result available between 12 and 24 
months on ART (median 17 months on ART, IQR 16-19). Overall, 75% of viral loads came 
from the MCH-ART study (Supplementary Table 9-6-2). Women with no viral load available 
were more likely to be <25 years old and newly diagnosed with HIV at entry into ANC. A 
higher proportion of those with viral loads available were estimated to be retained in care 
compared to those with no available viral load, regardless of retention definition and data 
source. Analyses predicting viral load ≥1000 copies/mL were conducted using complete 
cases (Supplementary Table 9-6-3) and in sensitivity analyses assuming all women with no 
viral load were ≥1000 copies/mL (Supplementary Table 9-6-4). 
When assessing the performance of each retention definition using a combination of all data 
sources to predict viral load <1000 copies/mL, any 180-day gap in care had the highest 
sensitivity (93% [95% CI 86-97%]) and AUC (0.792 [95% CI 0.757-0.826]). It also had a 
very low LR- (0.1 [95% CI 0.1-0.2) indicating good ability to rule out viral load ≥1000 
copies/mL. This was very similar when using only the clinic visit data (sensitivity 93% [95% 
CI 86-97%], AUC 0.732 [95% CI 0.696-0.767]). NPVs were above 80% for all definitions 
except for the 100% 6-month visit constancy using laboratory data, but a substantial 
proportion of those who were not considered retained had viral loads <1000 copies/mL with 
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PPVs ranging from 25 to 64%. The findings remained similar in sensitivity analyses 
assuming missing viral loads were ≥1000 copies/mL, although PPVs and AUCs all improved 
slightly (Supplementary Table 9-6-4). 
6.5 Discussion 
These results highlight that careful consideration is required to select the most appropriate 
retention definition depending on the available data sources. Different data sources and 
definitions of retention result in marked variation in the estimates of the proportion of 
patients retained in care over time. However regardless of data source or definition, the 
proportion of women retained declined over time and associations with known risk factors for 
non-retention remained consistent. Experiencing any 180-day gap in care had the strongest 
association with the clinical outcome of HIV viral load, although relatively strong 
associations were observed for all definitions using clinic visit data alone, or in combination 
with additional data sourcesClinic visit data, which is the most frequently used data source to 
measure retention in HIV care, identified over 80% of women estimated to be retained 
regardless of the definition used. These data are aligned to local visit schedules and allow for 
measurement of the local care cascade. Clinic visit data are usually available to programs and 
researchers in some format, but they are not always electronic and seldom linked across 
facilities. This makes it difficult to account for transfers and clinic switching, important 
considerations in maternal ART cohorts who are often required to transfer from integrated 
antenatal ART services to general ART clinics postpartum [14,37]. The use of interlinked 
clinic visit data in this cohort, where everyone had to transfer clinics, was a robust data 
source for estimating retention. If interlinked data sources are not available, active tracing of 
at least a sample of women would be critical to verify transfer and ascertain retention 
elsewhere [48–50]. 
Laboratory testing alone has been used as a surrogate marker for retention in care [14,15]. In 
high-income settings, laboratory testing often closely follows the schedule of clinic visits, and 
in that context using laboratory markers rather than clinic visits has been shown to slightly 
overestimate retention in care [51]. However, in most low-resource settings routine HIV 
laboratory tests are conducted far less frequently than clinic visits or ART dispensing [52,53]. 
In our cohort of women who started ART in pregnancy, viral load tests were expected at least 
every six months during pregnancy and breastfeeding, yet laboratory tests alone resulted in 
much lower estimates of retention than clinic visits suggesting that testing is not always done 
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as scheduled. Despite this, laboratory test data may be more likely than clinic visit data to be 
managed centrally and have the potential to link across clinics [15]. 
Regardless of data source or definition, retention in HIV care appeared to worsen over time 
and retention estimates through 24 months on ART using a combination of all data sources 
ranged from 41% to 72%. This is well below the UNAIDS target of 90% of those diagnosed 
with HIV being on ART [1], but in line with estimates of the second 90 in South Africa 
[3,54]. Retention in HIV care is a necessary precursor to viral suppression which is required 
to prevent perinatal, postnatal and sexual transmission, as well as to optimize maternal health. 
The low estimates of retention observed here present a threat to the success of ART 
programmes and emphasise the need for continued research into interventions to support 
sustained retention in HIV care. 
A major strength of this study was the ability to link routine health data for patients across 
facilities and therefore include women who had transferred or switched clinics (all women in 
this setting). Although similar data sources are often available in other low- and middle-
income countries, the availability of these data in electronic databases and linked across 
facilities is unique and may impact the translation of these findings to other settings. The 
findings using clinic visit data and laboratory test data are likely to be generalizable to other 
settings where mobility and transfer are less common, in so far as there is robust paper or 
electronic routine data collection. Routine health data is always subject to error and the 
completeness and quality of the data may have varied over time and by facility. Even in this 
setting, women attending private clinics or clinics outside of the Western Cape could not 
have been linked and would be considered not retained. Complex linking algorithms are used 
to ensure best linkage and prevent duplication, however women may have presented to a 
clinic using different identifying information and preventing linkage. Facility-recorded deaths 
were ascertained through the PHDC, but additional deaths that were not recorded in a health 
facility or occurred outside of the Western Cape may have resulted in overestimation of non-
retention in all data sources.  
We were unable to evaluate definitions based on scheduled visits or time without ART as 
data on next appointments and quantity of ART dispensed were not consistently available. 
Pharmacy refill data has shown great promise as a marker of both retention in HIV care and 
adherence to treatment. Central pharmacy dispensing databases, where available, may also 
provide data linked across facilities [55–57]. A previous study found little difference in 
estimates of retention when counting loss from last attended visit or from a missed scheduled 
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visit [58]. This is particularly reassuring when looking at retention across clinics where, if 
scheduled visits or dispensing quantities are not available electronically, abstracting these 
data from multiple health facilities would likely not be feasible. However, the fact that we 
could not investigate these data is an important limitation as these definitions are 
recommended by the WHO and frequently used by routine ART programs [46]. 
In an era of lifelong ART, and particularly where models of care require transfer between 
ART clinics as in the case of maternal ART, measures that allow ascertainment of retention 
beyond a single facility are critical. Within this framework, there is still need for careful 
consideration of the most appropriate retention definition to use based on available data 
sources, local models of care and intended use. Active tracing of women to ascertain 
retention status beyond the facility of interest is very resource-intensive. Resources should be 
invested into the establishment of unique patient identifiers and leveraging existing clinical, 
clerical and administrative data systems to form interlinked data sources with important uses 
for improving patient care as well as program monitoring and research. 
The tension between a need for context-specific measures, needed to inform local services 
and intervene in patient care, and comparable estimates of retention, needed for program 
monitoring, has been the subject of much discussion [10–13,58] and is highlighted again in 
this work. Alongside clear descriptions of the local context and available data sources, 
presentation of sensitivity analyses using different measurement approaches should be 
encouraged. Clinic visit data appears to be a robust source for measuring retention in care as 
it includes the granularity of data required for context-specific retention estimates as well as 
the breadth of data for more generalisable definitions. We suggest that researchers make use 
of a combination of both an ideal context-appropriate retention definition as well a more 
generalisable definition, such as any 180-day gap in care [11], to allow comparison within 
and between programs and research studies.  
6.6 Conclusion 
Using different interlinked data sources yielded markedly different findings with respect to 
definitions of retention in HIV care in this cohort of women who started ART in pregnancy. 
Benefits and challenges exist for each data source and research should consider the nature of 
the data source used as a critical factor in studies measuring retention. Clinic visit data that is 
linked across facilities provides a robust data source for measuring retention in HIV care. 
Resources should be prioritised to implement unique patient identifiers and leverage these 
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existing data sources to form interlinked health information systems to improve patient care 
and program monitoring. 
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Relevance of this paper to the thesis: 
This manuscript addresses issues of measuring retention as well as understanding factors 
that impact on retention in care postpartum. In particular it focuses on retention in care and 
mobility to access HIV care after leaving integrated antenatal and ART services after 
delivery. The paper highlights high levels of loss from care both at the initial transfer step 
and further along the cascade postpartum. It also shows that women access care in a wide 
geographic area and this clinic switching is not uncommon. This movement appears to be 
related to an increased risk of viraemia and this chapter highlights the need to support 
mobile patients in their HIV care and for data sources that are linked across health 
facilities to better monitor outcomes and intervene where needed.  
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7.1 Abstract 
Introduction: Linkage to care and mobility postpartum present challenges to long-term 
retention after initiating antiretroviral therapy (ART) in pregnancy, but there are few insights 
from sub-Saharan Africa. We aimed to describe postpartum linkage to care, mobility, 
retention and viral suppression after ART initiation in pregnancy. 
 
Methods: Using routine electronic data we assessed HIV-specific health contacts and clinic 
movements among women initiating ART in an integrated antenatal care (ANC) and ART 
clinic in Cape Town, South Africa. The local care model includes mandatory transfer to 
general ART clinics postpartum. We investigated linkage to care after leaving the integrated 
clinic and mobility to new clinics until 30 months on ART. We used Poisson regression to 
explore predictors of linkage, retention (accessing care at least once at both 12 [6 to <18] and 
24 [18 to <30] months on ART), and viral suppression (HIV viral load [VL] ≤50 and ≤1000 
copies/mL after 12 months on ART).  
 
Results: Among 617 women, 23% never linked to care; 71% and 65% were retained at 12 
and 24 months on ART, respectively, with 59% retained in care at both times. Those who 
linked (n=485) accessed HIV care at 98 different clinics and 21% attended ≥2 clinics. 
Women >25 years, married/cohabiting or presenting early for ANC were more likely to link. 
Younger and unemployed women were more likely to attend ≥2 clinics (adjusted risk ratio 
[aRR] 1.10 95% confidence interval [CI] 1.02-1.18 and aRR 1.06 95% CI 0.99-1.12, 
respectively). Age >25 years (aRR 1.17 95% CI 1.02-1.33) and planned pregnancy (aRR 1.20 
95% CI 1.09-1.33) were associated with being retained. Among 338 retained women with VL 
available, attending ≥2 clinics reduced the likelihood of viral suppression when defined as 
≤50 copies/mL (aRR 0.81 95% CI 0.69-0.95). Distance moved was not associated with VL. 
 
Conclusions: These data show that a substantial proportion of women do not link to 
postpartum ART care in this setting and, among those that do, long-term retention remains a 
challenge. Women move to a variety of clinics and young women appear particularly 
vulnerable to attrition. Interventions promoting linkage and continued retention for women 
initiating ART during pregnancy warrant urgent consideration. 
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7.2 Introduction 
Population movement has received much attention in the context of the HIV epidemic [1,2]. 
Migration and mobility may be associated with HIV acquisition and providing HIV care to 
mobile populations presents particular challenges [3–6]. In South Africa, movement between 
rural and urban areas for employment, education, healthcare, cultural and family reasons 
occurs frequently, involving all demographic groups, including women of reproductive age 
[7–9].  
Antiretroviral therapy (ART) during pregnancy and breastfeeding, and associated viral 
suppression, reduces mother-to-child transmission (MTCT), improves maternal health, and 
reduces sexual transmission [10]. However, these benefits hinge on women initiating ART, 
adhering to treatment, and remaining in care in the long term. Postpartum retention is a major 
challenge and there is an urgent need to understand how mobility may contribute to this [11–
15].  
In urban South Africa as well as other settings in sub-Saharan Africa, pregnant HIV-positive 
women who are not yet on ART start treatment during pregnancy in integrated clinics 
providing antenatal care (ANC) and HIV care including ART. Time in the integrated clinic 
after delivery varies, but ultimately women must transfer their HIV care and link to general 
ART clinics postpartum. Additional movement between healthcare facilities also occur due to 
relocation and patient choice. These movements may introduce challenges to the continuum 
of HIV care and maternal health services [3,4,16]. In South Africa, a recent analysis found 
that 38% of postpartum women who were considered lost to follow-up (LTFU) at the clinic 
of ART initiation were in care elsewhere, and 33% received care outside of the province 
where they started ART [13]. However, there are few data on the mobility of women with 
mandatory movement of ART care postpartum, and there is a need to understand the specific 
challenges related to linkage to care and mobility after delivery in these settings.  
To address this, we explored continuity of care including linkage, geographic mobility and 
retention in care in a cohort of women who initiated ART in an integrated ANC-ART clinic. 
The objectives were i) to describe linkage to care after leaving the integrated clinic and 
additional mobility after linking and ii) to explore whether frequency or distance of clinic 
movement were associated with outcomes of retention in care and, in a subset of women, 
viral suppression. 
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7.3 Methods 
Setting 
This is a secondary analysis of women enrolled into the Maternal & Child Health – 
Antiretroviral Therapy (MCH-ART) study, which investigated optimal ART services for 
pregnant and postpartum women (ClinicalTrials.gov NCT01933477). This study was 
conducted at a large primary healthcare clinic in Cape Town, South Africa in an area with 
high rates of unemployment and poverty [17]. ANC coverage is high (~95%) and the 
antenatal HIV seroprevalence is approximately 30% [18]. The clinic serves over 4000 women 
annually from a wide catchment area. Women from neighbouring areas of Cape Town as well 
as from other provinces are known to access services here [19].  
ART initiation and follow-up are provided with ANC by nurse-midwives throughout 
pregnancy. During the study period, ART eligibility was based on local public-sector 
guidelines (WHO stage III/IV disease or CD4 count ≤350 cells/µl until June 2013, and 
thereafter universal ART for pregnant women regardless of disease stage). All women 
initiated a fixed-dose combination of efavirenz, emtricitabine and tenofovir, and initiation 
usually occurred within a week of presentation for ANC. Per local standard of care, all 
women were transferred out to general ART services after delivery. They were provided with 
up to 3 months’ supply of ART and a transfer letter to their new clinic, chosen based on 
preference or proximity to where a woman lived. Women were instructed to attend the new 
clinic before the end of her ART supply but no additional support for linkage occurs in this 
setting.  
Data sources 
Data for this analysis came from multiple sources. Retrospective data from available routine 
electronic data sources were assembled for all enrolled women through a minimum of 30 
months on ART. Additional baseline data for all women, and for a subset of women 
additional prospectively collected data, were obtained from the parent study. The data sources 
are described in detail below. 
The parent study methods have been described previously [20]. Briefly, between April 2013 
and June 2014, 628 ART-eligible pregnant women were consecutively enrolled when they 
presented for ANC at the integrated clinic. Study measurement visits occurred prospectively 
through one month postpartum in all women and through 18 months postpartum in a subset 
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of breastfeeding women (n=471). Mandatory transfer out of the integrated clinic occurred at 6 
weeks postpartum for most women per local standard of care. By study design, 233 women 
remained in the integrated clinic for up to 12 months postpartum (median 7 months, IQR 2-
12). Data from the parent study provided details on baseline demographics, timing of ART 
initiation, delivery outcomes and last visit in the integrated clinic.  
As part of the parent study, routine electronic health data were abstracted retrospectively 
through at least 30 months after ART initiation for all women (final data point December 
2016). Data were abstracted from the National Health Laboratory Services (NHLS) database, 
which provides laboratory data for public health facilities in all provinces of South Africa. In 
addition, electronic data on pharmacy dispensing and clinic contacts, including facility 
recorded deaths were obtained from the Provincial Health Data Centre (PHDC) of the 
Western Cape Department of Health. These data are linked with a unique patient identifier 
and include all public health facilities in the Western Cape Province. Contacts at hospitals 
and other non-HIV services were excluded. 
Measures 
We brought together the above data sources to measure the following constructs. First, we 
defined linkage to care after leaving the integrated clinic based on evidence of at least one 
HIV-specific contact (routine ART clinic visit, antiretroviral (ARV) pharmacy refill or a CD4 
cell count or HIV VL laboratory test) between the last visit at the integrated clinic and 30 
months after ART initiation. Second, we assessed mobility, by determining the location and 
counting each clinic attended after leaving the integrated clinic. This was analysed as a binary 
variable of one versus ≥2 different clinics. Third, we created a global measure of retention in 
HIV care based on evidence of at least one HIV-specific contact at both 12 (6 to <18) and 24 
(18 to <30) months after ART initiation at any clinic (including the integrated clinic for any 
women who linked to care prior to 30 months on ART but had not been transferred out of the 
integrated clinic by 12 months on ART). In sensitivity analyses we also examined evidence 
of HIV-specific contact at only 24 (18 to <30) months after ART initiation and at 18 (12 to 
<24) months postpartum. A 12-month window was used in all definitions as, although routine 
ART visits and ARV dispensing are expected more regularly, routine HIV laboratory results 
(our only nationally available data source) are only expected annually in this setting. Fourth, 
among women considered to be retained in HIV care, we investigated HIV viral suppression 
based on any HIV RNA VL taken nearest to 24 months on ART and at least 12 months after 
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ART initiation. These were primarily routine care VL results from the NHLS database. 
However, if no routine VL was found, available VL results from the MCH-ART study were 
used. VLs were found for 338 women; 61% from NHLS. VL thresholds of ≤50 and ≤1000 
copies/mL were used to define suppression based on definitions of suppression and flags for 
treatment failure in the South African National ART guidelines [21]. 
Analysis 
Analyses were conducted in STATA 14 (STATA Corporation, College Station, TX). 
Descriptive analysis used frequencies and proportions, means with standard deviations (SD) 
or medians with interquartile ranges (IQR) with chi-squared tests, Fisher’s exact test, t-tests 
or rank sum tests as appropriate. ArcMap 10.3.1 (Esri, Inc., Redlands, CA, USA) was used to 
describe the spatial distribution of continued care after the integrated clinic. Multivariable 
Poisson regression models with robust standard errors were used to estimate the relative risk 
of each outcome [22]. Covariates that reached p<0.10 in bivariate analyses were included in 
model building using a step-wise approach. Although the parent MCH-ART trial intervention 
was not the focus of this analysis, the MCH-ART intervention did impact retention in HIV 
care at 12 months postpartum in the primary trial analysis [23] and some differences were 
seen for the retention outcomes in this analysis (Supplementary Table 9-7-6). To account for 
differences in subgroups of women who received continued prospective follow-up and/or 
delayed transfer out of the integrated clinic as part of the MCH-ART study, all multivariable 
models were adjusted for design status in the MCH-ART study in. Results are presented as 
crude or adjusted risk ratios (RR or aRR) with 95% confidence intervals (CI). In this 
exploratory secondary analysis which may not have had sufficient power to detect small 
associations, all associations reaching p<0.10 were discussed. 
Ethics 
All women included in this analysis completed written informed consent that included 
consent to review their routine medical records. Ethical approval was obtained from both the 
University of Cape Town Human Research Ethics Committee and the Columbia University 
Medical Centre Institutional Review Board. 
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7.4 Results  
Among 628 women who initiated ART in pregnancy, eight women were found to have died 
and three to have relocated out of South Africa during the study period (up to 30 months on 
ART). These women were excluded from further analysis. Of the remaining 617 women, the 
mean age was 29 years (SD 5.3), 41% were married/cohabiting, 38% were employed and 
26% had completed secondary school (Table 7-1). More than half the women (54%) were 
newly diagnosed with HIV in the incident pregnancy and 45% presented for ANC at ≤20 
weeks gestation. 
Linkage to care 
Figure 7-1 describes the flow of access to HIV care after leaving the integrated clinic and 
Table 7-1 describes the characteristics among women who did and did not link to a new clinic 
after their last visit in the integrated clinic. There were 132 women (21%) with no evidence 
of linking to HIV care during the follow-up period. Of these, nine women were not seen after 
their first ANC visit. Among the 485 women who did link to care, 384 (79%) had evidence of 
attending one clinic, 85 (18%) linked to two and 16 (3%) linked to three different clinics 
(Figure 7-1). There were 20 women who moved and linked to a new ART clinic while still 
pregnant, while the remaining 465 women linked to a new clinic after delivery.  
Figure 7-1 Flow of mobility for routine HIV care after leaving the integrated clinic through to 
30 months after ART initiation. 
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Women who did not link to care during the follow-up period were slightly younger (mean 
age 28 versus 29), less likely to be married/cohabiting (28% versus 45%) and more often 
diagnosed with HIV in this pregnancy (61% versus 53%), compared to women who did link 
to care (Table 7-1). They also presented for ANC later (mean gestation 23 versus 21 weeks). 
The associations between successful linkage and age >25 years (aRR 1.11 95% CI 1.00-
1.23), being married/cohabiting (aRR 1.13 95% CI 1.04-1.23) and presentation for ANC ≤20 
weeks gestation (aRR 1.11 95% CI 1.02-1.20) persisted in multivariable models (Table 7-2). 
 
Table 7-1 Description of 617 HIV-positive women who initiated ART during pregnancy, by 
linkage to HIV care after leaving the integrated clinic. Presented as n (%) unless specified. 
 Linked to care Did not link to care  All women p-value 
Number of women 485 (79) 132 (21) 617 (100)  
Median (IQR) months from 
ART initiation until last 
evidence of accessing care  
28 (22-29) 4 (2-8) 26 (12-29) <0.001 
Characteristics at 
enrolment 
    
Mean age (SD) 29 (5.4) 28 (5.3) 29 (5.3) 0.015 
Age ≤25 122 (25) 48 (37) 170 (28) 0.011 
Married/cohabiting 216 (45) 37 (28) 253 (41) 0.001 
Completed secondary 
school 
124 (26) 39 (30) 163 (26) 0.358 
Employed 182 (38) 52 (39) 234 (38) 0.695 
First pregnancy 83 (17) 29 (22) 112 (18) 0.199 
Intended pregnancy 146 (30) 35 (27) 181 (29) 0.422 
Diagnosed with HIV in this 
pregnancy 
255 (53) 81 (61) 336 (54) 0.072 
Mean weeks gestation(SD) 21 (7.4) 23 (7.8) 21 (7.5) 0.005 
Presented for ANC 
before 20 weeks 
gestation 
231 (48) 47 (36) 278 (45) 0.014 
Median (IQR) CD4 cell 
count at presentation for 
ANC (n=601) 
342 (235-509) 386 (253-555) 345 (236-513) 0.110 
Characteristics at 
delivery 
    
Place of delivery (n=597)     
Delivered in primary care 190 (41) 56 (43) 246 (41) 0.624 
Delivered at tertiary 
hospital 
277 (59) 74 (57) 351 (59)  
Delivery outcome     
Live birth  464 (96) 131 (99) 595 (96) 0.253 
Stillbirth 11 (2) 1 (1) 12 (2)  
Miscarriage 6 (1) 0 (0) 6 (1)  
Unknown 4 (1) 0 (0) 4 (1)  
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Table 7-2 Poisson regression model (n=617) predicting whether a woman linked to HIV care 
at any other clinic after the integrated clinic. Presented as unadjusted (RR) and adjusted 
(aRR) risk ratios with 95% confidence intervals (CI). 
 Crude Adjusted 
 RR 95% CI  aRR 95% CI  
Age >25 1.13 1.02-1.26  1.11 1.00-1.23  
Married/cohabiting 1.16 1.07-1.25  1.13 1.04-1.23  
Diagnosed with HIV in this pregnancy 0.93 0.85-1.01  -   
Presented for ANC ≤20 weeks 1.11 1.02-1.20  1.11 1.02-1.20  
 
Mobility 
After leaving the integrated clinic, women accessed care at 98 different clinics across South 
Africa, excluding the integrated clinic. The median distance moved for initial linkage was 1 
kilometre (km) (IQR <1-3, maximum 1271 km) and 95% of clinics initially linked to were in 
the Western Cape Province. After linkage, an additional 117 movements were observed and 
the distance between clinics increased with additional moves. The median distance of second 
(n=101) and third (n=16) move was 3 km (IQR 1-108) and 413 km (IQR 1-945) respectively, 
with 23% of the second and 25% of the third move being out of the Western Cape Province. 
7.4.1 Overall, 270 women (56%) remained within the integrated clinic health district 
(clinics <5 km away), 157 (32%) moved out of the district but stayed in the Cape 
Town Metropole, 12 (2%) moved out of the region but stayed in the Western Cape, 
and 46 (9%) accessed care in other provinces (Supplementary Table 9-7-1Chapter 7 
Supplementary Table 9-7-1). Figure 7-2 shows the geographic spread of clinics accessed A) 
within the Cape Town Metropole, and B) across South Africa. 
Of 485 women who successfully linked to care after the integrated clinic, 101 women (21%) 
moved to ≥2 clinics (maximum 3) during 30 months of follow-up (Figure 7-1,Supplementary 
Table 9-7-1). Younger age and being unemployed were associated with moving to ≥2 clinics 
(aRR 1.10 95% CI 1.02-1.18 and aRR 1.06 95% CI 0.99-1.12, respectively; Supplementary 
Table 9-7-2). Total follow-up time from ART initiation to the last available clinic visit did 
not differ by movement frequency (median 28 months in both groups, p=0.787). However, 
women found at ≥2 clinics were more likely to ever access care outside of Cape Town (38% 
versus 5%) and had a greater maximum distance between clinics (median 4km versus 1km) 
compared to women who did not move again after linking.  
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Figure 7-2 Maps of clinics attended for HIV care after leaving the integrated clinic (A) within 
the Cape Town Metropole and (B) within South Africa. 
Mobility, retention and HIV viral load 
Of the 485 women who did have evidence of successfully linking after the integrated clinic, 
438 (90%) and 398 (82%) women had evidence of being retained at 12 (6 to <18) and 24 (18 
to <30) months after ART initiation, respectively (Supplementary Table 9-7-1). Evidence of 
retention at both 12 and 24 months was found for 363 women (75% of women who linked) 
(Table 7-3). When combining those who did not link to care after transfer (n=132) and those 
who linked but were subsequently LTFU (n=122), 71% (n=438) and 65% (n=398) of women 
were retained at 12 and 24 months after ART initiation, respectively; 59% (n=363) of women 
were retained in care at both time points. 
Retention in care at both 12 and 24 months after ART initiation was associated with attending 
only one clinic, being >25 years old, being married, being employed, being multigravida, 
having a planned pregnancy and early presentation for ANC. The association with having a 
planned pregnancy (aRR 1.20 95% CI 1.09-1.33), age >25 years (aRR 1.17 95% CI 1.02-
1.33) and presenting for ANC ≤20 weeks (aRR 1.10 95% CI 0.99-1.21) persisted in 
multivariable models (Supplementary Table 9-7-3). In sensitivity analyses, having a planned 
pregnancy was similarly predictive of retention at 24 months after ART initiation and at 18 
months postpartum, and the association between being multigravida and being retained 
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maintained a similar effect size but reached statistical significance (Supplementary Table 9-7-
3). Distance moved was not associated with being retained in care. 
Table 7-3 Description of 485 HIV-positive women who linked to care after leaving the 
integrated clinic, by whether they were retained in HIV care at both 12 and 24 months after 
ART initiation. Presented as n (%) unless specified. 
 Retained Not retained All women p-value 
Number of women 363 (75) 122 (25) 485 (100)  
Characteristics at enrolment     
Mean age (SD) 29 (5.4) 28 (5.2) 29 (5.4) 0.025 
Age ≤25 81 (22) 41 (34) 122 (25) 0.013 
Married/cohabiting 173 (48) 43 (35) 216 (45) 0.017 
Completed secondary school 93 (26) 31 (25) 124 (26) 0.963 
Employed 144 (40) 38 (31) 182 (38) 0.093 
First pregnancy 56 (15) 27 (22) 83 (17) 0.089 
Intended pregnancy 124 (34) 22 (18) 146 (30) 0.001 
Diagnosed with HIV in this 
pregnancy 
184 (51) 71 (58) 255 (53) 0.151 
Mean weeks gestation (SD) 20 (7.2) 23 (2.6) 21 (4.4) 0.001 
Presented for ANC ≤20 weeks  184 (51) 47 (39) 231 (48) 0.020 
Median (IQR) CD4 cell count at 
presentation for ANC (n=474) 
336 (235-499) 346 (242-537) 342 (235-509) 0.269 
Characteristics at delivery     
Place of delivery (n=467)     
Delivered in primary care 141 (40) 49 (42) 190 (41) 0.694 
Delivered at tertiary hospital 210 (60) 67 (58) 277 (59)  
Delivery outcome     
Live birth  349 (96) 115 (94) 464 (96) 0.042 
Stillbirth 7 (2) 4 (3) 11 (2)  
Miscarriage 6 (2) 0 (0) 6 (1)  
Unknown 1 (<1) 3 (2) 4 (1)  
Characteristics postpartum     
Median (IQR) months from 
ART initiation until last 
evidence of accessing care  
29 (27-29) 15 (9-22) 28 (21-29) <0.001 
Number of clinics after the 
integrated clinic 
    
Attended 1 clinic 278 (77) 106 (87) 384 (79) 0.015 
Attended ≥ 2 clinics 85 (23) 16 (13) 101 (21)  
Median furthest distance (km) 
moved between clinics 
1.07 (0.69-
3.23) 
1.07 (0.01-7.87) 1.07 (0.69-
3.23) 
0.868 
Area moved after integrated 
clinic 
    
Same health district 207 (57) 63 (52) 270 (56) 0.252 
Cape Town Metropole 117 (32) 40 (33) 157 (32)  
Western Cape Province 10 (3) 2 (2) 12 (2)  
Out of the Western Cape 
Province 
29 (8) 17 (14) 46 (9)  
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VL measures at least 12 months after ART initiation were available for 338 of 363 women 
(93%) who were retained in HIV care at both 12 and 24 months after ART initiation 
(Supplementary Table 9-7-4). There were 273 (81%) and 294 (87%) women who were virally 
suppressed ≤50 and ≤1000 copies/mL, respectively (Supplementary Table 9-7-4 and 
Supplementary Table 9-7-5). Attending ≥2 clinics reduced the likelihood of having a VL ≤50 
copies/mL in multivariable models (aRR 0.81 95% CI 0.69-0.95); this association was not 
statistically significant for VL ≤1000 copies/mL (Table 7-4). Being diagnosed with HIV in 
the current pregnancy was associated with having a VL ≤50 and ≤1000 copies/mL at least 12 
months after ART initiation. Age >25 years predicted VL ≤50 copies/mL and being 
married/cohabiting or employed were predictive of having a VL ≤1000 copies/mL in 
multivariable models (Table 7-4). 
Table 7-4 Poisson regression model among 338 women who were retained in care and had a 
VL available at least 12 months after ART initiation, predicting A) VL ≤50 copies/mL at 
least 12 months after ART initiation, and B) VL ≤1000 copies/mL at least 12 months after 
ART initiation (n=325 with data complete). Presented as unadjusted (RR) and adjusted (aRR) 
risk ratios with 95% confidence intervals (CI). 
 Crude Adjusted 
A: VL ≤50 copies/mL at least 12 months after ART initiation 
 RR 95% CI  aRR 95% CI  
Attended ≥2 clinics after the integrated 
clinic 
0.80 0.68-0.94  0.81 0.69-0.95  
Age >25 1.18 1.01-1.38  1.17 1.01-1.36  
Completed secondary school 1.11 1.00-1.23  -   
Married/cohabiting 1.10 0.99-1.21  -   
Planned pregnancy 1.09 0.99-1.21  1.10 0.99-1.21  
Presented for ANC <20 weeks gestation 1.06 0.96-1.18  -   
Diagnosed with HIV in this pregnancy 1.15 1.03-1.27  1.15 1.04-1.28  
Employed 1.13 1.02-1.25  1.08 0.98-1.19  
B: VL ≤1000 copies/mL at least 12 months after ART initiation 
 RR 95% CI  aRR 95% CI  
Attended ≥2 clinics after the integrated 
clinic 
0.91 0.81-1.02  0.92 0.82-1.03  
Age >25 1.14 1.00-1.29  1.10 0.97-1.24  
Completed secondary school 1.08 0.99-1.17  -   
Married/cohabiting 1.14 1.05-1.23  1.14 1.06-1.24  
Planned pregnancy 1.10 1.02-1.19  -   
Presented for ANC <20 weeks gestation 1.08 0.99-1.17  -   
Diagnosed with HIV in this pregnancy 1.08 0.99-1.17  1.10 1.01-1.19  
Employed 1.13 1.04-1.22  1.12 1.04-1.21  
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7.5 Discussion 
This unique study describes outcomes over 30 months of follow-up for a cohort of women 
who initiated ART in an integrated ANC and ART clinic and who were required to transfer 
ART clinics after delivery. Overall, 20% of women did not link to a new clinic within 30 
months of ART initiation and an additional 21% were subsequently LTFU after linking. 
Cumulatively, 41% of women were not retained in care at both 12 and 24 months after ART 
initiation. Younger women emerged as consistently at risk for not linking to care, non-
retention, non-suppression and attending ≥2 different clinics.  
Our findings add to the limited literature on retention of postpartum women in Africa beyond 
12 months on ART [15]. Overall retention at 12 and 24 months after ART initiation (71% and 
65%, respectively) were broadly comparable to reports from other parts of sub-Saharan 
Africa. A recent study from Malawi, using a more stringent definition of retention, found that 
77% and 71% of women were retained at 12 and 24 months on ART, respectively [11]. In 
data from Zimbabwe and Mozambique, only 68% and 42% of women were still receiving 
ART 12 months after ART initiation [24,25]. A recent systematic review found a pooled 
estimate of 76% retained at 12 months on ART in African cohorts [15]. Reported retention in 
HIV care is often facility specific. Individuals who are transferred to new clinics are often 
considered retained in care, censored at the time of transfer or excluded from analyses 
[26,27]. In contrast, our results are from a cohort where all women were required to transfer 
care and access to HIV care was traced to any routine primary healthcare clinic in South 
Africa. It is of concern that, even after tracing women’s movement to different clinics, 41% 
of women were not retained through 12 and 24 months after ART initiation. Importantly, 
women who never linked to care after the integrated clinic accounted for half the LTFU seen 
in our cohort. This highlights the need to incorporate support for linkage to care where 
movement between ART clinics after delivery is required. 
Current infant feeding guidelines recommend that HIV-positive women breastfeed their 
children for up to 24 months postpartum, making continued postpartum retention critical not 
only for maternal health and sexual transmission, but also to prevent MTCT in the 
breastfeeding period [21,28]. Breastfeeding status and access to routine child health services, 
although not indicators readily available in routine data systems, may impact maternal 
mobility and engagement in HIV care. In addition, routine child health services are very well 
attended in many settings and could provide opportunities to re-engage mothers who fail to 
link or are LTFU from HIV care.  
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Despite concerning retention levels, these results showed reassuring levels of viral 
suppression among women who were retained in care in this cohort. Our results suggest that 
increased clinic movement could be associated with increased risk of viremia. However, we 
were unable to ascertain viral load outcomes for women who were not retained in care and 
therefore cannot conclusively determine the impact of mobility on HIV viral load. Younger 
age was a shared risk factor for not linking to care, more frequent mobility, non-retention and 
raised VL. This adds to the substantial evidence indicating that younger HIV-positive women 
are often at increased risk for poor treatment outcomes [15,29–33]. Although associations 
were small, younger age, timing of presentation for ANC and relationship status could flag 
women requiring additional support to link to care postpartum. Primigravity and unplanned 
pregnancy, previously linked to adverse maternal and child outcomes [34,35], may also flag 
women requiring targeted retention interventions. Although the impact of pregnancy 
intention on long-term ART outcomes is not clear, optimizing family planning services for 
both HIV-positive and negative women remains a vital component of strategies to prevent 
MTCT and improve maternal and child health. Importantly, interventions are needed not only 
at ART initiation facilities but also beyond the facility to promote continued retention in care 
when mobility is necessary.  
Women accessed care at a variety of different clinics. Although some clinics provide 
combined appointments for HIV-positive mothers and their children, many require different 
appointments for maternal ART and routine child health and quite often these services are 
offered at different clinics. We were unable to systematically assess each model of care, but 
this should be a consideration in future work. The clinic movement seen in this analysis has 
further implications for linking mother-child pairs and monitoring long-term child and 
maternal outcomes. In both routine programmes and research cohorts, retention in ART care 
is frequently based on whether an individual is still receiving care from the clinic at which 
they started treatment [36–38]. A review of studies in low- and middle-income countries that 
actively traced patients to ascertain their status, showed a pooled estimate of 19% of adults 
considered LTFU were continuing care at other clinics [39]. Although the most recent World 
Health Organisation recommendations for monitoring include using unique patient identifiers 
to allow linkage across health services, this is not a reality in many settings [40]. Availability 
of facility-linked data and the choice of data sources used will impact the ability to monitor 
long-term outcomes of women on lifelong ART and their children [41].  
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The results of this analysis should be interpreted with the following additional caveats in 
mind. Although a strength of this study is the availability of diverse data sources throughout 
the Western Cape Province and nationally for evaluating evidence of engagement in care, not 
all contacts with the health system are captured into routine electronic databases which could 
lead to underestimation of retention. Attempts were made to ascertain vital status using clinic 
records, but unknown deaths may contribute to non-linkage and non-retention. Both a 
strength and limitation is that these results are applicable to a cohort of women required to 
transfer their ART care after delivery. We were unable to classify additional mobility after 
linkage and outcomes may vary between formal clinic transfers and patient-initiated mobility. 
Another important limitation of this analysis is that the same data sources were used to define 
mobility and retention in care and the mobility patterns among women who were not 
observed to be in care cannot be known. Surprisingly, employment was not strongly 
associated with mobility or any of the outcomes in this study [2,42]. This is likely a limitation 
of the measure which only assessed employment status at entry into ANC. Women may have 
returned to or started work after delivery with possible impacts on both mobility and HIV 
care access. Studies which can assess mobility independently from access to routine health 
services and which can assess changing risk factors such as employment and relationship 
status over time, will be required to further understand postpartum mobility and the impact on 
ART outcomes.  
These data add important insights regarding mobility and retention in care in postpartum 
women up to 30 months after ART initiation in pregnancy. The step of moving care between 
clinics is a vulnerable step in the HIV care continuum and even women who manage to link 
successfully, particularly younger, unmarried women and those who present late for ANC, 
remain vulnerable to subsequent LTFU and viremia. Models of care to provide ART to 
pregnant and postpartum women need to accommodate women’s mobility and where they 
choose to access care. Facility-based interventions may not be sufficient to support 
postpartum retention. For example, South African differentiated models of care and mobile 
health (mHealth) interventions are starting to provide non-facility-based support for mothers 
[43,44]. Further consideration is needed on how continuous support for engagement in care 
can be provided as mothers living with HIV continue with their daily lives after delivery. 
 
7.6 Conclusions 
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We found that less than two thirds of women who started ART in an integrated ANC-ART 
clinic were retained in care at both 12 and 24 months after ART initiation. Losses occurred at 
the initial mandatory postpartum transfer and after successful linkage to care. Women who 
linked to care attended a wide range of facilities creating challenges for monitoring 
postpartum outcomes. Based on these data there is a clear and urgent need for interventions 
that extend outside of health facilities to help support postpartum women, and young mothers 
in particular, to remain engaged in lifelong ART care. 
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 Discussion and recommendations 
8.1 Synopsis of key findings 
8.1.1 Introduction 
This chapter provides a synopsis of the key findings of this thesis as a combined body of 
work, the overarching limitations, and recommendations for policy and future research. The 
results included in this thesis come from a cohort of women living with HIV who initiated 
antiretroviral therapy (ART) during pregnancy in Gugulethu, South Africa in 2013 and 2014. 
Most of the cohort started ART under Option B+, the policy of universal ART for pregnant 
and breastfeeding women. That makes this one of the first universal ART cohorts in the 
South African public sector and the findings offer novel insights into engagement in care 
following ART initiation in pregnancy under this policy. Some of the results that have been 
presented are also applicable to other populations on ART and provide lessons that can be 
extended to universal ART for all people living with HIV.  
To avoid repetition, presented here are the discussion points raised when considering the 
whole body of work included in this thesis, placing these in the context of relevant 
publications on maternal engagement in HIV care in sub-Saharan Africa (SSA). The 
discussion will focus on five themes that emerge across the results chapters: i) substantial 
disengagement from HIV care after ART initiation in pregnancy, ii) specific considerations 
among women starting ART in pregnancy around ART side effects, mobility and transfer of 
HIV care, iii) approaches to measuring ART adherence, iv) considerations for measuring 
retention in HIV care, and v) opportunities to support long-term engagement in HIV care.  
8.1.2 Substantial disengagement from HIV care after ART initiation in pregnancy 
The UNAIDS 90-90-90 targets aim to have 90% of people living with HIV know their status, 
90% of those who know their status remaining on ART, and 90% of those on ART 
virologically suppressed [1]. In 2017, it was estimated that 79% of people who knew their 
HIV status globally were on treatment; in South Africa, 68% of those who know their status 
are estimated to be on ART and 78% of those on ART are suppressed [2]. The gap to 
achieving the second 90, remaining on ART, is made up of both people who do not link to 
care after diagnosis and people who successfully start ART but are lost from care. Successful 
linkage to treatment following an HIV diagnosis, combined with improved HIV testing, is a 
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critical focus for achieving the 90-90-90 targets and has been identified as a key weak point 
[3]. However, given the scale-up of testing and treatment with universal ART and high rates 
of loss to follow-up (LTFU) reported in all populations, the proportion of those who start 
ART but are not retained in care is likely to be substantial [4,5]. This group has received less 
attention than linkage to treatment in the context of the UNAIDS targets and these two 
components are usually not disaggregated in 90-90-90 estimates [3,6]. Similarly, the gap to 
reach the third 90, viral suppression, also has multiple components including poor medication 
adherence, viral loads not completed and ART resistance. The components of retention in 
care and adherence to ART, together termed engagement in HIV care, were the focus of this 
thesis. 
The combined results of this thesis highlight substantial disengagement from care, both in the 
form of poor medication adherence as well as non-retention. In Chapter 3, almost a third of 
women reported at least one missed ART dose during pregnancy [7]. In the validation of the 
three-item self-reported adherence scale among pregnant and early postpartum women 
(Appendix 9.3), over 90% of women were virologically suppressed but almost all women 
reported some adherence difficulty [8]. In Chapter 5 we observed declining proportions of 
viral suppression over time, mirroring the trend in retention observed using 6-month visit 
constancy in Chapter 6. Results from Chapter 7 showed that only 59% of women had 
evidence of accessing routine HIV care around both 12 and 24 months on ART [9] and in the 
subset of women in Chapter 4 (median four years on ART), 30% of women had no detectable 
antiretrovirals (ARVs) and 28% had viral loads above 1000 copies/mL. Viral load data from 
the same cohort restricted to women who had ever suppressed showed that only 70% of 
women maintained viral suppression through one year postpartum (Figure 8-1) [10]. These 
combined findings align with data from other settings demonstrating high rates of LTFU and 
viremia after ART initiation in pregnancy [5,11–13].  
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Figure 8-1 The distribution of viral loads <50, 50-1000 and >1000 showing an increasing 
proportion of viremia over time among women in the MCH-ART cohort who ever suppressed 
in pregnancy, from Myer et al [14]. 
 
The data presented in this thesis add to a small but growing literature reporting on longer-
term outcomes of women who initiated ART in pregnancy. In Chapter 2, seven studies were 
identified that reported on adherence or retention at or after two years on ART [12,13,15–19]. 
Retention at around 24 months on ART was estimated in six studies. All studies used facility-
specific data sources although some actively traced patients considered LTFU to ascertain 
their outcomes. All studies used gap in care definitions and time-to-event analyses with the 
proportion retained as follows: 53% in eSwatini (not retained if ≥4.5 months with no visit) 
[15]; 59%, 71% and 74% in Malawi (lost if >60 days late for a visit) [12,13,20]; 78% in 
Ethiopia (lost if >90 days with no visit) [16]; 91% in Uganda (lost if >3 months with no visit) 
[17]. Retention through 24 months on ART in this thesis was 37% (95% CI 33-41) when non-
retained was defined as 150 days (or five months) with no visit (Chapter 6). This is lower 
than reported in eSwatini with a similar definition but where women were censored if they 
transferred to a new clinic [15]. In Chapter 7, using a more conservative, cross-sectional 
retention definition of any routine HIV contact between 18 and 30 months on ART, 65% of 
women were considered retained [9]. Only one published study has reported on ART 
adherence through 24 months on ART or longer in this patient population: in an observational 
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cohort in Malawi with adherence measured using pharmacy refill data, only 67% of women 
who started ART in pregnancy had ≥90% medication coverage over the two year period [12]. 
It was not possible to measure medication coverage in this thesis due to inconsistency in the 
availability of pharmacy refill data, but only 48% of women had evidence of any routine HIV 
care contact at least once in every 6-month window from ART start to 24 months on ART 
(Chapter 6). Moreover, in the subset of women with drug concentrations at 3-4 years 
postpartum (median four years on ART), only 70% had any detectable antiretrovirals 
(Chapter 4). 
According to modelling estimates, reaching the 90-90-90 targets by 2020 will result in the 
end of the HIV epidemic by 2030 [1], but these targets require people not only to test for HIV 
and link to treatment services, but to stay retained in HIV care and adherent to ART to ensure 
sustained virologic suppression. Thus, the observed level of disengagement from care is 
concerning for several reasons. First, there is ongoing risk of HIV transmission during 
pregnancy and postpartum through breastfeeding in the incident and future pregnancies. Over 
the past decade, with the phenomenal success of ART for PMTCT, the incidence of new HIV 
infections in children has dropped substantially [21], but an increasing proportion of all new 
infections in children are now due to postpartum transmission through breastfeeding [22]. 
Second, disengagement results in increased risk of transmission of HIV to HIV-uninfected 
partners, removing the benefit of reduced HIV incidence at a population level. Finally, and 
importantly, sustained engagement in ART services is crucial to optimize maternal health. 
This is necessary to ensure that mothers live long healthy lives and can support their families. 
In these ways, poor engagement in HIV care threatens the potential individual-, family- and 
population-level benefits of lifelong ART [23].  
The results of this thesis also provide some additional insight into the timing of loss from 
care. Chapter 7 showed considerable LTFU after transferring out of the integrated antenatal 
care (ANC) and ART clinic [9]. Previously the literature has shown that many women are 
lost from care shortly after delivery or cessation of breastfeeding [16,24–26] which may be 
due to a shift in motivation to remain engaged in care when transmission to the child is no 
longer a risk [26–28]. The results from this thesis suggest that the structure of the health 
service and the timing of transfer out of integrated antenatal and ART services may also have 
an impact on the timing of loss from care. Integration of services presents an opportunity to 
sustain engagement in care during pregnancy and breastfeeding [29–32], but may delay 
disengagement to a later point in time [33–35]. Careful consideration of the approach to and 
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impact of transferring care into and out of integrated maternal and child health services is 
required.  
Disengagement from care during pregnancy and postpartum presents a risk for perinatal or 
postnatal transmission and, as noted above, most research and interventions to date have 
focused on this period [5,36]. However, in order to ensure that the benefits of lifelong ART 
are sustained for subsequent pregnancies, for maternal health and for prevention of sexual 
transmission, support strategies can no longer focus only on the immediate outcomes of 
vertical transmission of HIV during pregnancy, delivery and breastfeeding [37]. Rather it will 
be essential to shift focus to sustained engagement in lifelong ART services. 
8.1.3 Specific considerations among women starting ART in pregnancy around ART side 
effects, mobility and transfer of HIV care  
Many barriers to engagement in HIV care exist across population groups: experience of and 
fear of experiencing ART side effects are known barriers to ART adherence in adult and 
adolescent cohorts [38,39]; mobility has historically been investigated as it relates to HIV 
transmission [40] but movement and travel are increasingly being recognised as barriers to 
continued engagement in ART services [41–44]; transferring the location of HIV care was 
found to be a barrier to ART uptake in pregnancy prior to a move towards integrated ANC 
and ART services [45] and has been noted as a vulnerable time for disengagement when 
transitioning young people from paediatric to adult ART services [46]. Each of these 
considerations have also been posited as barriers to ongoing maternal adherence and retention 
in HIV care, yet at the time of starting this thesis, quantitative analyses of these risk factors in 
maternal ART cohorts were lacking. Different populations may experience or respond to 
similar risk factors differently. The results of this thesis highlight some of the ways women 
who start ART in pregnancy may be particularly vulnerable to these factors and their effects. 
ARV regimens and side effects 
Results of Chapter 3 aligned with existing evidence that ART side effects are associated with 
poor medication adherence [27,47–50]. At the time this thesis was conceived, efavirenz 
(EFV)-based first-line ART regimens were recommended for all adults, including pregnant 
and breastfeeding women [51]. Side effects from first-line ART regimens are usually thought 
to be short-lived, however for women starting ART in pregnancy, these early side effects may 
be exacerbated by or experienced in combination with normal physical symptoms 
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experienced in pregnancy. With EFV specifically, there has also been concern raised about 
the impact of central nervous system (CNS) side effects [52,53]. The analysis presented in 
Chapter 3 is a unique quantitative exploration of patterns of self-reported side effects and the 
associations between specific groups of reported side effects and ART adherence. Almost all 
women (97%) in the cohort reported at least one side effect during pregnancy on an EFV-
based first-line regimen; 26% of the cohort fell into a high overall side effect group [7]. CNS 
side effects were the most common but alone they were not associated with an increase in 
missed ART doses. Notably, the results showed that it was the overall burden of self-reported 
side effects, rather than side effects affecting a specific system, that was associated with 
adherence. In pregnant women, and possibly other populations with comorbidities, the overall 
burden of side effects, regardless of underlying cause, may impact on adherence to ART. 
Side effects from EFV may also be heightened by slow EFV metabolism. In African 
populations, genetic polymorphisms resulting in slower EFV metabolism and higher 
concentrations of EFV in the body are relatively common and have been shown to be 
associated with an increase in adverse effects [54–56]. Although this thesis did not examine 
genetic polymorphisms in this population, among the subset of women at 3-4 years 
postpartum (n=137 in Chapter 4), 15% of those with any detectable EFV (11% overall) had 
EFV concentrations above 4µg/mL, possibly indicating slow EFV metabolism [55]. This 
proportion may be higher among the women who had discontinued ART. Due to concerns 
about toxicity and potential cost reduction, the ENCORE-1 trial investigated the efficacy of 
400mg EFV compared to the standard 600mg dosing and found it to be non-inferior with 
fewer EFV-related adverse events reported [57]. Additional studies are underway but the 
evidence for use in pregnant women is not yet thought to be sufficient [58] and genotype 
testing to inform EFV dosing is unlikely to be possible in most settings.  
New, more tolerable ARVs are becoming available, but side effects are unlikely to be 
eliminated. Dolutegravir is widely being rolled out in first-line regimens in low- and middle-
income countries [59–61]. It has far superior tolerability and efficacy to suppress viral load 
than other first-line ARVs [58,62], but mild side effects such as headaches and insomnia may 
still occur with dolutegravir and concerns remain about safety during the first trimester of 
pregnancy [62–64]. Currently EFV-based regimens are still recommended for women who 
are <8 weeks pregnant or who plan to conceive [60]. Although promoting early ANC 
attendance is a priority, only 25% of women presented for ANC before 12 weeks gestation in 
SSA in 2013 [65] and in the cohort evaluated in this thesis the average time of presentation 
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for ANC was 21 weeks gestation. Thus, most women initiating ART in pregnancy will be 
able to start on dolutegravir instead of EFV. However, very high rates of unplanned 
pregnancy, around 44% globally [66] and up to 70% in African cohorts [9,67–69], raise 
broader concerns about dolutegravir use among women of reproductive age while safety in 
early pregnancy is still being determined. 
Regardless of ARV regimen, it is possible that normal pregnancy symptoms, or symptoms 
and side effects from other conditions or medication, could be perceived as ART side effects 
regardless of the true tolerability of the regimen. During pregnancy specifically, women may 
have heightened awareness of their health and the safety of their unborn child, thus the 
association between perceived ART side effects and ART adherence may persist. These 
findings call for focused counselling specific to ART- and pregnancy-related side effects at 
the time of ART initiation and follow-up visits. This point is discussed further in Section 
8.1.6. 
Mobility and transfer of care 
Movement between ART clinics can occur due to relocation, personal preference, or through 
mandatory transfer required by the model of care. Mobility in South Africa is common with 
high levels of migration between rural and urban areas [70–72]. Historically under apartheid, 
“non-whites” were forced to migrate to economically profitable areas to work although they 
had to reside in rural areas. At this time, movement was difficult, highly regulated and 
strongly male dominated [71]. Following the transition to democracy after 1994, movement 
across South Africa became much easier and now women and men migrate equally across the 
country [71,73]. Between 2001 and 2011, 59% of in-migrants into the Western Cape province 
were female [72]. Today, people move around South Africa freely but often remain strongly 
connected to the geographic areas where they were born or grew up. There is evidence in the 
adult ART literature that mobility, either short-term travel or relocation, can impact on 
treatment adherence and retention in care [41–43,74]. Mobility has also been reported as a 
reason for disengagement from care in qualitative studies of pregnant and postpartum women 
[49,75,76] and travel from urban to rural areas to be with family and for cultural practices is 
common after delivery [71,76,77].  
Apart from being a barrier to engagement in HIV care, mobility also presents a challenge for 
measuring this construct. We know from adult ART cohorts, and more recently from 
maternal ART cohorts specifically, that a substantial proportion of patients considered LTFU 
183 
 
may be actively in care at another ART clinic [78–80]. Most analyses that have traced 
women’s outcomes to other clinics have been restricted to women considered LTFU 
[49,79,81]. Although the analyses presented in this thesis were not able to evaluate mobility 
independently of accessing HIV care, they provide novel and important insight into mobility 
to access HIV care among an entire cohort of women who started ART in pregnancy. The 
findings that the women who linked to care spread to nearly 100 different ART clinics, that 
21% moved two or more times and over 40% moved outside of the health district where they 
started ART, highlight high levels of mobility to access HIV care in this setting [9]. This 
confirms findings from a cohort in Johannesburg, South Africa showing both local clinic 
switching and long distance mobility postpartum [79]. 
Transferring care, as required by different models of care for providing ART services, is 
another reason for moving between clinics and can be associated with disengagement. 
Previous work in Gugulethu, prior to the roll out of Option B+, found that up to 25% of 
women transferred out of the integrated ANC and ART clinic postpartum did not have 
evidence of accessing care at a new clinic within a year of transfer using just laboratory data 
[35]. The results of Chapter 7, using combined routine data sources, provide new insights into 
loss from care after leaving an integrated ANC and ART clinic. In this cohort, 21% of women 
who had started ART in pregnancy had no evidence of linking to a routine ART clinic, 
excluding known deaths and relocations out of the country [9]. Infant feeding guidelines in 
South Africa follow the World Health Organization (WHO) recommendation of 
breastfeeding for at least 12 months yet transfer out of integrated services in South Africa 
occurs routinely at 6-10 weeks postpartum, making this finding particularly important for 
potential postnatal HIV transmission [82]. Some countries, including Malawi, Zimbabwe and 
Mozambique, extend integrated antenatal and ART services to provide integrated child health 
and maternal ART services for one to two years after delivery [33,49,83]. This model of care 
still usually requires transfer of ART care postpartum, and few studies have traced outcomes 
beyond transfer out of integrated postpartum maternal and child health services. Moreover, 
the optimal approach and timing of transferring care from integrated maternal and child 
health services to general ART services is unclear and requires investigation.  
Transfers and mobility, in the absence of interlinked data sources, make it difficult to link 
mother-baby pairs and therefore to monitor or intervene in both maternal and child health 
outcomes. As noted in Chapter 6 and discussed further in Section 8.1.5, there are a number of 
important considerations when deciding on the data sources and definitions to use when 
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measuring retention. For maternal cohorts, the use of data that can be linked across ART 
clinics is critical to be able to account for mandatory transfers and mobility between clinics 
for other reasons. Knowing which women are in care, regardless of which clinic they are 
attending, will ensure that resources can be focused on re-engaging women who are truly 
LTFU. 
8.1.4 Approaches to measuring ART adherence 
Poor adherence to ART is the primary reason for virologic failure and remaining adherent is 
critical to treatment success [84,85]. There are numerous ways to measure treatment 
adherence, all of which have pros and cons and none of which provide a perfect measure [86–
90]. Self-reported adherence is prone to bias and often overestimates adherence [91], and this 
thesis confirms that self-report is not an ideal adherence measure. Compared to drug 
concentrations, which are the most objective measure of actual exposure to ART, self-
reported adherence had worse ability to predict viral suppression. However, despite the issues 
with self-reported adherence, it is simple, immediate and inexpensive to measure. Until more 
reliable adherence measures are found that share these desirable characteristics, it is likely 
that self-reported adherence measures will continue to be used in routine and research 
contexts and ways to improve self-report measures are needed.  
The three-item self-reported adherence scale used in Chapters 4 and 5 [92,93], after 
validation for use in South Africa (presented in Appendix 9.3) [8] , did perform better than 
other self-report measures, reducing the commonly observed ceiling effect and resulting in 
greater variability of responses than reported using other measures [89,94,95]. In cross-
sectional analyses, the three-item score was associated with viral load but was only 
moderately able to discriminate between women with and without viral suppression.  
Part of the challenge of self-reported measures is that they reflect an individual’s perception 
of their own medication taking behaviour and their own biases. Longitudinal measures of 
self-reported adherence may be able to take some of this into consideration by measuring 
changes in reported adherence relative to the individual’s baseline reporting. The results of 
Chapter 5 show that a decrease in self-reported adherence, using the three-item scale 
described in Appendix 9.3, could predict viremia and perhaps overcome some of the issues 
with cross-sectional measures. A decrease in reported adherence across two consecutive visits 
was found to be consistently associated with viral load, with the strongest association 
observed among women who were virally suppressed at the first visit. Unfortunately, this 
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thesis was unable to assess the value of change in self-reported adherence over time in 
comparison to drug concentrations as drug concentrations were only measured at the LACE 
study visit, 3-4 years postpartum. These results present an innovative proof of concept for the 
use of change in self-reported adherence as a flag for viremia. This novel approach requires 
additional investigation as an interim adherence measure within routine settings with limited 
access to viral load or drug concentration measures. 
Chapter 4 showed, in line with previous research, that ARV drug concentrations in plasma 
and dried blood spots (DBS) are the best approach to measuring adherence and far 
outperform the cross-sectional self-reported adherence measure when predicting viral load. 
Tenofovir-diphosphate (TFV-DP) concentrations measured in DBS are a novel approach to 
measuring drug concentrations that have been used widely to measure adherence to pre-
exposure prophylaxis (PrEP) among individuals without HIV. Only a few studies have 
reported on TFV-DP in DBS to measure ART adherence among people living with HIV, and 
the results presented in Chapter 4 are the first to report on the association between TFV-DP 
concentration in DBS and viral load among a cohort of African women. The results support 
the findings of a recent study reporting a strong association between TFV-DP in DBS and 
viral suppression among people living with HIV in the United States [96], showing a similar 
dose response relationship between TFV-DP DBS concentrations and viral suppression. 
Although the analyses presented in this thesis were unable to match TFV-DP concentrations 
in DBS to actual doses taken, TFV-DP in DBS has been shown to provide insight into 
medication taking behaviour in the past 17 days [97,98]. Just as we often attempt to gather 
information on adherence in the past week or 30 days using self-reported measures, the 
longer half-life of TFV-DP in DBS provides a more nuanced understanding of ART 
adherence than plasma TFV or EFV levels which are informative about ART doses taken 
only in the past 4-5 days [99,100]. In Chapter 4, plasma EFV and TFV did not display the 
same dose-response relationship with viral suppression but had similar ability to TFV-DP in 
DBS to discriminate between women who were and were not virologically suppressed. This 
is notable as plasma drug concentration assays, although complex and costly relative to self-
report measures, are simpler and less expensive to run that TFV-DP assays in DBS and thus 
may be suitable interim adherence measures in settings with access to adequate laboratory 
resources. The technology for measuring drug concentrations is developing rapidly and 
options such as point of care urine assays may be available soon [101,102]. Advancements in 
cost and availability of drug concentration assays will make real-time adherence 
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measurement and immediate counselling or intervention a possibility, even in resource-
limited settings.  
While TFV-DP DBS concentrations are clearly the ideal measure of adherence for research 
settings, and plasma concentrations may provide a viable alternative, drug concentration 
assays are still unlikely to be rolled out in routine care in limited resource settings due to 
expense and the need for laboratory-based analyses. Thus, simple and inexpensive options of 
measuring ART adherence are still needed, and longitudinal self-report is one possibility for 
future consideration. 
8.1.5 Considerations for measuring retention in HIV care  
Retention in care is a key marker of the success of ART programmes. It is often measured for 
patient and programme monitoring as well as for research outcomes. The combined work of 
this thesis highlighted two important components to consider when measuring retention: the 
ascertainment of outcomes beyond a single facility and the choice of data sources used.  
Ascertaining outcomes beyond a single facility 
Facility-specific retention – the proportion of patients who start ART at the facility, or have 
been in care at the facility, who are still in care at the same facility – is commonly reported in 
the literature (Chapter 2:Table 2-1). Patients who have been transferred to other clinics may 
be excluded from analyses, censored or occasionally assumed to be retained in care. It is 
known that not all patients successfully link to a new clinic after transfer while others who 
do, do not always link to the intended clinic [35,103,104]. Patients are also known to 
sometimes “silently” transfer, or move their care to a new clinic without a documented 
transfer [79,80,105–107]. As noted in Chapter 2 and Section 8.1.3 above, transfers of care are 
often inevitable in the context of maternal ART and the timing and nature of the transfer 
varies across settings. The results of Chapter 7 also demonstrate that, in an urban area with a 
high density of ART clinics, women spread to a large number of different facilities to 
continue their ART care after delivery [9]. Measuring facility-specific retention, without 
accounting for outcomes following documented and “silent” transfers, can result in biased 
estimates of retention [108]. Thus, the ascertainment of outcomes beyond a single facility is 
particularly pertinent among women who initiate ART in pregnancy.  
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Interlinked data sources are recommended by the WHO to allow programmes to trace 
patients beyond the facility of ART initiation, to measure continuity of care and to intervene 
as needed [109]. The use of interlinked data sources, as described in Chapter 6, overcomes 
the issues of transfer, both formal and informal clinic switching, and mobility, and is going to 
be critical to accurately monitor long-term retention for both programme and individual 
intervention purposes. The use of interlinked data sources in research also enables the 
assessment of retention among study participants who move away from the research clinic or 
are lost to the study. In the research presented in this thesis, and in the primary MCH-ART 
trial analyses [29], the use of interlinked routine electronic data from a combination of data 
sources, available across all routine clinics in the Western Cape province and with laboratory 
data available from clinics nationally, allowed for the measurement of the retention in care 
without differentiation by retention in the study. This approach has clear benefits as loss from 
a study is often associated with LTFU from routine care, which in turn can be associated with 
research outcomes, often the case in HIV care retention studies [108,110]. 
Although the data sources exist in either paper or electronic systems in most settings in SSA, 
the existence of electronic data that links patients across different clinics in an area is very 
rare. Setting up interlinked data sources will be a resource intensive activity that relies firstly 
on the establishment of unique patient identifiers to facilitate linkage. However, in the long-
term, these data systems would reduce the need for active tracing for individual patient 
interventions. They have the potential to improve retention monitoring and patient outcomes 
in ART programmes and for other chronic conditions. Where no interlinked data sources are 
available but women are known to require a transfer of care, or in settings where mobility is 
common, active tracing of even a sample of women can reduce the bias introduced by 
facility-specific retention estimates and should be prioritised to ascertain patient outcomes 
beyond the facility of interest [78,108].  
The choice of data sources to measure retention 
The results of Chapter 6 emphasized the importance of considering the most appropriate 
measure of retention depending on the purpose of the estimate and the available data sources. 
Each data source may have a different expected frequency and set of considerations. 
Laboratory data for example, may be the most likely to be available centrally with links 
across facilities. This would allow for measures of retention that account for mobility and 
transfers. A recent analysis of retention in South Africa used the National Health Laboratory 
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Services database to estimate retention in this way and found considerable improvements in 
retention estimates compared to methods not accounting for transfer or mobility between 
clinics [111]. However, laboratory data, at least in low- and middle-income countries, may be 
limited as routine viral load testing usually only occurs annually or in some countries every 
two years [112]. 
Pharmacy refill data and patient visit data usually align well to local visit schedules. 
Administrative pharmacy dispensing databases often exist but may be facility-specific and 
thus not allow for consideration of care accessed at other clinics. If pharmacy data can be 
obtained including quantity or duration of ART dispensed, it can be a valuable measure of 
both retention in care as well as treatment adherence. Although pharmacy refill adherence 
measures do not provide a direct measure of medication taking behaviour, they have been 
shown to correlate well with clinical and biological outcomes [113,114]. In this thesis, 
pharmacy data were not fully evaluated as a stand-alone data source due to inconsistent 
availability of data across facilities, an issue that is discussed in more detail in Section 8.2. 
This difficulty accessing the data highlights some of the important real-world challenges that 
are often experienced with the use of routine data to measure retention, even within the 
relatively well-resourced health system and health information platforms in the Western 
Cape.  
Patient visit data is the most widely used data source to measure retention and, in this thesis, 
was found to be a robust data source. Although electronic medical records and health 
information systems are in place in many low- and middle-income countries, many still rely 
predominantly on paper patient records and clinic registers. In Chapter 6 of this thesis, clinic 
visit data accounted for over 80% of all women considered retained using a number of 
different retention definitions. This suggests that where these data are available electronically 
they may provide the best coverage of access to HIV care.  
One emerging challenge with both pharmacy and clinic visit data is due to the scale-up and 
changing landscape of differentiated models of care. Differentiated models of care may result 
in several different ART dispensing avenues and visit schedules in a single region or even a 
single clinic [115]. It may be difficult to identify which model of care any one patient is 
receiving and expected visit frequency is key to understanding context-specific retention in 
HIV care. For programme monitoring, a more broadly generalisable retention measure that 
can cut across programmes and models of care is desirable. The measure must be consistent 
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enough to allow comparison within a programme over time and comparison of outcomes 
across different programmes as well as research studies [116,117]. A 180-day gap with no 
visits has proven to be a robust marker of programme retention. Chi et al, in a large analysis 
across three continents, found that this length of gap in care minimised misclassification 
based on whether or not people returned to care in the 12 months after they had been counted 
as lost [117]. This definition was also the strongest predictor of viremia in Chapter 6 of this 
thesis. 
The appropriateness of using different data sources is likely to evolve over time as health 
information systems develop. Combining data sources may be useful to better understand 
engagement in care. For example, facility-specific clinic visit data could be used for a 
context-appropriate retention measure in the facility, while a central, linked laboratory or 
pharmacy data source could be used to ascertain whether patients not in care at the facility of 
interest are accessing care at another clinic. Together with investing in unique patient 
identifiers, where existing clinical, clerical or administrative data sources are available they 
should be leveraged as a starting point for developing interlinked health information systems. 
8.1.6 Opportunities to support long-term engagement in HIV care 
The results of this thesis show estimates of retention ranging from 41%-72% using different 
definitions and data sources in Chapter 6. Only 72% of women had viral loads <1000 
copies/mL among those who completed a study visit at 3-4 years postpartum in Chapter 4. 
This is could be an overestimate as women who returned to the study may have been more 
likely to be retained in HIV care compared to women who did not return. Overall, these 
findings are in line with estimates of the second and third 90s in South Africa [6,21], but well 
below the UNAIDS targets [1]. Together, these results highlight several important 
opportunities to support engagement in HIV care following ART initiation in pregnancy. This 
section will discuss these opportunities in the following two areas: i) preparation and 
counselling, and ii) interventions beyond the facility of ART initiation. These two broad areas 
are covered by an overarching need for patients, providers and health systems to be flexible 
to the changing needs of patients and the health services as women transition through 
pregnancy, breastfeeding and into post-breastfeeding motherhood. 
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Preparation and counselling 
The barriers presented by ART side effects and mobility are not unique to pregnant and 
postpartum women and have also been reported as barriers to engagement in care in adult and 
adolescent cohorts [38,42,46,118]. However, as discussed in Section 8.1.3, these barriers 
have some unique considerations among women starting ART in pregnancy and focused 
counselling on these issues may be a useful strategy to address these considerations. The 
novel quantitative findings on reported side-effects in pregnancy in Chapter 3 [7] and LTFU 
after transfer from an integrated antenatal and ART clinic in Chapter 7 [9], support findings 
from qualitative work conducted in Option B+ cohorts across SSA. A number of studies have 
found that women report ART side effects and a lack of counselling at ART initiation as 
reasons for poor engagement in care [18,48,49,119–121]. One study in Malawi found that 
women no longer in care reported receiving less counselling when they started ART 
compared to women who remained in care [75]. The same study highlighted that mobility 
resulted in challenges accessing HIV care in a new place. 
The results of Chapters 3 and 7 both call for adequate counselling and preparation within our 
ART programmes. Patient preparation about side effects during pregnancy, both related to 
HIV and ART as well as related to pregnancy or any other existing conditions, is critical to 
ensure women know what to expect. There is also a need to prepare women for any transfers 
of care required by local ART programmes and to provide specific counselling on how to 
navigate adherence and retention through times of mobility. Counselling and support 
interventions have shown promise to improve adherence and retention in HIV care in adult 
cohorts [122,123]. The impact of counselling messages specific to side effects, mobility and 
transfer, embedded into routine ART counselling for pregnant and postpartum women, 
requires investigation. 
Preparedness for ART has been a topic of much discussion in the era of test-and-treat due to 
concerns about the implications of rapid ART initiation on later outcomes. A recent 
systematic review found no association between rapid ART initiation and clinical outcomes 
and little evidence for increased LTFU [124]. Studies in pregnant women specifically report 
mixed results [125,126], but ART initiation as soon as possible in pregnancy is essential to 
ensure viral suppression by the time of delivery and minimise the risk of perinatal 
transmission. What is critical now is to ensure that the counselling on potential ART side 
effects, transfer of care and mobility, and long-term adherence beyond the pregnancy and 
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postpartum transmission risk periods is adequate, and that avenues exist for women requiring 
additional support. 
Moving beyond the facility of ART initiation 
For both the measurement and support of lifelong engagement in care it is not sufficient to 
focus only on the facility of ART initiation. The results of Chapter 7 show that women who 
started ART in the same clinic during pregnancy spread out to attend almost 100 different 
ART clinics in the first two years on treatment. Among women who linked to care after 
leaving the integrated clinic, 21% accessed two or more different clinics in the first two years 
on ART. Other studies have actively traced patients considered to be lost to follow-up and 
found a number of them to be attending other clinics [78,79,107,127]. The results presented 
in Chapter 7 are the first to document mobility for routine HIV care in a full cohort of 
postpartum women and they add important insights to an emerging literature on mobility and 
engagement in HIV care [42,43,76]. These novel findings draw attention to the critical need 
for interventions that bridge across facilities, facilitate continued engagement in care through 
times of geographic mobility or movement between clinics, and that can provide support for 
women living with HIV where they are and when they need it. 
The use of routine interlinked data sources is one way to support engagement in care beyond 
the facility of ART initiation. Existing routine clinical, administrative or clerical data sources, 
such as those obtained from the Provincial Health Data Centre for use in this thesis, can be 
linked using a unique patient identifier [128]. These data can then be used to flag patients 
considered LTFU or those with raised viral loads and reports listing patients requiring 
additional support or intervention can be generated for follow-up. Linking these data across 
facilities in a region will allow facilities to easily follow up on patients who have transferred 
care and will prevent facilities from investing resources into tracing patients who are actively 
engaged in HIV care elsewhere. Although the various data sources do exist in either paper or 
electronic form in most health services, many settings do not have established unique patient 
identifiers or the infrastructure to set up linked electronic data sources. This is a substantial 
barrier to the potential use of routine health data for both cohort monitoring and individual 
patient intervention.  
Community-based interventions also provide a platform to extend support beyond a specific 
facility and to intervene in some of the broader social barriers to engagement in care. In the 
Option B+ literature, lack of support from partners, family and the community is often cited 
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as a barrier to engagement in HIV care [11,47,129,130]. Stigma also remains a major barrier 
to engagement and can prevent women from seeking support when needed [47,131]. 
Community-level engagement has been highlighted as crucial to address issues of stigma and 
to improve social support for women living with HIV [132]. Peer models to support maternal 
ART can encompass both counselling, support and community engagement [18,133–135] and 
they have been successful in improving the uptake of ART in pregnancy and early infant HIV 
testing in SSA [136,137]. Community-based peer support models can be successfully 
implemented and have been found to perform similarly to facility-based models to improve 
engagement in HIV care in SSA and other low- and middle-income settings [138,139], 
including maternal ART uptake and retention under Option B+ specifically [18]. 
Community-based support interventions could provide an additional avenue to support long-
term engagement in care beyond the facility of ART initiation. 
Mobile health (mHealth) is another approach with the potential to offer support regardless of 
where a woman is accessing care. mHealth interventions have shown promise to improve 
ART adherence in adult cohorts as well as in the context of PMTCT [140,141]. Interventions 
using a mobile phone platform have the advantage that the mode of intervention resides with 
the patient or healthcare worker and is already part of their everyday life. It is therefore able 
to provide interventions that bridge across facilities and models of care to provide support 
even in the context of transfer and geographic mobility. In addition, mobile technology can 
be used as the platform to deliver many types of interventions to both patients (such as 
counselling, peer support, case management and adherence reminders) and healthcare 
workers (such as training and job aids). Interventions such as MomConnect in South Africa, a 
text message service to support all women during and after pregnancy, is one example of a 
national support intervention that is not tied to a single facility or region, however the impact 
of this on engagement in HIV care specifically has not yet been evaluated [142].  
Most mHealth interventions to date make use of short-text messaging service (SMS) or phone 
calls [143]. Smartphone technology provides a mobile platform for a multitude of interactive 
combination interventions [144]. It is estimated that about 51% of South Africans own a 
smart phone (Figure 8-2) and the technology is becoming more and more accessible, even in 
developing countries [145]. New intervention designs are emerging to take advantage of 
smartphone and wireless technology to support health outcomes. Just-in-time adaptive 
interventions (JITAIs) are interventions designed to “adapt over time to an individual’s time-
varying status, with the goal to address the individual’s changing needs for support” [146]. 
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They make use of technology such mobile applications to deliver prompts or provide access 
to specific support based on feedback received by the user at a particular time. Although 
barriers to access still exist, these and other mHealth intervention designs present an 
opportunity to provide long-term support to women living with HIV on a large scale, 
adapting to their changing needs as they transition through the stages of maternal lifelong 
ART, different clinics and different geographic areas. 
 
 
Figure 8-2 A map showing the proportion of adults who reported owning a smartphone in 
2017, from the Pew Research Center [145]. 
Summary 
Cutting across all the opportunities for supporting engagement in care is the need for 
flexibility. Hoddinott et al, in a large qualitative analysis of households in Zambia and South 
Africa, concluded that “responsive, flexible health service delivery systems designed to 
accommodate the many shifts in client circumstances” were critical to support engagement in 
HIV care [42]. This is pertinent in the context of maternal ART where a woman is going 
through many life transitions and, in parallel, transfers into and out of different ART services 
may be required. Over time, regimens and treatment practices will change, differentiated 
models of care will evolve and scale up, and patients will move between clinics and between 
geographical areas. Just as pregnant and postpartum women need to adapt to their changing 
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life circumstances, our health services, interventions and even the way we monitor 
engagement in HIV care must also adapt. 
Not only is there a need for adaptability in supporting long-term engagement in care, but 
there is also perhaps a need to acknowledge that despite our best efforts, just as with other 
chronic conditions, people living with HIV are unlikely to remain continuously engaged in 
HIV services for life [147–149]. It is crucial that there is also a focus on preparing patients 
and providers for potential lapses in care, identifying points of re-entry into care for patients 
who do disengage and promoting systems and attitudes that encourage re-engagement in HIV 
care as soon as possible when this occurs. 
8.2 Strengths and limitations 
Strengths and limitations specific to each analysis are presented within the discussion section 
of each chapter, however the following additional overarching strengths and limitations of 
this thesis should be considered.  
Both a strength and a limitation of this work is the cohort from which it is drawn. All the 
results presented in this thesis are from a single cohort of women who initiated ART during 
pregnancy at the time of roll out of universal ART for pregnant women in Gugulethu, South 
Africa. This is a strength as this cohort provides unique insights into adherence and retention 
during and after pregnancy from one of the first Option B+ cohorts in South Africa. Thus, 
this work provides lessons for universal ART in pregnant and postpartum women, but also 
for universal ART more broadly. A related limitation is the generalisability of the findings. 
While these findings are likely to be generalisable in many ways to other similar settings in 
South Africa and SSA, the results from this single cohort may not be directly applicable in 
other settings where aspects of the analyses such as the local model of care and available data 
sources differ. These results are situated within the context of an integrated antenatal and 
ART care model, with mandatory postpartum transfer to general ART clinics. The issues of 
transfer and mobility are relevant beyond this setting, but results should be transferred to 
other models of care with careful consideration of the potential differences. Similarly, the 
routine health data used in this thesis comes from an established health information exchange, 
the Provincial Health Data Centre of the Western Cape Department of Health. Although the 
component data sources are available in many other settings, the process of linking and 
deduplicating health records and the presence of a unique provincial patient identifier, both 
major advantages of this work, are quite unique to this setting. 
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Another disadvantage is that these results represent a relatively short follow-up time with 
retention outcomes through to 24 months on ART (Chapter 6) and adherence in a small 
sample of women at approximately four years on ART (Chapter 4). With universal ART for 
all, more focus is needed on long-term ART outcomes and patterns of engagement in HIV 
care over time. To date there have only been two studies reporting on routine care outcomes 
of women who initiated ART in pregnancy beyond three years on treatment [13,19]. Thus, 
despite this limitation, these findings contribute to our understanding of longer-term 
outcomes as well as methodological considerations as we move towards exploring long-term 
engagement in care after pregnancy. This cohort was also limited to women aged 18 years 
and older. Adolescents and young women are known to be vulnerable to poor retention and 
adherence[150,151] and younger age was consistently a risk factor for poor outcomes in this 
thesis but this work cannot speak directly to younger populations. 
Both self-reported and routine data sources are subject to known limitations which have been 
discussed in the results chapters. However, the use of these data sources was central to this 
thesis with a view towards readily available adherence and retention measures. Interlinked 
routine electronic data to measure retention has the potential for misclassification and we 
cannot be sure that the quality of data was the same across all clinics. However, the use of 
these data allowed ascertainment of retention outcomes in all women, even those lost from 
face-to-face study follow-up. Repeated self-reported adherence measures in the MCH-ART 
study provided unique data to examine longitudinal changes in self-reported adherence. 
Similarly, the numerous viral load measures collected by this study allowed for inclusion of 
viral load outcomes in all analyses except for Chapter 3. The analyses presented in Chapter 3 
were conducted early in the study when batched viral load results were not yet available. The 
study collected viral load measures and high study retention rates meant that viral load 
outcomes were available for almost all women, even those that were no longer engaged in 
routine HIV care.  
Another limitation of this work is that it only examined engagement in HIV care among 
mothers and did not include any child outcomes. Children’s engagement in routine health 
care, including adherence to infant HIV prophylaxis and visit attendance for early infant 
diagnosis, is crucial for optimal child health and patterns of engagement of mothers and their 
children are likely to be linked [152,153]. Reduced mother-to-child transmission of HIV and 
improved child health outcomes are key potential benefits of universal ART for pregnant and 
breastfeeding women. Furthermore, routine child health visits present an opportunity to 
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support maternal engagement in care in the postpartum period. The combined outcomes of 
maternal and child engagement in care, and how they are related, should be considered in 
future work.  
In addition, this thesis has focused on women who initiated ART during pregnancy but 
women who conceive on ART are also vulnerable to disengagement from care. There is some 
evidence that they may even have a greater risk of postpartum virologic failure compared to 
women who initiate ART in pregnancy [154]. Once on ART, women who conceive may be 
required to transition into integrated antenatal and ART services and then again transfer out 
to general ART services postpartum. These transitions require consideration in future 
research to ensure continuity of care in this critical period. 
8.3 Recommendations for policy, research practice and future research 
The findings of this thesis have provided insight into factors contributing to high levels of 
disengagement from ART during pregnancy and after delivery. They also provide evidence 
for novel approaches to measure ART adherence and considerations for using interlinked 
routine electronic health data to measure retention in care. Based on this evidence, this 
section will outline recommendations for policy, research practice and future research 
priorities. 
8.3.1 Policy recommendations 
The combined work of this thesis has resulted in three recommendations for policy. Firstly, a 
call for strengthened counselling about ART side effects among women starting ART in 
pregnancy, as well as preparation for postpartum transfer, mobility, and long-term 
engagement in ART care beyond the period of risk of perinatal or breastfeeding transmission 
of HIV. Ensuring that women are prepared for what to expect as they initiate ART during 
pregnancy, what side effects to expect for their specific regimen, and to navigate the 
transition to general ART care is a key step towards overcoming some of the barriers to 
sustained engagement in HIV care. The Western Cape province already has a Standard 
Operating Procedure for mobile patients, showing a move towards a health system that can be 
prepared for and adapt to patients’ changing circumstances [155]. The protocol covers both 
planned and unplanned travel, but work is still needed to counsel patients and train providers 
on the implementation of this protocol. Moreover, given the frequency of mobility outside of 
the province, this also needs to be extended into national protocols. 
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The second recommendation is around consideration of models of care for maternal ART. 
Integrated antenatal and ART care with continued integrated care for mother-baby pairs 
postpartum has shown clear benefits for sustaining engagement in care through the highest 
risk periods of pregnancy and breastfeeding and ensuring adherence to early infant diagnosis 
protocols [29,31,32]. It also offers the opportunity to integrate other critical services such as 
reproductive health and family planning services [156]. Programmes should consider 
implementing integrated maternal and child health services at least until the child’s final HIV 
status is ascertained following cessation of breastfeeding to minimise the risk of transmission 
and ensure rapid ART initiation if needed. Even with this policy, systems to support 
movement to a new clinic through transfer or times of mobility will still be needed. In 
addition, both research and programmes need to explore the optimal model and timing for 
transferring women out of integrated services into routine adult care when required to ensure 
ongoing engagement in care beyond this risk period. The optimal components of integrated 
care also require consideration but at a minimum should cover maternal ART and 
reproductive health services, infant wellness and immunisations, as well as early infant HIV 
diagnosis and either treatment or optimal referral of HIV-infected infants to paediatric care. 
Finally, the establishment of unique patient identifiers and the development of interlinked 
health information systems should be prioritised. In the era of universal lifelong ART, it is 
critical that patients be able to access HIV care wherever they move to over time. To be able 
to support this, it is critical for health information systems to be able to link across facilities. 
In maternal ART cohorts, there is also the need to link mother-baby pairs to ensure 
completion of the PMTCT cascade and intervene where necessary. Many countries already 
have existing clinical, clerical or administrative data systems that could be leveraged to start 
to form an interlinked health information system. There is probably no perfect system but 
linking data sources that already exist will provide a platform from which to develop 
interventions to improve patient care and strengthen programme monitoring. The Provincial 
Health Data Centre of the Western Cape is a useful case study of this approach. Although this 
thesis has focused specifically on the importance of these systems for ART programmes, the 
benefits will extend to all primary health services. 
8.3.2 Recommendations for research practice 
The recommendations for research practice speak to the measurement of ART adherence and 
retention in HIV care in research studies. The possible measures will be dependent on the 
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local setting, the scope of the research and available funding, but these recommendations aim 
to provide some guidance. 
For research measuring adherence, our findings confirm that the use of TFV-DP in DBS is a 
very strong measure of ART adherence among people living with HIV [96]. TFV-DP in DBS 
also has the added benefit of providing insight into dosing over a longer period than other 
drug concentration assays and therefore providing a more nuanced measure of adherence. 
This measure should be used in-so-far as resources allow. Plasma EFV and TFV 
concentrations were also strongly associated with viral suppression in Chapter 4, however 
previous research has found single plasma ARV concentrations to be poor predictors of viral 
load [157]. Plasma ARV concentrations provide a simpler and less expensive alternative to 
TFV-DP in DBS, but further research is needed to better understand the value of these assays 
to detect viremia or ARV resistance in the context of routine viral load monitoring. 
When measuring retention in HIV care, these results highlight the need for the inclusion of 
sensitivity analyses using different retention measurement approaches. Researchers need to 
carefully consider the most appropriate retention definition depending on the available data 
sources, the local context, the question being asked, and the intended use of the estimates. 
Based on this, researchers might choose a very context-specific primary retention definition 
to best meet their needs. However, in order to promote comparability within and between 
programmes and research studies, the inclusion of a more generalisable retention measure in 
sensitivity analyses, such as a 180-day gap in care which is widely used [116,117], should be 
encouraged. In addition, journals should encourage researchers to clearly describe the local 
model of care and the data sources used. This would allow readers to assess the rationale for 
the choice of measurement approach used and the potential impact of any differences in 
measurement approach across studies.  
Finally, researchers should be strongly encouraged to select data sources and definitions of 
retention that allow for consideration of mobility and transfer of care. Chapters 6 and 7 of this 
thesis clearly highlight the need to ascertain retention outcomes beyond the facility of ART 
initiation, particularly in settings with required health care transfers and where mobility is 
common. Attempts to ascertain retention outcomes beyond a single facility should be 
standard practice for research on long-term retention in HIV care. 
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8.3.3 Future research priorities 
This research points to a number of important future research priorities. Chapters 4 and 5 
demonstrated that drug concentrations are superior to self-reported adherence measures but 
that longitudinal self-reported adherence performs better than cross-sectional self-report. This 
work provides a proof of concept for the use of change in self-reported adherence to detect 
the risk of viremia, but questions remain about the feasibility and potential uses in routine 
care. Future research should validate the use of change in self-reported adherence as an 
interim adherence measure in a routine care setting. Viral loads alone do not differentiate 
between poor adherence or non-retention and ARV resistance. The value of both drug 
concentrations and change in self-reported adherence, in combination with routine viral load 
monitoring, still requires investigation and the potential value for flagging potential treatment 
resistance requires consideration. 
The results of Chapter 7 show that many women do not link to care after transferring from an 
integrated antenatal and ART clinic. Further research is needed to evaluate the optimal timing 
and approach to transfer of care. There is also a need for the development of interventions to 
support continued engagement in HIV care through the postpartum transfer and beyond. 
Future research into engagement in HIV care must consider mobility and movement between 
clinics in order to accurately measure engagement and to most effectively use resources to 
intervene in patient care. 
Lastly, there is growing recognition of the dynamic nature of retention and adherence, 
emphasising that patients will move in and out of care over their life on ART [148,149,158]. 
Most research, including this thesis, uses cross-sectional measures of adherence and retention 
or aggregate measures over time. These approaches do not consider the dynamic nature of 
engagement in care and do not necessarily provide accurate insights into an ART programme 
or an individual’s treatment status. As we shift focus to long-term engagement in HIV care, 
future research should include strategies to incorporate change in engagement in care into 
measurement approaches. It should also focus on understanding the impact of changing 
engagement in care over time as well as identifying opportunities to support re-engagement 
of patients who are lost. 
In summary, this thesis highlights the importance of future research on patterns of 
engagement in HIV over place and time as well as appropriate measures and interventions to 
support engagement in care in the long-term. All the individual-, family- and population-level 
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benefits of universal lifelong ART among pregnant and postpartum women can only be 
achieved through sustained engagement in HIV care. Thus, future research must prioritise 
better understanding and optimal support of lifelong ART.  
8.4 Conclusions 
This thesis investigated barriers to engagement in HIV care with specific considerations 
among pregnant and postpartum women. It also explored novel adherence measurement 
approaches and the use of routine interlinked data sources to measure retention in HIV care 
after ART initiation in pregnancy in South Africa. For both adherence and retention, 
regardless of measurement approach, the combined findings of this thesis highlight 
substantial disengagement from HIV care during and after pregnancy, posing a threat to the 
potential benefits of lifelong ART. 
Two aspects of this thesis speak to the need for improved ART counselling and preparation 
for potential barriers. This work provides new evidence of the high burden of self-reported 
ART side effects among women who start ART in pregnancy, finding that it is the overall 
side effect burden, rather than system-specific side effects, that are most strongly associated 
with ART adherence. Given the many normal physiological changes a women experiences 
during pregnancy, adequate preparation for potential ART side effects is needed to ensure 
optimal adherence in the early months on ART. In addition, this thesis presents a novel 
description of LTFU and mobility to different ART clinics following routine transfer out of 
integrated antenatal and ART services. These findings again call for the need for adequate 
counselling on how to navigate required transfers of care as well as how to remain engaged in 
care through times of mobility. ART counselling should place emphasis not only on the 
pregnancy and breastfeeding periods, but also on the importance of sustained long-term 
engagement in care for optimal maternal health.  
This thesis contributes pioneering results comparing TFV-DP in DBS, plasma EFV, plasma 
TFV and self-reported adherence to predict viral load among an African cohort of women 
living with HIV. Drug concentrations in DBS and plasma provide robust measures of 
adherence. In routine care settings with limited resources for viral load or drug concentration 
testing, the value of an innovative adherence measurement approach using longitudinal 
change in self-reported adherence warrants further investigation. 
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Lastly, the finding that women spread out to almost 100 different clinics after leaving an 
integrated antenatal and ART clinic is significant and provides evidence of the importance of 
interlinked data sources to accurately measure retention in care postpartum. These novel 
findings are likely to hold for other settings with required transfer of HIV care or where 
mobility is common. Even when using interlinked data, considerable variation in retention 
estimates was observed using different data sources and definitions, with clinic visit data 
emerging as the most robust data source for retention measurement. Recommendations 
include prioritising the establishment of unique patient identifiers and leveraging existing 
administrative, clerical and clinical data systems to improve patient care and programme 
monitoring. 
In conclusion, this thesis provides a unique picture of barriers to and considerations for the 
measurement of engagement in HIV care among pregnant and postpartum women. Despite 
substantial progress with the scale-up of ART programmes and uptake of lifelong ART, there 
is a critical need to focus on long-term sustained engagement in HIV care in order to realise 
the individual-, family- and population-level benefits of lifelong ART. Careful consideration 
of the appropriate measurement approach is required to accurately measure engagement in 
HIV care and to allow comparison within and between programmes and research. Just as 
women are adapting to many changes as they transition through pregnancy, breastfeeding and 
post-breastfeeding motherhood, the health system, providers and our measurement 
approaches, must be flexible to women’s changing health care needs and life circumstances. 
Further research is needed to evaluate optimal models of care for providing maternal ART 
and to develop interventions to support engagement beyond the facility of ART initiation. 
This ongoing work will be critical to ensure sustained maternal engagement in HIV care in 
the long term and ultimately to end the HIV epidemic. 
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9.2 Supplementary material for Chapters 3-7 
9.2.1 Chapter 3 
Supplementary Table 9-3-1 Comparison of the fit of Latent Class Analysis (LCA) models 
with different number of classes according to different criteria. 
N LL AIC aBIC Entropy BLR p min SIZE % 
1 -3618.07 7258.13 7269.95 1 - 100% 
2 -3323.78 6693.55 6718.25 0.75 <0.001 47% 
3 -3296.47 6662.94 6700.52 0.67 0.200 20% 
4 -3278.07 6650.13 6700.60 0.74 0.016 17% 
5 -3266.45 6650.89 6714.25 0.71 0.730 9% 
N = Number of latent classes; LL = Log-Likelihood; AIC = Akaike's Information Criterion; aBIC=sample size adjusted Bayesian 
Information Criterion; Entropy = Classification Entropy (as calculated by Mplus, i.e. rescaled so that values closer to 1 indicate better 
discrimination); BLR p = p-value for the Bootstrap Likelihood Ratio test with null hypothesis that the fit of the model with n classes is not 
different from the fit of the model with n-1 classes (50 bootstrap draws). 
 
Models with one through five latent classes were compared in order to identify the number of 
distinct patterns of SE reported by women starting ART during pregnancy. The sample-size 
adjusted Bayesian Information Criterion (aBIC), which some simulation studies have shown 
to be superior to other indices in the LCA, reached its minimum with both the three- and 
four-class solutions, with no meaningful differences.1 However, the lower value of the 
Akaike’s Information Criterion (AIC) and the results of the Bootstrap Likelihood Ratio test 
(BLR) both were in agreement, suggesting a better fit for the four-class model. Moreover, the 
four-class model was accompanied with higher classification entropy indicating a lower level 
of uncertainty in the classification of the individuals. The four-class solution was therefore 
selected to represent the data. The values of the various indices of fit used for the models and 
the results of the BLR test are reported here. 
Reference: 
1. Yang. Evaluating latent class analysis models in qualitative phenotype identification. 
Computational Statistics & Data Analysis. 2006; 50(4):1090-1104. 
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Supplementary Table 9-3-2 Multinomial logistic regression model predicting latent class 
membership. 
Class§ Predictor 
A) Crude associations 
(n=517, except CD4, n=500) 
B) Adjusted associations 
(n=500) 
  OR (95% CI) p-value OR (95% CI) p-value 
Class 2 One-year increase in age 0.99 (0.91-1.07) 0.042    
 Socioeconomic status       
 Low (ref)   (ref)  - 
 Middle 4.66 (4.66-4.66) <0.001 4.56 (1.71-12.17) 0.002 
 High 2.88 (1.04-7.94) 0.518 3.59 (1.28-10.07) 0.015 
 Married/cohabiting 0.67 (0.32-1.40) 0.379 1.19 (0.51-2.79) 0.680 
 Primigravid 2.68 (1.07-6.71) 0.469 1.71 (0.65-4.49) 0.277 
 
1 unit increase in natural 
logarithm of pre-ART CD4 
1.77 (0.98-3.20) 0.303 2.21 (1.04-4.70) 0.040 
 Diagnosed prior to pregnancy 0.52 (0.25-1.10) 0.380 0.66 (0.28-1.58) 0.351 
 ARV history       
 ARV naive (ref)  -    
 Previous PMTCT 0.86 (0.36-2.04) 0.443    
 Previous ART 0.51 (0.05-5.40) 1.209    
 
Increasing weeks gestation at 
ART start 
1.11 (1.06-1.16) 0.024 1.12 (1.03-1.22) 0.010 
 Increasing weeks on ART 0.93 (0.89-0.97) 0.021 1.00 (0.93-1.07) 0.911 
Class 3 One-year increase in age 1.01 (0.96-1.07) 0.042    
 Socioeconomic status       
 Low (ref)  - (ref)  - 
 Middle 2.98 (1.35-6.58) <0.001 2.9 (1.25-6.71) 0.013 
 High 2.7 (1.26-5.78) 0.518 3.04 (1.28-7.22) 0.012 
 Married/cohabiting 0.53 (0.28-0.99) 0.379 0.76 (0.38-1.52) 0.437 
 Primigravid 1.18 (0.50-2.81) 0.469 0.71 (0.27-1.90) 0.499 
 
1 unit increase in natural 
logarithm of pre-ART CD4 
1.35 (0.83-2.19) 0.303 1.65 (0.95-2.86) 0.077 
 Diagnosed prior to pregnancy 0.66 (0.36-1.21) 0.380 0.68 (0.34-1.36) 0.274 
 ARV history       
 ARV naive (ref)  -    
 Previous PMTCT 0.97 (0.47-1.97) 0.443    
 Previous ART 1.51 (0.37-6.17) 0.209    
 
Increasing weeks gestation at 
ART start 
1.03 (0.98-1.08) 0.024 1.02 (0.96-1.08) 0.575 
 Increasing weeks on ART 0.98 (0.94-1.01) 0.021 0.98 (0.93-1.02) 0.327 
Class 4 One-year increase in age 1.02 (0.97-1.07) 0.042    
 Socioeconomic status       
 Low (ref)  - (ref)  - 
 Middle 1.92 (0.96-3.83) <0.001 2.27 (1.06-4.86) 0.035 
 High 1.43 (0.72-2.82) 0.518 2.25 (0.99-5.10) 0.052 
 Married/cohabiting 0.7 (0.40-1.24) 0.379 0.93 (0.48-1.81) 0.829 
 Primigravid 1.12 (0.49-2.53) 0.469 0.99 (0.42-2.32) 0.974 
 
1 unit increase in natural 
logarithm of pre-ART CD4 
1.86 (1.13-3.07) 0.303 2.11 (1.23-3.63) 0.007 
 Diagnosed prior to pregnancy 0.67 (0.38-1.18) 0.380 0.79 (0.41-1.52) 0.489 
 ARV history       
 ARV naive (ref)  -    
 Previous PMTCT 1.11 (0.59-2.12) 0.443    
 Previous ART 0.22 (0.01-4.67) 0.209    
 
Increasing weeks gestation at 
ART start 
1.11 (1.06-1.16) 0.024 1.07 (0.99-1.16) 0.097 
 Increasing weeks on ART 0.91 (0.88-0.95) 0.021 0.95 (0.88-1.02) 0.169 
§ Compared to reference class 1  
225 
 
Supplementary Table 9-3-3 Description of demographic and clinical characteristics according to the frequency of side effects (SE), systems-
based SE categories, and latent SE classes.  
 
Median frequency of 
reported SE (IQR) 
Any GIT 
SE 
Any CNS 
SE 
Any skin 
SE 
Any 
systemic SE 
Class 1  
(high SE) 
Class 2 
(moderate SE, 
high systemic) 
Class 3 
(moderate SE, 
low systemic) 
Class 4  
(low SE) 
All women 5 (3-7) 417 (81) 437 (85) 161 (31) 406 (79) 133 (26) 89 (17) 156 (30) 139 (27) 
Median age (IQR) - 27 (24-31) 28 (25-32) 28 (24-31) 27 (24-31) 28 (24-31) 27 (23-31) 28 (25-32) 28 (25-33) 
Socioeconomic status          
lowest 6 (3-8) 161 (39) 168 (38) 66 (41) 149 (37) 63 (47) 27 (30) 51 (33) 56 (40) 
medium 5 (3-7) 120 (29) 127 (29) 43 (27) 121 (30) 32 (24) 34 (38) 47 (30) 39 (28) 
highest 5 (3-7) 136 (33) 142 (32) 52 (32) 136 (34) 38 (29) 28 (31) 58 (37) 44 (32) 
Education level          
Finished high school 5 (3-7) 108 (26) 114 (26) 39 (24) 106 (26) 26 (20) 25 (28) 49 (31) 34 (24) 
Did not finish high school 5 (3-8) 309 (74) 323 (74) 122 (76) 300 (74) 107 (80) 64 (72) 107 (69) 105 (76) 
Employment status               
Employed 5 (3-7) 151 (36) 159 (36) 58 (36) 152 (37) 46 (35) 38 (43) 55 (35) 54 (39) 
Not employed 5 (3-7) 266 (64) 278 (64) 103 (64) 254 (63) 87 (65) 51 (57) 101 (65) 85 (61) 
Relationship status               
Married/cohabiting 6 (3-8) 160 (38) 178 (41) 62 (39) 152 (37) 60 (45) 34 (38) 52 (33) 52 (37) 
Not married/cohabiting 5 (3-7) 257 (62) 259 (59) 99 (61) 254 (63) 73 (55) 55 (62) 104 (67) 87 (63) 
Median gravidity (IQR) - 2 (2-3) 2 (2-3) 2 (2-3) 2 (2-3) 2 (2-3) 2 (1-3) 2 (2-3) 2 (2-3) 
Primigravida 6 (3-7) 82 (20) 75 (17) 23 (14) 77 (19) 21 (16) 25 (28) 25 (16) 22 (16) 
Multigravida 5 (3-7) 335 (80) 362 (83) 138 (86) 329 (81) 112 (84) 64 (72) 131 (84) 117 (84) 
Timing of HIV diagnosis          
In the current pregnancy 6 (3-7) 230 (55) 236 (54) 90 (56) 179 (44) 65 (49) 54 (61) 88 (56) 79 (57) 
Prior to this pregnancy 5 (3-8) 187 (45) 201 (46) 71 (44) 227 (56) 68 (51) 35 (39) 68 (44) 60 (43) 
ARV history              
ARV naïve 5 (3-7) 303 (73) 316 (72) 112 (70) 299 (74) 96 (72) 67 (75) 111 (71) 100 (72) 
Previous PMTCT 5 (3-7) 100 (24) 104 (24) 40 (25) 92 (23) 32 (24) 20 (22) 37 (24) 37 (27) 
Previous ART 6 (4-8) 14 (3) 17 (4) 9 (6) 15 (4) 5 (4) 2 (2) 8 (5) 2 (1) 
Median CD4 cell count at 
ART initiation (IQR) § 
- 
351  
(235-528) 
355  
(239-528) 
345  
(213-528) 
354  
(236-531) 
318  
(220-466) 
403  
(246-548) 
367  
(239-539) 
400  
(276-589)* 
CD4≤200   6 (4-8)* 78 (19) 75 (18) 33 (22) 75 (19) 29 (23) 13 (15) 28 (19) 15 (11) 
CD4 201 - 350 6 (3-8) 122 (30) 130 (31) 45 (29) 116 (29) 43 (34) 24 (28) 42 (28) 41 (30) 
CD4>350 5 (3-7) 202 (50) 217 (51) 75 (49) 203 (52) 56 (44) 50 (57) 80 (53) 79 (59) 
Median gestation(weeks) at 
ART initiation (IQR) 
- 21 (16-26) 20 (16-26) 21 (16-26) 20 (16-26) 19 (15-23) 24 (19-30) 20 (15-26) 23 (18-29)** 
Median weeks on ART (IQR) - 19 (13-24) 19 (13-24) 19 (14-24) 19 (14-24) 21 (16-25) 16 (11-22) 19 (12-25) 16 (10-21)** 
§17missing CD4 counts 
 
  
*denotes p<0.05, **denotes p<0.001 using Kruskal Wallis for continuous 
and chi-squared for categorical variables 
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Supplementary Table 9-3-4 Logistic regression models predicting any missed dose. 
  A) Crude associations (n=517, 
except CD4, n=500) 
B) Adjusted associations using 
number of side effects (n=517) 
C) Adjusted associations using 
system categories (n=517) 
D) Adjusted associations using 
latent classes* (n=517) 
  OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
One-year increase in age 0.95 (0.92-0.99) 0.005      0.97 (0.93-1.01) 0.105 0.97 (0.93-1.01) 0.125 0.97                        (0.93-1.01)          0.094 
Socioeconomic status             
Low (ref)            
Middle 1.15 (0.73-1.81) 0.538          
High 1.11 (0.71-1.73) 0.640          
Married/cohabiting 0.72 (0.49-1.06) 0.097 0.72 (0.47-1.09) 0.116 0.77 (0.51-1.16) 0.213 0.73 (0.48-1.11) 0.137 
Primigravid 1.60 (1.01-2.54) 0.047 1.21 (0.71-2.09) 0.482 1.17 (0.68-2.01) 0.575 1.16 (0.67-2.01) 0.593 
1 unit increase in natural logarithm of 
pre-ART CD4 
1.00    (0.49-2.03) 0.991               
Diagnosed prior to pregnancy 0.96 (0.66-1.39) 0.825               
ARV history             
ARV naive (ref)            
Previous PMTCT 0.69 (0.44-1.08) 0.107          
Previous ART 1.06 (0.38-2.93) 0.909          
Increasing weeks gestation at ART 
start 
0.98 (0.95-1.01) 0.113       
   
Increasing weeks on ART 1.03 (1.01-1.05) 0.011 1.02 (0.99-1.04) 0.128 1.02 (1.00-1.04) 0.111 1.02    (1.00-1.04) 0.113 
Any GIT SE 2.51 (1.45-4.34) 0.001    1.78 (1.00-3.17) 0.051    
Any CNS SE 1.76 (1.01-3.09) 0.047    1.25 (0.68-2.30) 0.479    
Any Skin SE 1.34 (0.91-1.99) 0.138    1.18 (0.79-1.79) 0.419    
Any Systemic SE 3.48 (1.97-6.13) <0.001    2.65 (1.46-4.81) 0.001    
Increasing no. of reported SE 1.21 (1.12-1.30) <0.001 1.20 (1.12-1.29) <0.001       
Class 1 (high SE) 1 (ref)        1 (ref)  
Class 2 (moderate SE, high systemic) 0.72 (0.19-1.26) 0.389       0.79 (0.45-1.39) 0.409 
Class 3 (moderate SE, low systemic) 0.62 (0.24-1.00) 0.124       0.61 (0.37-0.99) 0.046 
Class 4 (low SE) 0.17 (0.04-0.31) <0.001       0.25 (0.14-0.45) <0.001 
*Panel D is adjusted for the 
probability of class membership 
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Supplementary Table 9-3-5 Reported reasons provided for missing 30 or more ART doses. 
 Reason for missing 30 or more ART doses 
1.  “I ran out of treatment and did not go back to get more from clinic, I did not have 
transport money”  
2.  “I feel stressed, that is why I'm not taking my treatment. I vomit after taking the 
pill” 
3.  “I ran out of treatment…I wanted to avoid side effects” 
4.  “Because of side effects. I vomited and lost appetite” 
5.  “I stopped taking treatment due to exams, because they made me sleepy and 
weak. After that I became lazy to collect, avoiding explaining why I defaulted” 
6.  “After being discharged at hospital [after delivery], I did not come back to fetch my 
treatment. I was very late for my scheduled appointment to collect treatment and 
was afraid thereafter to come again. There is no reason for not taking treatment and 
it is not hard to take.”  
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9.2.2 Chapter 4 
Supplementary Figure 9-4-1 Histograms of a) plasma efavirenz, b) plasma tenofovir, c) 
tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS), d) self-reported 
adherence in the past 30 days (three-item scale score).  
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Supplementary Figure 9-4-2 Unadjusted area under the receiver operating characteristics 
(ROC) curves of DBS TFV-DP (grey), plasma EFV (green), plasma TFV (maroon), and self-
reported adherence (blue) to predict viral suppression; n=137. 
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Supplementary Figure 9-4-3 Scatter plot of tenofovir-diphosphate (TFV-DP) in DBS and 
plasma tenofovir (TFV) concentrations. 
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Supplementary Table 9-4-1 Characteristics of DBS TFV-DP thresholds restricted to women 
who report taking ART in the last 30 days (n=87). Odds ratios (OR) predicting viral load 
<50, <400 and <1000 copies/mL are presented. 
 TFV-DP threshold 
(approximate doses per 
week1) 
<350 (<2) 350-699 (2-3) 700-1249 (4-6) ≥1250 (7) 
Total number of women 27 19 41 30 
Median viral load log10 
copies/mL (IQR) 
3.7 (2.5-4.6) 1.3 (1.3-1.3) 1.3 (1.3-1.3) 1.3 (1.3-1.3) 
Median viral load 
copies/mL (IQR) 
4884 (282-38325) 20 (20-20) 20 (20-20) 20 (20-20) 
Viral load <50 copies/mL 
Viral load <50 
copies/mL, n (%) 
5 (19) 16 (84) 36 (88) 29 (97) 
OR (95% CI) Ref 23 (5-113) 32 (8-122) 128 (14-1172) 
aOR2 (95% CI) Ref 28 (5-142) 34 (8-139) 135 (14-1268) 
Viral load <400 copies/mL 
Viral load <400 
copies/mL, n (%) 
7 (26) 17 (89) 39 (95) 30 (100) 
OR (95% CI) Ref 24 (4-133) 56 (11-293) Omitted 
aOR2 (95% CI) Ref 35 (5-230) 74 (12-462) Omitted 
Viral load <1000 copies/mL 
Viral load <1000 
copies/mL, n (%) 
8 (30) 17 (89) 39 (95) 30 (100) 
OR (95% CI) Ref 20 (4-109) 46 (9-240) Omitted 
aOR2 (95% CI) Ref 29 (5-178) 59 (10-360) Omitted 
1As previously described by Castillo-Mancilla et al (CID, 2018) 
2Adjusted for age and duration on ART 
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Supplementary Table 9-4-2 Univariable logistic regression models predicting viral load <50, 
<400 and <1000 copies/mL among 137 women. 
 Viral load <50 
copies/mL 
OR 95% CI 
Viral load <400 
copies/mL 
OR 95% CI 
Viral load <1000 
copies/mL 
OR 95% CI 
Increasing years of age 1.10 (1.02-1.18) 1.11 (1.03-1.20) 1.08 (1.00-1.17) 
Increasing years on ART 1.38 (0.28-6.75) 1.76 (0.33-9.26) 2.30 (0.43-12.40) 
Increasing BMI (kg/m2) 1.05 (1.00-1.11) 1.04 (0.99-1.09) 1.04 (0.99-1.10) 
Serum Creatinine (n=74) 1.01 (0.95-1.07) 1.03 (0.96-1.10) 1.03 (0.96-1.10) 
 
 
 
Supplementary Table 9-4-3 Women with detectable plasma tenofovir (TFV) and efavirenz 
(EFV) concentrations but very low tenofovir-diphosphate concentration in dried blood spots 
(DBS TFV-DP). 
Patient Viral load 
(copies/mL) 
DBS TFV-DP 
(fmol/punch) 
Plasma TFV  
(ng/mL) 
Plasma EFV  
(µg/mL) 
1 20 178 25.2 1.16 
2 20 209 15.1 2.04 
3 87 270 47.5 1.12 
4 88741 136 22.6 0.54 
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9.2.3 Chapter 5 
Supplementary Figure 9-5-1 Proportion of women with adherence scores ≥80 and HIV viral 
loads ≤1000 copies/mL among 434 with at least one study visit after V0 (first visit with a 
viral load ≤50 copies/mL after ART initiation during pregnancy). Data are shown from V0 
through up to 8 additional visits (V1-V8).  
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Supplementary Figure 9-5-2 Sensitivity analyses showing the proportion of women with 
adherence scores ≥80 and HIV viral loads ≤1000 copies/mL among from V0 (first visit with a 
viral load ≤50 copies/mL or, if never suppressed, first visit at least 16 weeks after ART 
initiation during pregnancy). Data are shown for A) women with at least 4 consecutive visits 
after V0, and B) for all included women from V0 through up to 8 additional visits (V1-V8). 
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Supplementary Figure 9-5-3 Random selection of individual three-item self-reported 
adherence scale scores and 10 times the log10 viral load over time. 
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Supplementary Table 9-5-1 Distribution of self-reported adherence and HIV viral load among 434 women at consecutive measurement times 
from V0 (the first visit with viral load ≤50 copies/mL after ART initiation in pregnancy) through up to 8 additional visits. Results presented as n 
(%) unless otherwise specified. 
 V0 V1 V2 V3 V4 V5 V6 V7 V8 
Number of women 434 434 427 403 363 328 260 140 39 
Postpartum 123 (28) 332 (77) 427 (100) 403 (100) 363 (100) 328 (100) 260 (100) 140 (100) 39 (100) 
Median months postpartum 
(IQR) 
1 (0.2-2) 0.2 (0.1-1) 1 (1-3) 3 (3-6) 6 (6-9) 9 (8-12) 12 (9-14) 18 (12-18) 18 (18-19) 
Median months on ART 
(IQR) 
3 (1-4) 5 (3-6) 6 (5-7) 8 (6-10) 11 (9-13) 14 (12-15) 17 (14-19) 21 (16-23) 23 (21-23) 
Individual adherence items 
Mean (SD) 
         
1. Proportion of days with no 
missed doses in past 30 days 
98 (6) 99 (6) 98 (10) 98 (12) 98 (6) 98 (9) 96 (16) 99 (9) 99 (5) 
2. How good a job did you do 
taking your medication in 
the past 30 days? 
78 (15) 81 (14) 81 (15) 82 (16) 83 (14) 81 (16) 81 (17) 83 (14) 85 (12) 
3. How often did you take 
your medicines as directed 
in the past 30 days? 
84 (15) 84 (15) 84 (16) 85 (16) 86 (15) 86 (14) 84 (17) 88 (14) 89 (12) 
Mean 3-item score (SD) 87 (10) 88 (9) 88 (11) 88 (12) 89 (9) 88 (10) 87 (14) 90 (10) 91 (7) 
Median 3-item score (IQR) 89 (78-94) 89 (83-94) 89 (83-94) 89 (83-94) 89 (83-94) 89 (83-94) 89 (83-94) 93 (83-94) 89 (88-94) 
3-item score ≥80 305 (70) 338 (78) 345 (81) 335 (83) 319 (88) 272 (83) 222 (85) 127 (91) 35 (90) 
3-item score ≥90 154 (35) 176 (41) 176 (41) 179 (44) 180 (50) 136 (41) 118 (45) 74 (53) 19 (49) 
3-item score =100 59 (14) 61 (14) 55 (13) 62 (15) 45 (12) 53 (16) 31 (12) 23 (16) 8 (21) 
          
Viral load ≤50 copies/mL 434 (100) 394 (91) 374 (88) 338 (84) 298 (82) 255 (78) 196 (75) 105 (75) 26 (67) 
Viral load ≤1000 copies/mL 434 (100) 415 (96) 392 (92) 352 (87) 316 (87) 273 (83) 216 (83) 116 (83) 32 (82) 
Mean log10 viral load (SD) 1.6 (0.02) 1.7 (0.6) 1.8 (0.8) 1.9 (0.9) 2.0 (0.9) 2.1 (1.0) 2.1 (1.0) 2.1 (1.0) 2.1 (0.9) 
Median log10 viral load (IQR) 1.6 (1.6-1.6) 1.6 (1.6-1.6) 1.6 (1.6-1.6) 1.6 (1.6-1.6) 1.6 (1.6-1.6) 1.6 (1.6-1.6) 1.6 (1.6-1.7) 1.6 (1.6-1.7) 1.6 (1.6-2.6) 
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Supplementary Table 9-5-2 Change in self-reported adherence and change in viral load from 
Vi to Vi+1 among 2085 visit pairs from 433 women who ever suppressed, presented as n (%). 
 Viral load 
stayed ≤50 
copies/mL 
Viral load 
stayed >50 
copies/mL 
Viral load 
decreased 
from >50 to 
≤50 copies/mL 
Viral load 
increased from 
≤50 to >50 
copies/mL 
All visit 
pairs 
Number of visit pairs 1828 (88) 127 (6) 26 (1) 104 (5) 2085 
Changed in self-
reported adherence 
     
Change ≤4 missed 
doses, both Likert 
items stayed the same 
1082 (59) 61 (58) 12 (46) 54 (52) 1209 (58) 
Increased by ≥1 level 
or ≥5 missed doses on 
any item  
389 (21) 30 (24) 7 (27) 21 (20) 447 (21) 
Decreased by ≥1 level 
or ≥5 missed doses on 
any item  
357 (20) 36 (28) 7 (27) 29 (28) 429 (21) 
 
Supplementary Table 9-5-3 Sensitivity analyses showing univariable GEE models for change 
in each reported adherence from Vi to Vi+1 to predict viremia >50 and >1000 copies/mL at 
Vi+1 including all visits from first suppression or from 16 weeks on ART among women 
who never suppressed. Results presented as odds ratios with 95% confidence intervals; 
statistically significant associations are in bold. 
 All women from first suppression or 16 weeks on ART 
Number of women 451 
Number of visit pairs 2151 
 Number of visit 
pairs, N (%) 
To predict viral 
load >50 copies/mL 
To predict viral 
load >1000 
copies/mL 
Change in item 1 (missed dose)     
No change in missed doses 1670 (78) Ref Ref 
Increased ≥1 missed dose 230 (11) 0.94 (0.66-1.32) 0.93 (0.64-1.35) 
Decreased ≥1 missed dose 251 (12) 1.40 (1.07-1.83) 1.25 (0.95-1.64) 
Change in item 2 (good job)     
No change 1883 (88) Ref Ref 
Increased ≥1 level 145 (7) 1.08 (0.76-1.55) 0.93 (0.60-1.44) 
Decreased ≥1 level 123 (6) 1.90 (1.39-2.60) 1.70 (1.24-2.33) 
Change in item 3 (how often)    
No change 1655 (77) Ref Ref 
Increased ≥1 level 247 (11) 0.95 (0.73-1.24) 0.79 (0.57-1.08) 
Decreased ≥1 level 249 (12) 1.25 (0.94-1.65) 1.03 (0.77-1.38) 
Change in combined score    
No change in missed doses 586 (27) Ref Ref 
Increased ≥1 missed dose 811 (38) 0.97 (0.79-1.20) 0.94 (0.75-1.16) 
Decreased ≥1 missed dose 754 (35) 1.16 (0.96-1.41) 1.12 (0.92-1.37) 
Change ≤4 missed doses 1251 (58) Ref Ref 
Increased ≥1 level or ≥5 missed doses 460 (21) 0.99 (0.78-1.24) 0.92 (0.71-1.19) 
Decreased ≥1 level or ≥5 missed doses 440 (20) 1.26 (1.03-1.54) 1.19 (0.97-1.46) 
Change ≤9 missed doses or 1 level 1369 (64) Ref Ref 
Increased ≥2 levels or ≥10 missed doses 398 (19) 0.91 (0.72-1.16) 0.88 (0.67-1.15) 
Decreased ≥2 levels or ≥10 missed doses 384 (18) 1.20 (0.98-1.47) 1.19 (0.95-1.47) 
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Supplementary Table 9-5-4 Multivariable GEE models to predict viral load >50 and >1000 
copies/mL at Vi+1 among 2085 visit pairs from women who ever suppressed. The primary 
predictors were A) one level change in item 2 of the adherence scale, and B) ≥5 dose change 
in item 1 or a one level change in item 2 or 3 of the adherence scale. Statistically significant 
associations are in bold. 
 A. One level change in item 2 B. ≥5 dose change in item 1 or a one level 
change in item 2 or 3 
 >50 copies/mL >1000 copies/mL >50 copies/mL >1000 copies/mL 
 aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) 
Increasing years of 
maternal age 
0.95 (0.92-0.98) 0.96 (0.92-1.00) 0.95 (0.92-0.98) 0.96 (0.92-1.00) 
Increasing months on ART 1.04 (1.00-1.08) 1.08 (1.03-1.13) 1.04 (1.00-1.08) 1.08 (1.04-1.13) 
Married/cohabiting 0.65 (0.46-0.91) 0.57 (0.37-0.88) 0.65 (0.47-0.91) 0.57 (0.37-0.88) 
Employed 0.77 (0.56-1.07) 0.61 (0.40-0.94) 0.79 (0.57-1.09) 0.62 (0.40-0.95) 
Increasing weeks gestation 
at presentation for 
antenatal care 
1.04 (1.01-1.06) 1.05 (1.02-1.08) 1.04 (1.01-1.06) 1.05 (1.02-1.08) 
Increasing baseline 
reported adherence score 
0.95 (0.89-1.01) 0.93 (0.86-1.00) 0.95 (0.89-1.01) 0.93 (0.86-1.00) 
Viral load >50 copies/mL 
at Vi 
34.45 (23.58-50.35) 10.23 (7.21-14.51) 35.94 (24.36-53.01) 10.12 (7.14-14.33) 
Increasing months between 
Vi and Vi+1 
1.33 (1.16-1.53) 1.21 (1.06-1.38) 1.33 (1.16-1.53) 1.21 (1.06-1.38) 
Change in adherence score 
from Vi to Vi+1 
    
score remained the same Ref Ref Ref Ref 
score increased  1.31 (0.73-2.35) 1.21 (0.69-2.14) 1.23 (0.82-1.83) 1.09 (0.74-1.61) 
score decreased  2.60 (1.57-4.30) 1.91 (1.15-3.17) 1.62 (1.11-2.38) 1.42 (1.00-2.03) 
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Supplementary Table 9-5-5 Sensitivity analyses showing multivariable GEE models to 
predict viral load >50 and >1000 copies/mL at Vi+1 including 2151 visit pairs from first 
suppression or from 16 weeks on ART among women who never suppressed. The primary 
predictors were A) one level change in item 2 of the adherence scale, and B) ≥5 dose change 
in item 1 or a one level change in item 2 or 3 of the adherence scale. Statistically significant 
associations are in bold. 
 All women from suppression or 16 weeks on ART 
 A. One level change in item 2 B. ≥5 dose change in item 1 or a one 
level change in item 2 or 3 
 >50 copies/mL >1000 copies/mL >50 copies/mL >1000 copies/mL 
 aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) 
Increasing years of maternal 
age 
0.95 (0.92-0.98) 0.94 (0.91-0.98) 0.95 (0.92-0.98) 0.94 (0.91-0.98) 
Increasing months on ART 1.02 (0.98-1.07) 1.07 (1.03-1.11) 1.03 (0.98-1.07) 1.07 (1.03-1.12) 
Married 0.68 (0.49-0.95) 0.59 (0.39-0.88) 0.69 (0.50-0.97) 0.59 (0.39-0.89) 
Employed 0.78 (0.57-1.07) 0.65 (0.44-0.97) 0.81 (0.59-1.11) 0.66 (0.44-0.98) 
Increasing weeks gestation 
at presentation for antenatal 
care 
1.03 (1.01-1.05) 1.05 (1.02-1.08) 1.03 (1.01-1.05) 1.05 (1.02-1.08) 
Increasing baseline reported 
adherence score 
0.96 (0.90-1.03) 0.94 (0.97-1.01) 0.96 (0.90-1.03) 0.94 (0.87-1.02) 
Viral load >50 copies/mL at 
Vi 
72.49 (46.12-
113.93) 
15.79 (11.00-
22.66) 
79.32 (49.79-
126.34) 
15.72 (1.96-
22.54) 
Increasing months between 
Vi and Vi+1 
1.35 (1.16-1.57) 1.19 (1.04-1.36) 1.35 (1.16-1.57) 1.19 (1.04-1.36) 
Change in adherence score 
from Vi to Vi+1 
    
score remained the same Ref Ref Ref Ref 
score increased  1.30 (0.70-2.41) 1.20 (0.71-2.04) 1.20 (0.77-1.88) 1.01 (0.70-1.47) 
score decreased  2.58 (1.49-4.48) 1.78 (1.05-3.04) 1.62 (1.06-2.47) 1.25 (0.88-1.77) 
  
Supplementary Table 9-5-6 Univariable GEE models to predict viral load >50 and >1000 
copies/mL at Vi+1 among 2085 visit pairs from women who ever suppressed. Results 
presented as odds ratios with 95% confidence intervals; statistically significant associations 
are in bold. 
 viral load >50 copies/mL viral load >1000 copies/mL 
Increasing years of maternal age 0.95 (0.92-0.99) 0.95 (0.91-0.99) 
Increasing months on ART 1.13 (1.10-1.16) 1.15 (1.12-1.78) 
Married 0.53 (0.35-0.80) 0.51 (0.31-0.83) 
Employed 0.64 (0.43-0.94) 0.54 (0.34-0.86) 
Completed high school 0.77 (0.50-1.20) 0.76 (0.45-1.26) 
Increasing weeks gestation at 
presentation for antenatal care 
1.03 (1.01-1.06) 1.04 (1.01-1.07) 
Primigravida 1.23 (0.77-1.98) 1.14 (0.65-1.98) 
Diagnosed in this pregnancy 0.86 (0.59-1.25) 0.82 (0.53-1.28) 
Increasing baseline adherence score 0.94 (0.86-1.01) 0.92 (0.85-1.00) 
Increasing months between Vi and Vi+1 1.39 (1.29-1.49) 1.41 (1.31-1.51) 
Viral load >50 copies/mL at the previous 
visit 
33.93 (23.99-48.01) 17.22 (12.46-23.79) 
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9.2.4 Chapter 6 
Supplementary Table 9-6-1 Data source descriptions. 
Data source name Description Included in HIV-specific 
contacts 
Clinic visits Information on clinic visits attended and 
medication received that is captured 
from the patient folder into the 
provincial clerical information system 
by a data clerk 
Visits marked as ART 
visits and records of 
antiretroviral drugs 
dispensed 
Laboratory tests Laboratory test results covering all 
public health facilities in South Africa 
CD4 and HIV viral load 
tests 
Pharmacy 
dispensing 
Pharmacy dispensing records from the 
central administrative pharmacy 
databases used in most public health 
facilities in the province 
Dispensing of any 
antiretroviral drugs used to 
treat HIV 
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Supplementary Table 9-6-2 Characteristics of 617 women who initiated ART during 
pregnancy enrolled in the MCH-ART study, and the subset of 475 women who had a viral 
load available between 12 and 24 months on ART. Displayed as n (%) unless specified. 
 Whole cohort Women with 
a 12-24 
month viral 
load available 
Women with no 
12-24 month 
viral load 
available 
Number of women 617 475 142 
Characteristics at presentation for ANC    
Mean age (SD) 29 (5) 29 (5) 28 (5) 
Age <25 years 170 (28) 124 (26) 46 (32) 
Currently employed 234 (38) 181 (38) 53 (37) 
Finished high school 163 (26) 124 (26) 39 (27) 
Married/cohabiting 253 (41) 193 (41) 60 (42) 
Newly diagnosed HIV+ in this pregnancy 336 (54) 252 (53) 84 (59) 
Mean gestation at presentation for ANC 
(SD)1 
21 (8) 21 (7) 22 (8) 
Presented for ANC prior to 20 weeks 
gestation 
293 (48) 226 (48) 67 (48) 
Median CD4 cell count at ART start2 345 (237-515) 348 (241-417) 340 (234-503) 
CD4 <350 cells/µL 305 (51) 231 (50) 74 (52) 
Enrolment in MCH-ART study    
Observational cohort only 152 (25) 60 (13) 92 (65) 
SOC trial arm 236 (38) 212 (43) 24 (17) 
Intervention trial arm 229 (37) 203 (45) 26 (18) 
Retention estimates    
All data sources    
Cross-sectional (0-12 m) 614 (100) 474 (100) 140 (99) 
Cross-sectional (12-24 m) 445 (72) 395 (83) 50 (35) 
6m visit constancy (0-24 m) 294 (48) 277 (58) 17 (12) 
12m visit constancy ((0-24 m) 445 (72) 395 (83) 50 (35) 
HRSA-HAB (0-24 m) 378 (61) 343 (72) 35 (25) 
No 180-day gap 256 (41) 243 (51) 13 (9) 
Clinic visit data only    
Cross-sectional (0-12 m) 610 (98) 470 (100) 140 (94) 
Cross-sectional (12-24 m) 388 (63) 349 (74) 39 (26) 
6m visit constancy (0-24 m) 251 (40) 232 (49) 19 (13) 
12m visit constancy ((0-24 m) 387 (62) 349 (74) 38 (26) 
HRSA-HAB (0-24 m) 324 (52) 297 (63) 27 (18) 
No 180-day gap 211 (34) 198 (42) 13 (9) 
Viral load 12-24 m on ART    
Viral load <1000 copies/mL  354 (75)  
Viral load <50 copies/mL  319 (67)  
1 Gestation at presentation for antenatal care (ANC) was available for 613 women; 2 CD4 
counts available for 601 women; SD – standard deviation; m – months  
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Supplementary Table 9-6-3 Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of different definitions 
of non-retention up to 24 months on ART, to predict viral load (VL) ≥1000 copies/mL among women with a viral load available 12-24 months on 
ART (n=475).  
 
Data source 
VL≥1000 
(n=121) 
VL<1000 
(n=354) 
Sensitivity Specificity PPV NPV AUC LR+ LR- Crude OR 
<
1
0
0
%
 6
-m
o
n
th
 v
is
it
 
co
n
st
a
n
cy
 
Clinic visits, laboratory 
tests & pharmacy 
 
99 97 82 (74-88) 72 (67-77) 50 (43-58) 92 (88-95) 0.77 (0.73-0.81) 3.0 (2.5-3.6) 0.3 (0.2-0.4) 11.9 (7.1-19.9) 
Clinic visits & 
laboratory tests 
 
102 111 84 (77-90) 69 (64-73) 48 (41-55) 93 (89-96) 0.77 (0.72-0.81) 2.7 (2.2-3.2) 0.2 (0.2-0.3) 11.8 (6.9-20.0) 
Laboratory tests 
 
116 340 96 (91-99) 4 (2-7) 25 (22-30) 74 (49-91) 0.50 (0.48-0.52) 1.0 (1.0-1.0) 1.0 (0.4-2.8) 0.9 (0.4-2.6) 
Clinic visits 108 132 89 (82-94) 63 (57-68) 45 (39-52) 95 (91-97) 0.76 (0.72-0.80) 2.4 (2.1-2.8) 0.2 (0.1-0.3) 13.7 (7.4-25.1) 
<
1
0
0
%
 1
2
-m
o
n
th
 v
is
it
 
co
n
st
a
n
cy
 
Clinic visits, laboratory 
tests & pharmacy 
 
51 29 42 (33-52) 92 (88-94) 64 (52-74) 82 (78-86) 0.67 (0.62-0.72) 5.2 (3.4-7.7) 0.6 (0.5-0.7) 8.2 (4.8-13.8) 
Clinic visits & 
laboratory tests 
 
53 30 44 (35-53) 92 (88-94) 64 (53-74) 83 (79-86) 0.61 (0.52-0.72) 5.2 (3.5-7.7) 0.6 (0.5-0.7) 8.4 (5.0-14.1) 
Laboratory tests 
 
67 90 55 (46-64) 75 (70-79) 43 (35-51) 83 (78-87) 0.65 (0.60-0.70) 2.2 (1.7-2.8) 0.6 (0.5-0.7) 3.5 (2.3-5.5) 
Clinic visits 69 54 57 (48-66) 85 (81-88) 56 (47-65) 85 (81-89) 0.71 (0.66-0.76) 3.7 (2.8-5.0) 0.5 (0.4-0.6) 7.2 (4.5-11.4) 
<
1
0
0
%
 H
R
S
A
-H
A
B
 Clinic visits, laboratory 
tests & pharmacy 
 
77 55 64 (54-72) 85 (80-88) 58 (49-67) 87 (83-91) 0.74 (0.69-0.79) 4.1 (3.1-5.4) 0.4 (0.3-0.5) 9.5 (6.0-15.2) 
Clinic visits & 
laboratory tests 
 
83 60 69 (60-77) 83 (79-87) 58 (50-66) 89 (85-92) 0.76 (0.71-0.80) 4.1 (3.1-5.3) 0.4 (0.3-0.5) 10.7 (6.7-17.2) 
Laboratory tests 
 
107 290 88 (81-94) 18 (14-23) 27 (23-32) 82 (72-90) 0.53 (0.50-0.58) 1.1 (1.0-1.2) 0.6 (0.4-1.1) 1.7 (0.9-3.1) 
Clinic visits 91 84 75 (67-83) 76 (72-81) 52 (44-60) 90 (86-93) 0.76 (0.71-0.80) 3.2 (2.6-3.9) 0.3 (0.2-0.4) 9.8 (6.1-15.7) 
A
n
y
 1
8
0
-d
a
y
 g
a
p
 
Clinic visits, laboratory 
tests & pharmacy 
 
112 120 93 (86-97) 66 (61-71) 48 (42-55) 96 (93-98) 0.79 (0.76-0.83) 2.7 (2.3-3.2) 0.1 (0.1-0.2) 24.3 (12.0-48.9) 
Clinic visits & 
laboratory tests 
 
112 147 93 (86-97) 59 (53-64) 43 (37-50) 96 (92-98) 0.76 (0.72-0.79) 2.2 (2.0-2.6) 0.1 (0.1-0.2) 17.5 (8.7-35.2) 
Laboratory tests 
 
120 350 99 (96-100) 1 (0.3-3) 26 (22-30) 80 (28-100) 0.50 (0.49-0.51) 1.0 (1.0-1.0) 0.7 (0.1-6.5) 1.4 (0.2-12.4) 
Clinic visits 112 162 93 (86-97) 54 (49-60) 41 (35-47) 96 (92-98) 0.73 (0.70-0.77) 2.0 (1.8-2.3) 0.1 (0.1-0.3) 14.7 (7.3-29.6) 
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Supplementary Table 9-6-4 Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of different definitions 
of non-retention 0-24 months on ART, to predict viral load (VL) ≥1000 copies/mL, assuming missing viral loads were ≥1000 copies/mL (n=617). 
 
Data source 
VL≥1000 
(n=263) 
VL<1000 
(n=354) 
Sensitivity Specificity PPV NPV AUC LR+ LR- Crude OR 
<
1
0
0
%
 6
-m
o
n
th
 v
is
it
 
co
n
st
a
n
cy
 
Clinic visits, laboratory 
tests & pharmacy 
 
222 97 84 (80-89) 73 (68-77) 70 (64-75) 86 (82-90) 0.79 (0.75-0.82) 3.1 (2.6-3.7) 0.2 (0.2-0.3) 14.3 (9.6-21.5) 
Clinic visits & 
laboratory tests 
 
225 111 86 (81-90) 69 (64-73) 67 (62-72) 987 (82-90) 0.77 (0.74-0.80) 2.7 (2.3-3.2) 0.2 (0.2-0.3) 13.0 (8.6-19.5) 
Laboratory tests only 
 
258 340 98 (96-99) 4 (2-7) 43 (39-47) 74 (49-91) 0.51 (0.50-0.52) 1.0 (1.0-1.1) 0.5 (0.2-1.3) 2.1 (0.8-5.7) 
Clinic visits only 234 132 89 (85-93) 63 (57-68) 64 (59-69) 88 (84-92) 0.76 (0.73-0.79) 2.4 (2.1-2.8) 0.2 (0.1-0.3) 13.6 (8.7-21.1) 
<
1
0
0
%
 1
2
-m
o
n
th
 
v
is
it
 c
o
n
st
a
n
cy
 
Clinic visits, laboratory 
tests & pharmacy 
 
143 29 54 (48-61) 92 (88-94) 83 (77-88) 73 (69-77) 0.73 (0.70-0.76) 6.6 (4.6-9.6) 0.5 (0.4-0.6) 13.4 (8.5-20.1) 
Clinic visits & 
laboratory tests 
 
146 30 56 (49-62) 92 (88-94) 83 (77-88) 74 (69-78) 0.74 (0.70-0.77) 6.6 (4.6-9.4) 0.5 (0.4-0.6) 13.5 (8.6-21.0) 
Laboratory tests 
 
185 90 70 (64-76) 75 (70-79) 67 (61-73) 77 (72-82) 0.73 (0.69-0.76) 2.8 (2.3-3.4) 0.4 (0.3-0.5) 7.0 (4.9-9.9) 
Clinic visits 177 54 67 (61-73) 85 (81-88) 77 (71-82) 78 (73-82) 0.76 (0.73-0.79) 4.4 (3.4-5.7) 0.4 (0.3-0.5) 11.4 (7.8-16.8) 
<
1
0
0
%
 H
R
S
A
-H
A
B
 Clinic visits, laboratory 
tests & pharmacy 
 
184 55 70 (64-75) 85 (80-88) 77 (71-82) 79 (75-83) 0.77 (0.74-0.81) 4.5 (3.5-5.8) 0.4 (0.3-0.4) 12.7 (8.6-18.7) 
Clinic visits & 
laboratory tests 
 
196 60 75 (69-80) 83 (79-87) 77 (71-82) 81 (77-85) 0.79 (0.76-0.82) 4.4 (3.5-5.6) 0.3 (0.2-0.4) 14.3 (9.7-21.2) 
Laboratory tests 
 
245 290 93 (89-96) 18 (14-23) 46 (42-50) 78 (68-86) 0.56 (0.53-0.58) 1.1 (1.1-1.2) 0.4 (0.2-0.6) 3.0 (1.7-5.2) 
Clinic visits 209 84 80 (74-84) 76 (72-81) 71 (66-76) 83 (79-87) 0.78 (0.75-0.81) 3.4 (2.8-4.1) 0.3 (0.2-0.3) 12.4 (8.5-18.3) 
A
n
y
 1
8
0
-d
a
y
 g
a
p
 
Clinic visits, laboratory 
tests & pharmacy 
 
241 120 92 (88-95) 66 (61-71) 67 (62-72) 91 (87-95) 0.79 (0.76-0.82) 2.7 (2.3-3.1) 0.1 (0.1-0.2) 21.4 (13.1-34.7) 
Clinic visits & 
laboratory tests 
 
241 147 92 (88-95) 59 (53-64) 62 (57-67) 90 (86-94) 0.75 (0.72-0.78) 2.2 (1.9-2.5) 0.1 (0.1-0.2) 15.4 (9.5-25.0) 
Laboratory tests 
 
262 350 99 (98-100) 1 (0.3-3) 43 (39-47) 80 (28-100) 0.50 (0.50-0.51) 1.0 (1.0-1.0) 0.3 (0.1-3.0) 3.0 (0.3-26.9) 
Clinic visits 244 162 93 (89-96) 54 (49-60) 60 (55-65) 91 (86-95) 0.74 (0.71-0.77) 2.0 (1.8-2.3) 0.1 (0.1-0.2) 15.2 (9.2-25.3) 
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9.2.5 Chapter 7 
Supplementary Table 9-7-1 Description of 485 HIV-positive women, who had evidence of 
linking to care after leaving the integrated clinic, by the number of different clinics attended 
up to 30 months after ART initiation. Presented as n (%) unless specified. 
 Attended 1 
clinic 
Attended ≥2 
clinics  
All women p-value 
Number of women 384 (79) 101 (21) 485 (100)  
Characteristics at enrolment     
Mean age (SD) 29 (5.3) 28 (5.3) 28 (25-32) 0.034 
Age ≤25 86 (22) 36 (36) 122 (25) 0.006 
Married/cohabiting 169 (44) 47 (47) 216 (45) 0.650 
Completed secondary school 104 (27) 20 (20) 124 (26) 0.136 
Employed 152 (40) 30 (30) 182 (38) 0.068 
First pregnancy 61 (16) 22 (22) 83 (17) 0.161 
Intended pregnancy 114 (30) 32 (32) 146 (30) 0.697 
Diagnosed with HIV in this 
pregnancy 
199 (52) 56 (55) 255 (53) 0.516 
Mean weeks gestation (SD) 21 (7.4) 21 (7.4) 21 (7.4) 0.373 
Presented for ANC ≤20 weeks 183 (48) 48 (48) 231 (48) 0.981 
Median (IQR) CD4 cell count at 
presentation for ANC (n=481) 
341 (236-522) 343 (211-496) 341 (235-509) 0.344 
Characteristics at delivery     
Place of delivery (n=467)     
Delivered in primary care 150 (40) 40 (42) 190 (41) 0.826 
Delivered at tertiary hospital 221 (60) 56 (58) 277 (59)  
Delivery outcome     
Live birth  369 (96) 95 (94) 464 (96) 0.486 
Stillbirth 8 (2) 3 (3) 11 (2)  
Miscarriage 5 (1) 1 (1) 6 (1)  
Unknown 2 (1) 2 (2) 4 (1)  
Characteristics postpartum     
Median (IQR) months from 
ART initiation until last 
evidence of accessing care  
28 (21-29) 28 (22-29) 28 (21-29) 0.787 
Median furthest distance (km) 
moved between clinics (SD) 
1.06 (0.01-2.55) 4.14 (1.73-863.78) 1.07 (0.69-3.23) <0.001 
Area moved after integrated 
clinic 
    
Same health district 231 (60) 39 (39) 270 (56) <0.001 
Cape Town Metropole 133 (35) 24 (24) 157 (32)  
Western Cape Province 5 (1) 7 (7) 12 (2)  
Out of the Western Cape 
Province 
15 (4) 31 (31) 46 (9)  
Retention in HIV care after ART 
initiation 
    
Retained at 12 months 340 (89) 98 (97) 438 (90) 0.010 
Retained at 24 months 310 (81) 88 (87) 398 (82) 0.136 
Retained at 12 and 24 months 278 (72) 85 (84) 363 (75) 0.015 
Retained at 18 months after 
delivery 
315 (82) 90 (89) 405 (84) 0.088 
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Supplementary Table 9-7-2 Poisson regression model among 485 women who linked to care 
after the integrated clinic, predicting whether women moved to more than one additional 
clinic. Presented as unadjusted (RR) and adjusted (aRR) risk ratios with 95% confidence 
intervals (CI). 
 Crude Adjusted 
 RR 95% CI  aRR 95% CI  
Age ≤25 1.09 1.02-1.18  1.10 1.02-1.18  
Not employed 1.06 1.00-1.13  1.06 0.99-1.12  
 
Supplementary Table 9-7-3 Poisson regression model among 485 women who linked to care 
after the integrated clinic, predicting A) retention in care at 12 and 24 months after ART 
initiation, B) retention in care at 24 months after ART initiation, and C) retention in care at 
18 months postpartum. Presented as unadjusted (RR) and adjusted (aRR) risk ratios with 95% 
confidence intervals (CI). 
 Crude Adjusted 
A: retention in care at 12 and 24 months after ART initiation 
 RR 95% CI  aRR 95% CI  
Age >25 1.17 1.02-1.34  1.17 1.02-1.33  
Married/cohabiting 1.13 1.02-1.26  -   
Primigravida 0.88 0.75-1.04  -   
Planned pregnancy 1.20 1.09-1.33  1.20 1.09-1.33  
Presented for ANC <20 weeks 
gestation 
1.13 1.02-1.25  1.10 0.99-1.21  
Employed 1.09 0.98-1.21  -   
B: retention in care at 24 months after ART initiation 
 RR 95% CI  aRR 95% CI  
Age >25 1.06 0.95-1.17  -   
Married/cohabiting 1.07 0.99-1.16  -   
Primigravida 0.89 0.78-1.02  0.87 0.76-0.99  
Planned pregnancy 1.15 1.07-1.24  1.17 1.08-1.27  
Presented for ANC <20 weeks 
gestation 
1.08 0.99-1.17  -   
Employed 0.92 0.85-1.00  1.07 0.99-1.16  
C: retention in care at 18 months postpartum 
 RR 95% CI  aRR 95% CI  
Age >25 1.07 0.97-1.18  -   
Married/cohabiting 1.07 0.99-1.16  -   
Primigravid 0.89 0.78-1.01  0.87 0.77-0.99  
Planned pregnancy 1.14 1.06-1.22  1.16 1.07-1.25  
Presented for ANC <20 weeks 
gestation 
1.06 0.98-1.15  -   
Employed 1.04 0.93-1.13  -   
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Supplementary Table 9-7-4 Description of 338 women with viral load (VL) ≤50 and >50 
copies/mL who were retained at both 12 and 24 months after ART initiation and had a VL 
available at least 12 months after ART initiation. Presented as n (%) unless specified. 
 VL ≤50 
copies/mL 
VL >50 
copies/mL 
All women p-value 
Number of women 273 (81) 65 (19) 338 (100)  
VL source     
NHLS 174 (64) 32 (49) 206 (61) 0.031 
MCH-ART study 99 (36) 33 (51) 132 (39)  
Median (IQR) months 
postpartum at time of VL test 
18 (18-20) 18 (17-21) 18 (18-20) 0.933 
Median months since ART start 
at time of VL test 
23 (22-24) 23 (21-24) 23 (21-24) 0.449 
Characteristics at enrolment     
Mean age (SD) 30 (5.4) 27 (4.8) 29 (5.4) 0.003 
Age ≤25 53 (19) 22 (34) 75 (22) 0.012 
Married/cohabiting 133 (49) 24 (37) 157 (46) 0.087 
Completed secondary school 74 (27) 11 (17) 85 (25) 0.089 
Employed 117 (43) 18 (28) 135 (40) 0.025 
First pregnancy 39 (14) 13 (20) 52 (15) 0.251 
Intended pregnancy 101 (37) 17 (26) 118 (35) 0.099 
Diagnosed with HIV in this 
pregnancy 
149 (55) 24 (37) 173 (51) 0.010 
Mean weeks gestation (SD) 21 (8.9) 20 (7.1) 20 (7.2) 0.118 
Presented for ANC ≤20 weeks 
gestation 
143 (52) 29 (45) 172 (51) 0.260 
Median (IQR) CD4 cell count at 
presentation for ANC (n=330) 
341 (235-520) 350 (232-440) 337 (235-504) 0.525 
Characteristics at delivery     
Place of delivery (n=327)     
Delivered in primary care 109 (41) 25 (41) 134 (41) 0.999 
Delivered at tertiary hospital 157 (59) 36 (59) 193 (59)  
Delivery outcome     
Live birth 263 (96) 63 (97) 326 (96) 0.131 
Stillbirth 4 (1) 1 (2) 5 (1)  
Miscarriage 6 (2) 0(0) 6 (2)  
Unknown 0 (0) 1 (2) 1 (<1)  
Characteristics postpartum     
Number of clinics after the 
integrated clinic 
    
Attended 1 clinic 221 (81) 40 (62) 261 (77) 0.001 
Attended ≥ 2 clinics 52 (19) 25 (38) 77 (23)  
Median furthest distance (km) 
moved between clinics 
1.06 (0.69-3.04) 1.99 (0.71-3.23) 1.06 (0.69-3.23) 0.110 
Area moved after integrated 
clinic 
    
Same health district 160 (58) 35 (54) 195 (57) 0.508 
Cape Town Metropole 89 (33) 21 (32) 110 (33)  
Western Cape Province 6 (2) 3 (5) 9 (3)  
Out of the Western Cape 
Province 
118 (7) 6 (9) 24 (7)  
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Supplementary Table 9-7-5 Description of 338 HIV-positive women with viral load (VL) 
≤1000 and >1000 copies/mL who were retained at both 12 and 24 months after ART 
initiation and had a VL available at least 12 months after ART initiation. Presented as n (%) 
unless specified. 
 VL ≤1000 
copies/mL 
VL >1000 
copies/mL 
All women p-value 
Number of women 294 (87) 44 (13) 338 (100)  
Characteristics at enrolment     
Mean age (SD) 29 (5.4) 27 (5.0) 29 (5.4) 0.010 
Age ≤25 59 (20) 16 (36) 75 (22) 0.015 
Married/cohabiting 146 (50) 11 (25) 157 (46) 0.002 
Completed secondary school 78 (27) 7 (16) 85 (25) 0.130 
Employed 126 (43) 9 (20) 135 (40) 0.005 
First pregnancy 42 (14) 10 (23) 52 (15) 0.148 
Intended pregnancy 109 (37) 9 (20) 118 (35) 0.031 
Diagnosed with HIV in this 
pregnancy 
156 (53) 17 (39) 173 (51) 0.074 
Mean weeks gestation (SD) 21 (8.9) 23 (7.0) 20 (7.2) 0.012 
Presented for ANC <20 weeks 
gestation 
155 (53) 17 (39) 172 (51) 0.081 
Median (IQR) CD4 cell count 
at presentation for ANC 
(n=328) 
345 (237-512) 320 (200-436) 337 (235-504) 0.253 
Characteristics at delivery     
Place of delivery (n=327)     
Delivered in primary care 118 (42) 16 (37) 134 (41) 0.590 
Delivered at tertiary hospital 166 (58) 27 (63) 193 (59)  
Delivery outcome     
Live birth 283 (96) 43 (98) 326 (96) 0.736 
Stillbirth 4 (1) 1 (1) 5 (1)  
Miscarriage 6 (2) 0 (0) 6 (2)  
Unknown 1 (<1) 0 (0) 1 (<1)  
Characteristics postpartum     
Number of clinics after the 
integrated clinic 
    
Attended 1 clinic 232 (79) 29 (66) 261 (77) 0.055 
Attended ≥ 2 clinics 62 (21) 15 (34) 77 (23)  
Area moved after integrated 
clinic 
    
Same health district 170 (58) 25 (57) 195 (57) 0.398 
Cape Town Metropole 94 (32) 16 (36) 110 (33)  
Western Cape Province 7 (3) 2 (5) 19 (3)  
Out of the Western Cape 
Province 
23 (8) 1 (2) 24 (7)  
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Supplementary Table 9-7-6 Description of study outcomes by the design of follow up 
received in the parent MCH-ART study. 
 Not enrolled in 
the MCH-ART 
trial  
(no prospective 
follow-up after 
delivery) 
Enrolled in the 
MCH-ART trial 
and received 
standard transfer 
out of the 
integrated clinic 
Enrolled in the 
MCH-ART trial 
and received 
delayed transfer 
out of the 
integrated clinic 
Number of women 152 236 229 
Median months of follow-up 
after leaving the integrated 
clinic 
26 (24-27) 25 (24-26) 18 (14-23) 
Linked to care 122 (80) 193 (82) 170 (74) 
If linked (n=485), attended ≥2 
clinics 
28 (23) 32 (17) 41 (24) 
Retained in care at 12 months on 
ART 
106 (70) 176 (75) 193 (84) 
Retained in care at 24 months on 
ART 
95 (63) 149 (63) 158 (69) 
Retained at both 12 and 24 
months on ART 
80 (53) 136 (58) 150 (66) 
Number of women retained in 
care at both 12 and 24 months 
on ART and with viral load after 
12 months on ART available 
(n=341) 
62 (41) 132 (56) 147 (64) 
Viral load ≤50 copies/mL 52 (84) 104 (79) 119 (81) 
Viral load ≤1000 copies/mL 57 (92) 113 (86) 126 (86) 
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9.3 Validation of the self-reported adherence measure used in Chapters 4 and 5 
 
Phillips TK, Brittain K, Mellins CA, Zerbe A, Remien RH, Abrams EJ, Myer L, Wilson 
IB. A self-reported adherence measure to screen for elevated HIV viral load in pregnant 
and postpartum women on antiretroviral therapy. AIDS Behav 2017; 21:450–461. 
 
Relevance of this paper to the thesis: 
This manuscript is included in this thesis as an appendix as it presents a preliminary cross-
sectional validation of the self-reported adherence scale used in Chapters 4 and 5. The paper 
shows that a simple three-item self-reported adherence scale that was developed in the United 
States, was successfully translated into isiXhosa with good psychometric characteristics and 
moderate ability to detect viremia. This initial work laid the foundation for the longitudinal 
analyses in Chapter 5. 
 
Contribution of the student and co-authors: 
TP conceived the design with support from IW and LM. IW originaly developed the self-
report scale in the United States and provided technical and conceptual feedback. TP 
conducted the analysis and drafted the manuscript. All co-authors reviewed the manuscript 
and provided conceptual and intellectual comment. All authors were involved in the final 
draft of the manuscipt. 
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Abstract 
Maternal adherence to antiretroviral therapy (ART) is a concern and monitoring adherence 
presents a significant challenge in low resource settings. We investigated the association 
between self-reported adherence, measured using a simple three-item scale, and elevated viral 
load (VL) among HIV-infected pregnant and postpartum women on ART in Cape Town, 
South Africa. This is the first reported use of this scale in a non-English speaking setting and 
it achieved good psychometric characteristics (Cronbach α=0.79). Among 452 women 
included in the analysis, only 12% reported perfect adherence on the self-report scale, while 
92% had a VL<1000 copies/mL. Having a raised VL was consistently associated with lower 
median adherence scores and the area under the curve for the scale was 0.599, 0.656 and 
0.642 using a VL cut off ≥50, ≥1000 and ≥10000 copies/mL, respectively. This simple self-
report adherence scale shows potential as a first stage adherence screener in this setting. 
Maternal adherence monitoring in low resource settings requires attention in the era of 
universal ART, and the value of this simple adherence scale in routine ART care settings 
warrants further investigation. 
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Introduction 
Expanding access to antiretroviral therapy (ART) for HIV-infected pregnant and postpartum 
women living in low- and middle-income countries (LMIC) has improved maternal health 
and reduced the risk of mother-to-child transmission (PMTCT) [1–3]. These improvements 
rely on optimal adherence to ART both during pregnancy and following delivery. Following 
successful initiation of treatment, the next challenge is successful implementation of the ART 
regimen for as long as a woman remains on lifelong ART [4]. Treatment implementation and 
persistence among pregnant and postpartum women is often suboptimal [5–7], and 
measurement of ART adherence in LMICs presents a significant challenge. 
Long a standard tool for monitoring HIV treatment in high-income countries, viral load (VL) 
testing is being promulgated by the World Health Organization (WHO) as an important tool 
for HIV patient management in LMIC [2]. Although VL may be influenced by numerous 
factors, including drug resistance, poor ART adherence is the main cause of non-suppressed 
VL globally [8–11] and identification of patients with adherence difficulties is a major goal 
of VL testing. Viral load is indispensable for determining treatment failure and is potentially 
a valuable tool to reinforce adherence, however it is expensive, measurement is often 
infrequent, and it also does not directly capture medication taking behaviour. Because of this, 
both clinicians and researchers are interested in the development of measures which can be 
conducted frequently with limited resources, which adequately capture patient behaviour, and 
which can potentially identify adherence problems prior to the development of high viremia 
[2,12–14]. 
There are trade-offs for virtually every approach to measuring medication adherence [15,16]. 
Objective adherence measures, such as electronic drug monitoring (EDM), are often 
significantly associated with VL, but are generally not feasible in low resource settings [17–
20]. EDM is also prone to measurement bias. Although objective, EDM does not directly 
measure medication taking and may overestimate adherence if pills are pocketed. Pill counts 
are inexpensive but require time from trained staff and are prone to pill dumping. Pharmacy 
refill has shown potential but is retrospective and still relies on the assumption that patients 
ingest the medication they have collected. Self-report is also prone to social desirability, 
recall bias and question misinterpretation, as well as ceiling effects, where large fractions of a 
population score at the top of a scale [9,16]. However, self-reported adherence measures are 
simple and inexpensive to administer and are often the only practical method available for 
routine adherence monitoring in low resource settings [9,21]. Self-reported adherence has at 
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times been shown to correlate with VL and objective adherence measures, with the added 
advantage of allowing for the immediate discussion between patient and provider of reasons 
for adherence problems and potential solutions [21].  
There are a multitude of self-reported measures available both in research and in routine care, 
and there has been ongoing work to improve the validity, reliability and practicality of these 
measures [9,16,17,21–25]. One concern with self-report is that the adherence questions asked 
may be understood differently by different people and that varying recall periods and types of 
questions illicit responses of varying accuracy [22,23]. Through a rigorous process of 
cognitive interviewing, Wilson et al found that many of the phrases commonly used in self-
reported adherence tools were not consistently understood across a diverse cohort in the 
United States (US) [26]. Following interviews and a larger field test, they selected the three 
best performing and consistently understood items to form a simple three-item adherence 
screening tool [26]. The tool has potential to be a first stage adherence screener to prompt 
discussion of adherence problems and to flag individuals requiring more resource-intensive 
second stage screening, adherence counselling and intervention as appropriate. These items 
have not yet been tested outside the US [26,27].  
There is an urgent need for low cost, sensitive and easy to administer adherence screening 
tools that have been tested in diverse contexts, including among pregnant and postpartum 
women for whom non-adherence has consequences for both individual health and 
transmission risk [14,22,23,28,29]. To fill this gap, we assessed the above mentioned, short 
self-report adherence measure in a cohort of pregnant and post-partum women in South 
Africa who had persisted on treatment up to the time of assessment. We translated the 
adherence items into the predominant local language, isiXhosa, and aimed to investigate the 
performance of the scale as a screening tool to identify sub-optimal adherence, using VL as 
the reference standard. A secondary aim was to assess differences in reported adherence 
across sociodemographic subgroups, including psychosocial risk groups. 
Methods 
We conducted a cross-sectional analysis of self-reported adherence and VL using data from a 
larger multi-phase implementation science study which aims to optimize ART services for 
maternal and child health (MCH-ART study, ClinicalTrial.gov NCT01933477). The study 
took place at a large public sector primary care facility in Cape Town, South Africa. The 
surrounding community is characterised by high levels of poverty and unemployment, and 
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high HIV prevalence (33% of antenatal clinic attenders were HIV-infected in 2013). ART 
services have been provided at this facility since 2004 and all care is provided free of charge. 
Participants 
Between April 2013 and June 2014, consecutive HIV-infected women, 18 years and older, 
booking for antenatal care (ANC) and eligible to start ART were approached to enrol. ART 
eligibility was based on CD4≤350 cells/µL and clinical staging until July 2013, when 
universal ART for all pregnant women was introduced [30]. ART initiation and follow-up is 
routinely provided by nurse-midwives working within the antenatal clinic. As per local 
PMTCT guidelines, all ART-eligible women initiate a once daily fixed-dose combination of 
efavirenz (EFV), emtricitabine (FTC) or lamivudine (3TC), and tenofovir (TDF). Dispensing 
is monthly for the first 4 months on treatment and every 1-2 monthly thereafter. Adherence is 
assessed at routine ART consultations by either self-report of missed doses or pill counts, 
with adherence support and counselling provided by trained lay counsellors to those who 
need it.  
Of 658 eligible women, 628 were enrolled in the MCH-ART study (3 women refused 
participation and 27 were not successfully enrolled prior to delivery due to advanced 
gestation at ANC booking). All women provided written informed consent prior to 
participation and completed up to four study measurement visits between ART initiation and 
six weeks post-delivery, with study visits occurring separately from routine ART and ANC 
services. This study was reviewed and approved by the Human Research Ethics Committee 
of the University of Cape Town, Faculty of Health Sciences as well as the Institutional 
Review Board of the Columbia University Medical Centre. 
Procedures 
Study visits including adherence assessments were scheduled a) at 2-4 weeks after ART 
initiation, b) at 34 weeks gestation, c) within 7 days of delivery, and d) at 6 weeks 
postpartum. They included interviewer-administered questionnaires and venepuncture for VL 
testing. We translated all interview measures into isiXhosa, the predominant local language, 
with back translation to confirm accuracy [31]. Questionnaires were administered by trained 
isiXhosa-speaking interviewers working in private rooms. 
 
 
254 
 
Measures 
Demographic characteristics, including age, education level, gravidity, timing of HIV 
diagnosis and prior antiretroviral (ARV) use were collected at enrolment. A composite 
poverty score, including employment and a standardised asset index score, was compiled and 
used to categorise participants into tertiles based on their relative level of disadvantage. 
Self-reported adherence was measured using a three-item adherence scale, developed through 
rigorous cognitive interviewing, as previously reported [26,27]. The three items included (1) 
an assessment of the number of days with missed ART doses in the preceding 30 days; (2) a 
scale rating of how good a job you did taking your medicines in the preceding 30 days and 
(3) a scale rating of how often you took your medicines the way you were supposed to in the 
preceding 30 days (Table 9-1). The items making up the tool were previously found to be 
consistently understood by a diverse cohort in the US where the tool had excellent internal 
consistency (α=0.86) [26]. 
Depression was measured using the Edinburgh Postnatal Depression Scale (EPDS), a 10-item 
measure of recent depressive symptoms validated for use both in antenatal and postnatal 
women. We used a threshold value of ≥13 for possible major depression as described in the 
original scale development [32].  
Alcohol use in the 12 months prior to booking for ANC was measured using the Alcohol Use 
Disorders Identification Test (AUDIT), one of the most widely used measures of risky 
alcohol use. The full 10-item tool was developed by the WHO to identify people with 
hazardous or harmful patterns of alcohol consumption. In this analysis, we have used the 
AUDIT-C tool, comprised of the first three items in the AUDIT, to serve as a rapid screening 
tool for problem drinking. We used the recommended threshold of three or above to identify 
hazardous drinking [33]. 
HIV RNA VL was measured at all study visits. We conducted venepuncture for HIV RNA 
VL at each study measurement visit. Five mL venous blood was drawn for testing conducted 
by the National Health Laboratory Services using the Abbott RealTime HIV-1 assay (Abbott 
Laboratories, Illinois, USA). Viral load and self-reported adherence measures always took 
place on the same day. All items in the adherence tool refer to the 30 days prior to the 
measurement visit, meaning reported adherence problems were likely to reflect in the VL 
measure. We included women in this analysis who had at least one study visit including VL 
and adherence measurement after at least 16 weeks on treatment, and who had persisted on 
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ART from initiation up to the time of assessment. These restrictions were used to ensure that, 
assuming good treatment implementation, all women could be reasonably expected to have 
reached viral suppression at the time of assessment [30,34]. 
 
Table 9-1 Three-item self-reported adherence scale items. 
 
Analyses 
Data were analysed in STATA V12.0 (Stata Corporation, College Station, Texas, USA). The 
distribution of the three individual adherence items was described using medians with 
interquartile range (IQR). In addition, an aggregate scale was developed, based on a re-
coding of each item with equal weighting, to create a score ranging from 0-100, with the 
latter representing the best possible self-reported adherence. We assessed internal consistency 
using Cronbach’s alpha, and determined the association between VL and the adherence scale 
using logistic regression and Receiver Operating Characteristic (ROC) curve analysis. In the 
primary analyses, we used a VL cut point of 1000copies/mL to indicate elevated VL based on 
local and international threshold for treatment failure and regimen change [2,30]. This 
measure was based on a single VL, taken at the same time as the self-reported adherence 
assessment. Additional cut points of 50 and 10000 cps/mL were used in sensitivity analyses. 
We compared the area under the curve (AUC) for the three-item scale across 
sociodemographic and psychosocial categories in order to compare the performance of the 
scale across different subgroups.  
 
Item Response 
1. In the last 30 days, on how many days did you miss at least 
one dose of any of your HIV medicines? 
# of days (0-30) 
 
2. In the last 30 days, how good a job did you do at taking 
your HIV medicines in the way that you were supposed to? 
Very poor = 1 
Poor = 2 
Fair = 3 
Good = 4 
Very good = 5 
Excellent = 6 
3. In the last 30 days how often did you take your HIV 
medicines in the way that you were supposed to? 
Never = 1 
Rarely = 2 
Sometimes = 3 
Usually = 4 
Almost always = 5 
Always = 6  
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Results 
Patients 
A total of 628 women were enrolled in the parent study. We included 452 women who had at 
least one study visit that included adherence and VL measures after a minimum of 16 weeks 
on ART. The majority of exclusions (n=169) were as a result of having insufficient time on 
ART at all available study assessments. An additional 7 women were missing the required 
measures and were also excluded. When we compared women excluded and included, we 
found no differences at baseline other than a later gestation at ART initiation among women 
excluded, as expected with the cut off of 16 weeks on treatment. All included women had 
persisted on treatment up to the time of the assessment and they are described in Table 9-2. 
The median age was 28 years, 74% of women had not completed secondary school and 41% 
were married or cohabiting. The median pre-ART VL was 10,587copies/mL (IQR, 2,603-
43,099copies/mL). Twenty-six percent of women reported hazardous drinking prior to ANC 
booking, and 10% of women had an EPDS score suggesting possible depression. At the time 
of the adherence assessment, 33% (n=147) of women were pregnant (median gestation 34 
weeks) and the remaining 305 women had recently delivered (median time postpartum 1.4 
weeks). The median duration of ART use at the time of adherence assessment was 19 weeks 
(IQR, 18-21 weeks), and 92% of women had VL below 1000copies/mL.  
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Table 9-2 Description of 452 women who started ART during pregnancy and had an 
adherence assessment and viral load (VL) after at least 16 weeks on ART.  
 Median (IQR) or N (%) 
At the time of booking for ANC 
Median age (IQR) 28 (25-32) 
18-24 111 (24) 
25-30 193 (43) 
30+ 148 (33) 
Education  
Completed secondary school 117 (26) 
Did not complete secondary school 335 (74) 
Poverty level (assets + employment)  
Least poverty 144 (32) 
Moderate poverty 147 (32) 
Most poverty 161 (36) 
Hazardous drinking (Median AUDIT-C score) 0 (0-3) 
Below threshold (<3) 334 (74) 
Above threshold (≥3) 118 (26) 
Depression Symptoms (Median EPDS score) 4 (1-8) 
Below threshold (<13) 405 (90) 
Above threshold (≥13) 47 (10) 
Relationship  
Single 265 (59) 
Married/ Cohabiting 187 (41) 
HIV diagnosis/previous ARV exposure  
Diagnosed in this pregnancy 241 (53) 
Diagnosed before; no past ARV use 88 (20) 
Diagnosed before with past ARV use 123 (27) 
Previous antiretroviral exposure  
ARV naive 329 (73) 
Past ART use 18 (4) 
Past PMTCT 105 (23) 
Median gravidity (IQR) 2 (2-3) 
Primigravida 80 (18) 
Pre-ART HIV VL  
<50 copies/mL 16 (3) 
50-1000 copies/mL 54 (12) 
1001-10,000 copies/mL 148 (33) 
10,001-100,000 copies/mL 186 (41) 
>100,000 copies/mL 48 (11) 
At the time of adherence assessment 
Pregnant at time of sampling 147 (33) 
Median gestation (weeks) 34.1 (34.0-34.4) 
Postpartum at time of sampling 305 (67) 
Median weeks postpartum (IQR) 1.4 (1-6) 
Median weeks of ART use at time of sampling 19.4 (17.7-21.1) 
Median VL at the time of assessment (IQR) 10587 (2603-43099) 
<50 copies/mL 374 (83) 
50-1000 copies/mL 30 (9) 
1001-10,000 copies/mL 20 (4) 
10,001-100,000 copies/mL 13 (3) 
>100,000 copies/mL 5 (1) 
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Item and scale characteristics 
Table 9-3 shows descriptive statistics for the three individual adherence items and the 
combined scale. The item scores were higher (better adherence) for the item assessing days 
on which doses were missed (mean 97.1, median 100) compared with the rating and 
frequency items (means (medians) 78.5 (83.3) and 82.6 (83.3), for item 2 and 3 respectively). 
The distributions of the individual adherence items and the scale score are displayed in Figure 
9-1. All histograms were right-skewed with high levels of reported adherence on all three 
individual items, however in the combined three-item scale, only 12% of women (n=55) 
reported the highest score in all three items and achieved a perfect score in the combined 
scale. The overall Cronbach’s alpha was good, at 0.79. 
 
Table 9-3 Summary of item and scale characteristics. All item scores converted to a 
standardised score out of 100. 
 Item summary Cronbach’s Alpha 
 
Mean 
(SD) 
Median 
(IQR) 
Max score 
obtained 
item-test 
correlation 
item-rest 
correlation 
average inter-
item 
correlation 
alpha 
Days missed 
item (Item 1) 
97 
(13) 
100 
(100-100) 
100 0.823 0.600 0.596 0.747 
Rating item  
(Item 2) 
79 
(16) 
83 
(67-83) 
100 0.834 0.621 0.569 0.725 
Frequency item  
(Item 3) 
83 
(17) 
83 
(67-100) 
100 0.860 0.672 0.504 0.670 
three-item scale  86 
(13) 
89 
(78-94) 
100 - - 0.556 0.790 
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Figure 9-1 Histogram showing distribution of individual items and the combined three-item 
scale score. 
 
Table 9-4 describes the distribution of item responses across sociodemographic and 
psychosocial strata and by VL above or below 1000 copies/mL. Overall, variations in scale 
scores within subgroups were of small magnitude, and varied significantly only by education, 
with higher scores among women who had completed secondary school compared to those 
who had not (p<0.001). Duration of ART use did not alter the scale score; however, women 
with longer time on treatment were more likely to have a raised VL using a cut off of both 50 
and 1000copies/mL (p<0.001) (Table 9-5). 
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Table 9-4 Distribution of scale responses across participant subgroups and stratified by viral 
load (VL) ≥1000 copies/mL. Presented as median (IQR) of standardised score and area under 
the curve (AUC) for predicting VL ≥1000 copies/mL. 
 Median three-item scale score (IQR) ROC analysis 
 All women 
N=452 
VL<1000 
N=414 
VL≥1000 
N=38 
AUC p-value 
(AUC 
across 
categories) 
All women 88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (75.6-88.9) 0.656  
Age       
18-24 88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (77.8-83.3) 0.676 0.952 
25-30 88.9 (77.8-94.4) 88.9 (80-94.4) 83.9 (48.9-94.4) 0.643  
30+ 88.9 (77.8-94.4) 88.9 (77.8-94.4) 82.2 (77.8-88.9) 0.639  
Education      
Completed 
secondary school 
 88.9 (83.3-94.4)*  92.2 (83.3-94.4)* 88.9 (81.1-88.9) 0.735 0.295 
Did not complete 
secondary school 
87.8 (77.8-94.4) 88.9 (77.8-94.4) 78.9 (75.6-94.4) 0.643  
Poverty level (assets + 
employment) 
     
Least poverty 88.9 (77.8-94.4) 88.9 (77.8-94.4) 83.3 (77.8-88.9) 0.631 0.281 
Moderate poverty 88.9 (77.8-94.4) 88.9 (77.8-94.4) 77.8 (77.8-83.3) 0.762  
Most poverty 88.9 (77.8-94.4) 88.9 (81.1-94.4) 81.1 (62.2-94.4) 0.617  
Relationship      
Single 88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (77.8-88.9) 0.668 0.770 
Married/ Cohabiting 88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (71.1-94.4) 0.635  
HIV diagnosis/previous 
ARV exposure 
     
Diagnosed in this 
pregnancy 
88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (71.1-94.4) 0.629 0.441 
Diagnosed before; 
no past ARV use 
88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (63.3-83.3) 0.758  
Diagnosed before 
with past ARV use 
88.9 (77.8-94.4) 88.9 (77.8-94.4) 80.6 (76.7-91.7) 0.641  
Hazardous alcohol use 
(AUDIT-C) 
     
Below threshold 
(<3) 
88.9 (77.8-94.4) 88.9 (81.1-94.4) 81.1 (77.8-94.4) 0.635 0.327 
Above threshold 
(≥3) 
88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (71.1-83.3) 0.729  
Depressive symptoms 
(EPDS) 
     
Below threshold 
(<13) 
88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (76.7-91.7) 0.639 0.394 
Above threshold 
(≥13) 
87.8 (77.8-94.4) 88.9 (77.8-94.4) 77.8 (11.1-83.3) 0.752  
Pregnant or postpartum 
at time of assessment 
     
Pregnant 88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (77.8-88.9) 0.677 0.867 
Postpartum 88.9 (77.8-94.4) 88.9 (81.1-94.4) 77.8 (71.1-88.9) 0.655  
Median weeks on 
treatment 
     
16-20 88.9 (77.8-94.4) 88.9 (77.8-94.4) 81.1 (75.6-94.4) 0.639 0.777 
20.1-24 88.9 (77.8-94.4) 88.9 (78.9-94.4) 82.2 (78.9-88.9) 0.646  
>24 88.9 (77.8-94.4) 93.3 (81.1-94.4) 77.8 (11.1-88.9) 0.719  
*p<0.05, **p<0.001 using Kruskal Wallis or Wilcoxon Rank Sum tests for scores within participant subgroups 
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Table 9-5 Proportion of women virally suppressed (<50 & <1000 copies/mL) by weeks on 
ART at the time of sampling (n=452).  
 VL<50 
N=374 
VL≥50 
N=78 
VL<1000 
N=414 
VL≥1000 
N=38 
Median weeks on ART at 
time on sampling (IQR) 
19.4 (17.6-21) 19.5(18-22.9) 19.4(17.6-21) 20.4(18-27.4) 
16-20 weeks 221(59) 45(58)** 247(60) 19(50)** 
20.1-24 weeks 134(36) 17(22) 145(35) 6(16) 
>24 weeks 19(5) 16(21) 22(5) 13(34) 
*p<0.05, **p<0.001 using Chi-squared Test for differences by viral load (VL) category 
 
Relationships of three-item scale to viral loads 
Crude and adjusted associations between the three-item adherence scale and VL ≥50, and 
≥1000copies/mL are presented in Table 9-6. In bivariate analyses, having a raised VL was 
consistently associated with lower median scores on the adherence scale using a VL cut off of 
both ≥50 (median adherence scores 88.9 and 83.3, p=0.005), and ≥1000 copies/mL (median 
adherence scores 88.9 and 81.1, p=0.001). These associations persisted in multivariable 
analyses which adjusted for age and education. The AUC for the three-item scale was 0.599, 
0.656 and 0.642 using a VL cut off of ≥50, ≥1000 and ≥10000 copies/mL, respectively 
(Figure 9-2). The AUC using a VL cut off of 1000copies/mL remained above 0.6 and did not 
vary significantly across subgroups of sociodemographic and psychosocial characteristics 
(Table 9-4).  
 
Table 9-6 Distribution of three-item adherence scale scores stratified by VL≥50, and 
VL≥1000 copies/mL respectively (N=452). Scores presented as median (IQR) of a 
standardised score out of 100. 
 Number 
of 
women 
Median three-item 
score(IQR) 
Crude regression 
coefficient (95% CI) 
Age & education adjusted 
regression coefficient 
(95% CI) 
VL<50 374 
 88.9  
(77.8-94.4) * 
-0.03  
(-0.05, -0.02) ** 
-0.03  
(-0.05, -0.01) * 
VL≥50 78 
83.3  
(77.8-92.2) 
  
VL<1000 414 
 88.9  
(77.8-94.4) * 
-0.05  
(-0.07, -0.03) ** 
-0.04  
(-0.06, -0.02) ** 
VL≥1000 38 81.1(75.6-88.9)   
*p<0.05, **p<0.001 using the Wilcoxon Rank Sum test & logistic regression for differences by viral 
load (VL) category 
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Figure 9-2 Receiver operating characteristic curves for three-item scale detecting VL≥50 (a) 
and VL≥1000 (b). 
 
The sensitivity and specificity of the adherence scale for predicting VL ≥50, and 
≥1000copies/mL, is presented in Table 9-7. Using a scale score cut off of <80, the scale had a 
low sensitivity for detecting those who truly had a VL above 50 or 1000 copies/mL (36 and 
45%, respectively). Using a scale score cut off of <90, 74% and 76% of women with VLs 
≥50 and ≥1000copies/mL were correctly identified using the three-item adherence scale, and 
a cut off of <100 identified more than 90% of women with VLs ≥50 and ≥1000copies/mL. 
All cut off scores resulted in very high negative predictive values with women with summary 
scale scores above or equal to 80, 90 and 100, having a 94, 95 or 98% chance of having a 
VL<1000copies/mL, respectively. 
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Table 9-7 Sensitivity, specificity and positive and negative predictive values of three-item 
adherence scale predicting viral load ≥50 and ≥1000 copies/mL, using a scale cut off score of 
<80, <90 and <100. 
 Viral load Sensitivity Specificity PPV NPV 
Adherence (three-
item scale score) 
Detectable 
(≥50) 
Non-detectable 
(<50) 
  
  
Non-adherent (<80) 28 97 36% 74% 22% 85% 
Adherent (≥80) 50 277      
Detectable 
(≥50) 
Non-detectable 
(<50) 
    
Non-adherent (<90) 58 224 74% 40% 21% 88% 
Adherent (≥90) 20 150     
 Detectable 
(≥50) 
Non-detectable 
(<50) 
    
Non-adherent (<100) 73 324 94% 13% 18% 91% 
Adherent (100) 5 50      
Detectable 
(≥1000) 
Non-detectable 
(<1000) 
    
Non-adherent (<80) 17 108 45% 74% 14% 94% 
Adherent (≥80) 21 306      
Detectable 
(≥1000) 
Non-detectable 
(<1000) 
    
Non-adherent (<90) 29 253 76% 39% 10% 95% 
Adherent (≥90) 9 161     
 Detectable 
(≥1000) 
Non-detectable 
(<1000) 
    
Non-adherent (<100) 37 360 97% 13% 9% 98% 
Adherent (100) 1 54     
(PPV – positive predictive value, NPV – negative predictive value) 
 
Discussion 
This analysis had three main findings. First, the three-item self-reported adherence scale that 
we tested in pregnant and post-partum women on ART in South Africa had good 
psychometric characteristics and did not demonstrate the ceiling effects that self-report items 
often show. Second, self-reports had significant associations with elevated VL in both 
bivariate and multivariable models, and third, using ROC curves, the scale had only moderate 
ability to discriminate between patients elevated and non-elevated VL. 
The scale used in our analysis consisted of three simple and easily understood adherence 
questions developed in English through a process of cognitive interviewing. Reviews have 
shown that self-reported measures range from single items asking for the number of 
prescribed doses missed in a specified time period to numerous complex items requiring 
detailed recall; very few studies report using the same self-reported adherence measure, 
making it difficult to compare results across studies [9,21,23]. An analysis in South Africa 
evaluating the performance of five commonly used self-reported adherence questions found 
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that all questions were poor predictors of virologic and/or immunologic failure [35]. 
Similarly, another study in Cape Town using a short adherence scale in HIV-infected adults 
found no correlation between the scale score and having a detectable VL [36]. Both of these 
studies used recall periods of seven days, much shorter than the 30-days used in our analysis. 
In the current analysis we found that although the effect sizes were relatively small, all 
individual adherence items, as well as the three-item scale, were significantly correlated with 
VL. The cognitive interviewing approach used in developing this scale, which resulted in a 
word choice aimed at minimizing social desirability as well as misinterpretation, may have 
resulted in improved responses to the adherence questions even in this new setting. 
The distribution of each item and the three-item scale (Figure 9-1) found in this study was 
very similar to that reported in the US population of predominantly male adults on ART, 
though in our cohort a lower proportion obtained maximum scores on all three items and 
reached a score of 100 on the combined scale [26]. Our data did not show a large ceiling 
effect, a common problem for self-report adherence measures [9,16]. While ceiling effects 
can occur if the population is in fact highly adherent, in many cases it is rather a result of 
patients overestimating their adherence, typically due to social desirability effects [36–38]. 
While we did observe a ceiling effect for the missed doses item alone (80% reporting no 
missed doses), only 12% of women reported perfect adherence in the three-item scale. This 
three-item scale was developed paying particular attention to a word choice that optimizes 
accurate reporting. This scale may therefore be more sensitive to reported non-adherence than 
other scales that have shown more prominent ceiling effects, although this cannot be known 
definitively unless scales are compared head to head in the same populations. Previous 
studies in pregnant and postpartum women in Latin America and in Kenya using combination 
adherence scores based on pill counts and self-report have reported optimal adherence in 
more than 80% of women [10,39]. This aligns with our results using missed doses alone, and 
also with the finding of 92% of women with VL below 1000copies/mL at the time of 
assessment, however this is much higher than the 12% that we found using the combined 
scale score. Although there are few data assessing the performance of self-reported adherence 
measures in pregnant and postpartum women in low resource settings or in this particular 
context, the lack of a ceiling effect may be indicative of a more at risk population than other 
cohorts previously studied, and perhaps the three-item scale, which has been developed to be 
sensitive to reported non-adherence, is detecting more subtle difficulties with treatment 
implementation that have not yet impacted on VL. 
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Our results found that the three-item adherence scale scores were consistently significantly 
associated with elevated VL, however the effect sizes were relatively small. This is mirrored 
in the ROC analyses and suggests that although the three-item scale score is associated with 
VL, it may not be a very strong predictor of having an elevated VL. For the purposes of a 
first stage screening tool, we are looking for a measure with high sensitivity rather than 
perfect predictive ability, as would be required for a diagnostic tool. The scale achieved an 
AUC of 0.656 to detect a VL≥1000copies/mL, similar to what has been previously reported 
for different self-report measures as well as for pharmacy refill and VL, though lower than 
other combined self-report questions and lower than EDM and VL [19,40–42], and with 
further evaluation shows potential to fill this gap. 
Global recommendations are moving towards making VL monitoring the standard of care for 
ART programmes, however in reality there are still likely to be problems with access in low 
resource settings due to feasibility and cost constraints. With infrequent VL testing and 
potential delays in feedback of results in many low resource settings, there is still a need for 
interim adherence assessments, particularly in the time sensitive context of PMTCT [2]. In 
many settings, adherence self-reports will remain the most feasible option that allows for 
rapid assessment of adherence risk and immediate feedback and counselling. Our findings 
suggest that this simple, low cost adherence screening tool may provide an early warning of 
poor adherence and prompt second stage adherence screening or VL testing. With a cut point 
of <90 or <100, the combined scale was able to detect 76 and 97% of women with VL above 
1000copies/mL, respectively. This is an important advance for first stage self-reported 
adherence screening, with reported sensitivities of other tools ranging from 24-57% [23]. 
This scale had very high negative predictive values (94-98% depending on the scale cut-off) 
meaning that women with above threshold adherence scores had a very small probability of 
having a raised VL and could be potentially screened out of more resource intensive second 
stage adherence screening.  
Although this scale shows promising performance in this setting, further research is needed to 
determine how appropriate it will be in a routine care setting and how it could fit into local 
routine ART management plans. In this analysis, considering anyone scoring below the 
maximum score on any item as non-adherent (a combined scale score of <100), 88% of 
women reported some adherence difficulty. However, at the time of assessment 92% of 
women had a VL<1000copies/mL and 360 women who had a VL below 1000copies/mL 
reported some adherence difficulty. An unexplored benefit of this scale is the opportunity of 
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the health care provider to discuss adherence challenges and solutions immediately after any 
reported difficulty with implementing treatment is admitted. This finding of suboptimal 
reported adherence in the absence of raised VL, points perhaps to more subtle early 
adherence difficulties being detected by this scale in a cohort of women recently initiated on 
ART. These women may be at increased risk of non-adherence and poor treatment outcomes 
over time and their early reports of adherence difficulty may provide an opportunity for 
additional adherence counselling, before their adherence behaviour can impact their VL. 
Further investigation into the longitudinal prognostic value of this scale should be considered 
and use of this simple tool in routine care as a flag to prompt further assessment and decide 
on an appropriate adherence support intervention may warrant consideration [14,26]. The 
successful use of this translated scale suggests that it can withstand cross-cultural adaptation 
and may also be useful in other settings. 
Although, these data suggest that this three-item scale could successfully be used as a first 
stage adherence screening tool, the following limitations must be noted. The scale was 
administered by trained research interviewers outside of the routine ART care service, 
reducing the risk of social desirability bias and in the absence of the time constraints normal 
in a busy routine ART clinic. For these reasons, generalizability to routine clinical settings in 
high volume ART clinics is not known. In this analysis we were not able to compare the 
three-item scale to other objective adherence measures. We were also unable to compare this 
tool with adherence measures taken at routine ART follow up visits as these data were not 
available. We were able to compare the three-item scale to single missed doses item alone, a 
common measure of adherence in routine care, however an important next step will be to 
evaluate how this tool could be used in routine care and comparing it to measures currently in 
use in low resource settings. Pharmacy dispensing records and pill count have also been 
recommended as potential adherence measurement tools in low resource routine programme 
settings and comparison and combination with these measures will be an area of future 
research focus [19,42–44]. Optimal cut off values and an appropriate diagnosis and 
intervention strategy based on the scale result need to be established for routine clinical care. 
Although this tool appears to be valid and well understood across diverse populations, the 
optimal cut-offs and possible second stage screening and interventions are likely to differ 
across population groups so further research in other contexts is recommended. It must also 
be noted that the women in this study were all newly initiated on ART but had persisted on 
treatment to the time of assessment. How the scale will perform if used repeatedly over time, 
and generalizability of our findings to treatment experienced cohorts is not known. 
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Conclusion 
In summary, these findings show that a simple three-item self-reported adherence scale could 
be used to screen for poor adherence and potentially flag current or pending elevated VL in 
this HIV-infected pregnant and postpartum population on ART. This is the first reported use 
of this scale outside of the US and it has performed well after translation in this setting. 
Adherence monitoring during pregnancy and after delivery in low resources settings requires 
more attention in the era of universal ART for all pregnant and breastfeeding women, and 
with further validation within routine care, this simple scale may add value to maternal 
adherence monitoring in low resource settings. 
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